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Influenza A virus M2 (A/M2) forms a homotetrameric channel in viral membranes that is highly selective
for protons. A/M2 has been extensively studied by electrophysiologists, biophysicists, structural
biologists and biochemists in order to understand the mechanism and selectivity of proton conductance
from the structural basis. Medicinal chemists have also studied A/M2 as therapeutic target for anti-flu
drugs. However, research on A/M2 drug binding lead to entirely different binding sites of two very similar
anti-flu drugs. In light of the urgency in developing novel antivirals against drug resistant A/M2 mutants, it
is imperative to solve this discrepancy in order to guide the next generation of antiviral discovery. This
highly contentious debate was settled in favor of pore blocking through collaborate efforts with Dr. Mei
Hong in Iowa State University. We showed by solid state NMR that the single high affinity
pharmacologically relevant drug binding site locates at the N-terminal lumen with amine pointing towards
C-terminal using 13C-2H rotational echo double-resonance NMR distance measurement of 13C-labeled
M2TM and deuterated amantadine in lipid bilayers. Guided by the high resolution structure of drugcomplexed M2, rational drug design based on BL-1743 scaffold lead to a series of spiran amines, which
are not only 10 fold more active than amantadine, but also has moderate activity against drug resistant
mutants V27A and L26F. Subsequent optimization improved the potency with IC50s down to low
micromolar range. By substituting the carbon quaternary center with silicon, silaspiran amines were
designed and synthesized and show higher antiviral potency than their carbon analogs. Finally in
searching for novel scaffolds, a library of inhibitors was selected based on the structure and activity
relationship results from previous studies and screened against M2. It was found that A/M2 is able to
accommodate inhibitors with diverse scaffolds. In conclusion, this thesis study solved the A/M2 drug
binding site controversy and developed a series of potent A/M2 inhibitors that are promising as drug
candidates.
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ABSTRACT

DESIGN AND PHARMACOLOGICAL CHARACTERIZTION OF INHIBITORS
OF INFLUENZA A VIRUS M2 PROTON CHANNEL

Jun Wang

Supervisor: Professor William F. DeGrado

Influenza A virus M2 (A/M2) forms a homotetrameric channel in viral membranes that is
highly selective for protons. A/M2 has been extensively studied by electrophysiologists,
biophysicists, structural biologists and biochemists in order to understand the mechanism
and selectivity of proton conductance from the structural basis. Medicinal chemists have
also studied A/M2 as therapeutic target for anti-flu drugs. However, research on A/M2
drug binding lead to entirely different binding sites of two very similar anti-flu drugs. In
light of the urgency in developing novel antivirals against drug resistant A/M2 mutants, it
is imperative to solve this discrepancy in order to guide the next generation of antiviral
discovery. This highly contentious debate was settled in favor of pore blocking through
collaborate efforts with Dr. Mei Hong in Iowa State University. We showed by solid state
NMR that the single high affinity pharmacologically relevant drug binding site locates at
the N-terminal lumen with amine pointing towards C-terminal using
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C-2H rotational-

echo double-resonance NMR distance measurement of 13C-labeled M2TM and deuterated
amantadine in lipid bilayers. Guided by the high resolution structure of drug-complexed
v

M2, rational drug design based on BL-1743 scaffold lead to a series of spiran amines,
which are not only 10 fold more active than amantadine, but also has moderate activity
against drug resistant mutants V27A and L26F. Subsequent optimization improved the
potency with IC50s down to low micromolar range. By substituting the carbon quaternary
center with silicon, silaspiran amines were designed and synthesized and show higher
antiviral potency than their carbon analogs. Finally in searching for novel scaffolds, a
library of inhibitors was selected based on the structure and activity relationship results
from previous studies and screened against M2. It was found that A/M2 is able to
accommodate inhibitors with diverse scaffolds. In conclusion, this thesis study solved the
A/M2 drug binding site controversy and developed a series of potent A/M2 inhibitors that
are promising as drug candidates.
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Chapter 1
Introduction of influenza A virus M2 proton channel and its importance
as antiviral drug targets

1.1 Influenza A virus infection is a serious human health threat
The influenza virus, most notably the H1N1and H5N1 strains, poses a serious threat to
human health. Each year in the US, the virus is directly responsible for the death of
36,000 people, 114,000 hospitalizations,1 70 million missed workdays and 38 million lost
school days in a regular flu season.2 The estimated loss to the economy is $3-15 billion.
During pandemics (1957 and 1968) approximately 70% of the US population was
infected and in 1918/19 the estimate of death associated with Spanish influenza ranges
from 20-40 million (1 in 100 people worldwide). Typical flu infections are mild and
generally lead to a full recovery, whereas highly pathogenic strains of the virus often
cause life-threatening illness even among healthy adults. The outbreak of highly
pathogenic H5N1 avian influenza virus in 1997 and 2004/5 caused the death of millions
of chickens and had a very high mortality rate among the limited number of infected
humans. During the H1N1 pandemic in 2009,3 the flu virus rapidly spread throughout the
world when no vaccine was available. This caused great concern about the transmission
of avian virus mutants among humans. Influenza viruses can mutate in two ways:
antigenic drift and antigenic shift.4 Antigenic drift due to point mutations of the viral
negative strand RNAs generates slightly modified antigens on the virus surface, while
antigenic shift causes reassortment of RNAs between viruses that infect avian
1

populations and viruses that infect humans (Figure 1.1). The latter is a more serious
problem since it produces different antigenic determinants, for which there is little preexisting immunity. Thus there is a great need for anti-influenza therapeutics. Currently
there are two classes of licensed small-molecule drugs in use to treat influenza virus
infection: amantadine and rimantadine, which target the virus′ M2 proton channel, and
Tamiflu (oseltamivir), which targets the virus surface protein neuraminidase.5

Figure 1. 1 | Reassortment of influenza viruses from different species. Figure from
(Carolyn Buxton Bridges, MD, Influenza Branch, Division of Viral and Rickettsial
Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia: "Human
influenza viruses and the potential for inter-species transmission." )

1.2 Influenza virus family and compositions
There are three types of influenza viruses (A, B and C), all belong to orthomyxoviridae
family.6 Influenza B and C viruses both infect humans, but are less pathogenic compared
2

with influenza A and do not cause pandemics. Influenza A viruses infects multiple
species, including human, swine, birds and ferrets. It is one of the most serious human
diseases. Symptoms of flu infection include high fever, headache, tiredness, dry cough
and body aches, and it is more deadly for people with health complications, like pregnant
women, young children, seniors older than 65, and people with chronic medical
conditions (such as asthma, diabetes, and heart disease).7 Flu viruses are transmitted
through the airway by sneeze or cough of infected people. Occasionally, people can also
get infected by indirect contact mediated by viruses contaminated surfaces, then touching
their eyes, mouth and nose.

Influenza virus contains a genome made up of 8 single strand RNA segments, each
encoding a different viral protein (Figure 1.2). The reassortment of RNA segments from
different species of influenza A viruses, called antigenic shift, allows the virus to avoid
detection by the human immune defense system. This is highly problematic from the
standpoint of vaccine development since it is impractical to predict when, where and how
reassortment may occur. Antigenic shifts can lead to viruses with novel immunological
signatures to which pre-existing immunity in the population is lacking. This has the
potential to cause deadly worldwide pandemic disease if the virus also has high
replicative fitness and human-human transmissibility. In comparison, antigenic drift
caused by point mutation of one particular virus species only leads to annual epidemic
flu.

3

Figure 1. 2 | Influenza virus membrane proteins and genetic compositions. Figure from 8
with permission from Elsevier.
There are three membrane associated proteins displayed on influenza virus’ surface,
hemagglutinin (HA), neuraminidase (NA), and M2 protein, each of which play an
essential role in the viral replication cycle and are targets of vaccines and antivirals.
Currently there are 16 hemagglutinin subtypes (H1-H16) and 9 neuraminidase subtypes
(N1-N9), and they are the antigenic determinants of influenza virus and can undergo all
possible combinations giving rise to different influenza A viruses subtypes, e.g. H1N1,
H5N1, H3N2 etc. The majority of viral envelop proteins are hemagglutinin (80%) and
neuraminidase (17%) at approximately a 4 to 1 ratio. M2 represents a small portion (3%)
with 5-10 channels per virion.9
4

Inside the virus are viral ribonucleoproteins (vRNPs) structures that contain eight
different segments of negative sense, single stranded RNA, encoding for the eleven viral
proteins10 (Figure 1.2). RNA segment 1 codes for polymerase basic protein 2 (PB2), 2 for
polymerase basic protein 1 (PB1), 3 for polymerase acidic protein (PA), 4 for
hemagglutinin (HA), 5 for nucleocapsid protein (NP), 6 for neuraminidase (NA), 7 for
matrix protein 1 (M1) and 2 (M2) and 8 for non-structural protein 1 (NS1) and 2 (NS2).
PB1, PB2 and PA are the three P(polymerase) proteins, which are present at 30-60 copies
per virion. NP is the predominant structural protein subunit of the nucleocapsid and also
plays an essential role in viral RNA replication. Viral matrix protein (M1) underlies the
lipid bilayer through association with the cytoplasmic tail of M2, and is the most
abundant virion protein. NS2 (also known as NEP) protein is a structural component of
the virion and appears to form an association with M1 protein and is involved in the
export RNP complex from the nucleus. NS1 protein, when expressed, is not packed
inside the virions and plays a role in suppressing host antiviral responses.

Standard nomenclature for a specific influenza strain is summarized in Figure 1.3.

5

Figure 1.3 Nomenclature of influenza virus. Figure from11

1.3 Influenza A virus replication cycle and antiviral drug targets8, 12-15
Influenza virus enters the cell by first interacting with the cell surface receptor containing
sialic acid through hemagglutinin, then internalized through receptor mediated
endocytosis (Figure 1.4). Once in the endosome, the low pH inside the endosome
activates the M2 proton channel, which functions to equilibrate the pH of the virus
interior with that of the acidic endosome. The lowering of the pH within the virus has two
outcomes: first, it triggers the conformational change of hemaglutinin to the low-pH
form, leading to fusion of viral and cellular membrane. Second, the low pH in viral
interior leads to disruption of the interactions between viral ribonucleoprotein (vRNP)
complex and the M1 protein, an important step in viral uncoating.16 The structure of
hemagglutinin was solved by X-ray crystallography17 which lead to the design of viral
fusion inhibitors that either prevent or accelerate the low pH form HA formation.
Additionally, for some subtypes of influenza A virus, the M2 proton channel activity
helps maintain a neutral pH in the lumen of the trans-Golgi network to prevent premature
triggering of the hemagglutinin to the low-pH form.18-20 The adamantane class of
antivirals block this uncoating process.21 Once the viral RNA is transported to the
nucleus, the negative sense strands of RNA are transcribed to positive sense RNA
(mRNA) first before being replicated and translated into viral proteins. Viral RNA
replication and transcription are carried out by three polymerase subunits, PA, PB1, PB2
and nucleoprotein NP in the nucleus can be inhibited by viral RNA polymerase
6

inhibitors,22 and there is a growing interest in developing viral polymerase inhibitors as
structural information becomes available.23 Next, the translation of mRNA into viral
proteins can be inhibited by small interfering RNAs (siRNAs),24 and its efficiency was
further demonstrated in an animal study.25 In the late stage of viral replication, the viral
proteins repack into progeny virions, but before they can be released into the circulation
system, neuraminidase has to cleave the sialic acid receptor. This process can be inhibited
by

neuraminidase

inhibitors

(eg,

Tamiflu

and

Zanamivir).26

Moreover,

immunomodulators are also in development to reduce the inflammation initiated by
influenza A virus infections.12

7

Figure 1. 4 | Influenza virus replication cycle and checkpoints for antivirals inhibition.
Figure from 27 with permission from NPG.

1.4 Influenza A virus chemotherapy
While immunization offers the first line defense against influenza A virus infection, its
effectiveness is greatly diminished due to the extraordinary ability of the viruses to
change their genetic makeup and escape from the host immune system. Thus, novel
antivirals are in great need to fight against influenza virus infections during pandemics
and seasonal epidemics.

In theory, small molecule inhibitors targeting any of the

checkpoints during influenza virus replication cycle can be developed into antiviral
drugs.28 Currently there are two classes of small-molecule drugs on the market to treat
influenza virus infection (Figure 1.5): amantadine and rimantadine, which target the
virus′ M2 proton channel, and Tamiflu (oseltamivir) and zanamavir, which targets the
virus surface protein neuraminidase. A few other anti-flu drugs targeting NS1, NP and
viral polymerases are in still in development.12

Figure 1. 5 | Chemical structures of four proven antivirals drugs for treatment of influenza
virus infection.

Compared with neuraminidase, A/M2 protein is more conversed with only a few major
mutations like V27A, S31N and L26F conferring drug resistance and transmissibility.29-31
8

Part of the reason for the low mutation rate of A/M2 is due to the stringent sequence
requirement for A/M2 function. To conduct protons, A/M2 has to allow formation and
interchange of a number of functional conformers, each required for gating and
conducting protons (Figure 1.6). Any mutation which shifts these low energy barrier
interconvertable ensembles to one or more stable conformations is potentially disfavored
due to the loss of function. It has been shown in vitro through analytical
ultracentrifugation (AUC) experiments that mutation of pore lining residues and residues
at the helix-helix interface of A/M2 to alanine and phenylalanine result in a more stable
homotetramer compared with wild-type, except His37, which is required for selective
proton conductance.32,

33

Thus, the amino acid sequence of M2 is not optimized for

overall thermodynamic stability, but rather a compromise between stability and function.
From the drug development point of view, it would be ideal to target the most
conservative protein such that antivirals are effective across different subtypes of flu
viruses. In this regard, A/M2 is advantageous over neuraminidase as a drug target in
influenza virus inhibition; despite both of them are proven drug targets. Nevertheless, a
combination of antivirals drugs are desired in the case of highly virulent flu outbreaks. 12,
34

9

a)

b)

Figure 1. 6 | Representation of A/M2 ensemble and conformation selection by A/M2
inhibitors. a) A/M2 conducts proton through equilibrium of a series of low energy barrier
ensembles. The channel opens outside to allow protons to diffuse into the channel or
open inside to release the proton. The conformational change is mediated by His37
protonation and deprotonation. b) Channel blockers like amantadine inhibits the A/M2
channel by binding one or more conformations and stabilizes them, thus creating a large
energy barrier for conformational interconversion.

10

A large number of drug resistant mutations were selected in cell culture under
amantadine selection pressure, including L26F; V27 to A, S, G, or D; A30 to T, E, or P;
S31N

19, 35

(Figure 1.7), and a subset of these mutations were also found in infected

patients that were treated with amantadine.36 Not all of the mutant viruses maintain the
transmissibility of wt viruses and many of these mutations have the tendency to revert in
the absence of drugs.19, 37 Only three major mutations were identified from large scale
genome sequencing of transmissible viruses from 1918 to 2008,29, 38 among which S31N
is the predominant drug resistant mutation in H3N2 and H1N1 subtypes, followed by
V27A and L26F. The latter two mutations were found to be predominant in certain flu
seasons. A highly conductive channel would be toxic to the infected host cell and would
lead to cell death before the assembly and budding of the progeny virus. Another function
of A/M2 is to equilibrate the pH across the Golgi in order to prevent the premature
conformational change of the viral fusion protein, hemagglutinin (HA).18-20 A/M2 and
hemagglutinin have co-evolved and acted in concert with each other. A particularly acidlabile hemagglutinin would require an A/M2 variant like D44N with higher proton
conductance capability to maintain neutrality in the late Golgi to prevent a premature
conformational change in the hemagglutinin before reaching the cell surface.39 Taken
together, only three major mutations in A/M2, namely S31N, V27A and L26F satisfy
both the functional and evolutionary requirements of influenza viruses, thus becoming
dominant in currently circulating strains.

11

a)

b)

Figure 1. 7 | Amino acid sequence of influenza A virus strain A/Udron/72 and its
mutations. a) Domain structure of influenza A virus M2 protein. b) A/M2 drug resistant
mutations isolated from cell culture treated with amantadine.

1.5 A/M2 structure and drug binding site
AM2 is a homotetrameric, type III integral membrane protein containing: 1) a short Nterminal region that is important for the protein’s incorporation into the virion;40 2) a
transmembrane (TM) helix that is required for tetramerization, drug binding and proton
channel formation;41-44 3) a C-terminal amphiphilic helix that is involved in membrane
localization, budding and scission;45,

46

and 4) a C-terminal tail that interacts with the

matrix protein M1.47 Although native A/M2 protein is palmitoylated (Cys50) and
phosphorylated (Ser64), these modifications have no effect on its channel-forming
properties in cell membrane.48, 49 The protein also has cysteine residues at position 17 and
19 on the viral N-terminal exterior, which form a mixture of covalent dimers and
tetramers.50 However, these disulfides are not essential for M2 assembly into functional
tetrameric channel, and the mutants whose Cys17 and Cys19 are mutated to Ser are still
12

fully active in oocytes.48, 51 Structures of the drug complexed transmembrane domain of
A/M2 (A/M2TM) were solved using X-ray crystallography52 and solution NMR53 (Figure
1.8). The overall structures were similar, showing left handed packing of a
homotetrameric bundle. The differences between these two structures are: (1) The helix
tilt in the X-ray structure is 30-40o, while the solution NMR structure is 23o. This
difference might result from several factors: (a) Solubilization environment - crystal was
grown in octylglucoside (OG) micelle at pH 5.5, which confers the open conformation of
M2.

In

contrast,

the

NMR

structure

was

solved

in

1,2-Dihexanoyl-sn-

glycerophosphocholine (DHPC) at pH 7.5, which confers the closed conformation of M2.
(b) The protein sequences used for X-ray and solution NMR studies were different. The
X-ray structure was solved with transmembrane segment (residues 25-46), solution NMR
study used a longer sequence with an extra C-terminal amphiphilic helix (residues 2060). (2) The striking difference is where the drug binds. In the X-ray structure, the
electron density inside the cavity at the N-terminal lumen matches that of amantadine,
leading to a pore blocking mechanism of drug action. In solution NMR, four rimantadine
molecules were found on the C-terminal exterior side at the helices interface. The
transmembrane helices are in close contact such that there was not enough room to
accommodate rimantadine inside the channel. Based on this structure, an allosteric
inhibition mechanism was proposed where the drug would selectively stabilize the closed
conformation of M2, thus preventing channel opening.

13

From a drug discovery perspective, it is imperative to figure out which drug binding site
is the pharmacological relevant binding site. This is one of the goals of my thesis work.

Figure 1. 8 | X-ray and solution NMR structures of drug bound A/M2TM. Left: X-ray
structure of A/M2TM (25-46)G34A with electron density inside the channel matching
amantadine (PDB code: 3C9J). Right: Solution NMR structure of A/M2TMC (21-61)
with four rimantadine binding to the peripheral of the channel (PDB code 2RLF). Figures
from 52, 53 with permission from ACS and NPG.

1.6 Literature review of A/M2 inhibitors
Amantadine was first discovered by scientists at DuPont to have antiviral activity in 1964
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and was approved by the U S Food and Drug Administration (FDA) in 1966 for the

treatment of influenza A virus infection in 1966. Subsequently, a close structural analog
of amantadine, rimantadine, received FDA approval in 1994 and has been shown to have
higher potency and reduced central neuron system (CNS) side effects. Unfortunately
most of the currently circulating strains of influenza virus have become resistant to the
adamantane class of drugs, causing the CDC to issue a recommendation to discontinue
their use.54 Thus oseltamivir (Tamiflu) is the only remaining orally administered anti-flu
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drug on the market. Increasing number of oseltamivir resistant cases have been reported
in recent years.55,

56

Thus there is great need to develop novel antivirals with higher

potency and broad spectrum inhibition. Extensive medicinal chemistry efforts have been
devoted to synthesize amantadine analogs, including 1-substituted adamantane,57,

58

substituted adamantane,59-61 2,2-disubstitued adamantane, 2,2-spiro adamantane57,

62, 63

2-

and 1,2-annulated adamantine64 (Figure 1.9). Quite a few compounds have been
identified to be more potent than rimantadine.4, 5 But the cytopathic effect (CPE) assay65
that was used to test these compounds is not target specific, so it is difficult to correlate
the structures with M2 inhibition. Moreover, the influenza A virus strains that were tested
lack the S31N or V27A M2 mutation, so it is not clear whether any of these compounds
might work against virus carrying amantadine resistant mutations.

Figure 1.9 | Structures of representative adamantane anlogs as anti-flu inhibitors.
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Aside from amantadine, only very few scaffolds other than adamantane have been
explored for antiviral activities against influenza A virus (Figure 1.10), including 1norbornylamine,66 tricyclic ICI 130685,67 BL-1743,68 bicycle[2,2,2]octane69 and
isopinocampheylamine.70 There are also a few patented polycyclic compounds that claim
to have antiviral activity, e.g. pentacycloundecane amines,71 aminopolycyclodecanes,72
aminotricyclononanes,73 pentacycloalkane amines,74 but their detailed mechanism of
action have not been fully explored. In this regard, despite the importance of A/M2 as a
proven drug target and the urgency to develop potent A/M2 blockers, there is very
limited structure and activity relationship information about A/M2 inhibitors. Moreover,
a majority of the current circulating influenza A viruses carry drug resistant mutations
such as L26F, V27A, S31N and S30T, none of which have been shown to be druggable.
In this thesis study, I aim to identify novel scaffolds that may provide new avenues for
developing

antagonists

of

A/M2.

The

spirene

guanidine

analogue,

2-[3-

azaspiro(5,5)undecanol]-2- imidazoline (BL-1743) was choosen as an initial hit
compound for the structure and activity relationship study, as its antiviral activity has
been shown to be A/M2 specific, and it is also easier to synthesize and diversify from the
chemistry point of view.
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Figure 1. 10 | Structures of non-adamantane based anti-influenza A viruses agents.

1.7 Introduction of M2 drug screening assays
1.7.1 Two electrode voltage patch clamp assay
The gold standard of measuring compound activity on an ion channel is the patch clamp.
Even though it is low throughput, the high quality data generated from this assay offers
insights in guiding drug design. In the patch clamp assay, a constant electrical potential
(voltage clamp) is applied across an electrically isolated area (patch) of membrane
containing the protein of interest, and the current is recorded directly in real time under
different conditions, e.g. in the presence or absence of inhibitor.

The protein assayed can either be expressed in cell membrane or reconstituted in
artificially formed bilayer-like vesicles. Both single channel and whole cell current
recording are possible, but in the case of A/M2, due to the extremely small conductance
per channel, whole cell recording are applied for drug screening purpose. In a typical
17

screening assay experiment, Oocyte expressing A/M2 channel is clamped at -20 mV.
Xenopus laevis (African clawed frog) oocytes are large cells with exceeding 1 mm in
diameter and are therefore easy to manipulate, and can be induced to express transport
proteins of interest by intracytoplasmic injection of mRNA encoding the desired protein.
Initially oocyte is bathing at pH 8.5 buffer, where A/M2 channel is closed; then A/M2
channel is activated by lowering the buffer solution to pH5.5. When the inward A/M2
current reaches maximum, the 100 μM inhibitor was applied for 2 min at pH5.5 buffer
solution. The remaining current after 2 min application was compared to the maximum
current before the application of the inhibitor. The potency of the inhibitors was
expressed as percentage inhibition of A/M2 current by 2 min application of 100 μM
inhibitors. Typical trace of the current change is shown in Figure 1.11.

Figure 1. 11| Current trace of A/M2 channel upon acidic activation and compound
inhibition.

1.7.2 Plaque reduction assay
To test the in vivo activity of inhibitors, plaque reduction assay of recombinant influenza
A virus was performed. In the plaque reduction assay, the infectious ability of virus on
MDCK cells was monitored in the presence of different doses of inhibitors. If the
inhibitor is inactive, the virus particle will multiply and infect MDCK cells, thus forms
18

localized area of ‘plaque’, which can be monitored as areas of dead/destroyed cells
detected by general cellular stains or as areas of infected cells detected by immunostaining. On the other hand, if the virus replication is inhibited by potent inhibitors, no or
less plaque will form under the same condition. In a typical procedure, confluent
monolayers of MDCK cells were incubated with the wt Udorn virus [100 plaque-forming
units (pfu) per well] and V27A/L38F mutant virus (1000 and 100 pfu per well) in a
DMEM/1%bovine serum albumin mixture for 1 h at 37 oC. The inoculums were
removed, and the cells were washed with phosphate-buffered saline (PBS). The cells
were then overlaid with DMEM-containing 0.6% Avicel microcrystalline cellulose (FMC
BioPolymer, Philadelphia, PA) and NAT (2.0 μg/mL). To examine the effect of drugs on
plaque formation, monolayers were preincubated with DMEM supplemented with the
indicated concentrations of the drugs at 37 oC for 30min, and virus samples were
preincubated with a DMEM/1% BSA mixture with the indicated concentrations of the
drugs at 4 oC for 30 min before infection. Two to three days after infection, the
monolayers were fixed and stained with a naphthalene black dye solution (0.1%
naphthalene black, 6% glacial acetic acid, and 1.36% anhydrous sodium acetate).

Figure 1. 12 | Plaque reduction assay of influenza A virus in the presence of different
concentrations of amantadine. Figure from75 with permission from ACS.
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1.7.3 Circular Dichroism binding assay
The structural changes resulted from drug binding to M2TM can be monitored by circular
dichroism (CD) spectroscopy. M2TM adopts a α-helix structure when reconstituted in
detergents, showing minimal at θ223 and θ209 in CD spectrum. Under condition of
intermediate to high peptide/detergent ratio (>1:400), binding of drug promotes a shift of
monomer/tetramer equilibrium to drug bound tetramer, which has significantly higher
intensity of ellipticity at 223nm (θ223). Drug binding constants are derived by plotting the
change at θ223 against drug concentration. In practice, the ellipticity ratio θ223/ θ209 instead
of the absolute value at θ223 is used for data fitting in order to minimize the small
concentration differences during titration. This assay was first used for amantadine
binding and later applied to other inhibitors. Binding constants derived from the CD
binding assay are in general agreement with electrophysiology assay data. Typical trace
of a CD binding assay is shown below (Figure 1.13):
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Rimantadine
Amantadine

Figure 1. 13 | CD binding assay of amantadine and rimantadine to M2TM in DPC
micelle. Figure from75 with permission from ACS.

1.8 Drug design principle of A/M2 inhibitors
The design of A/M2 inhibitors started with our X-ray crystal structures of A/M2TM (2546) (PDB: 3C9J, 3BKD) solved in n-octylglucoside (OG) micelle76 (Figure 1.14), and
also the most recent SSNMR structure of amantadine complexed A/M2TM77 (PDB:
2KQT). These structures represent conformational states from higher (pH 7.5) to lower
pH (pH 5.5). In principle, any conformation of A/M2, either at high, medium or low pH
can be used for the design of A/M2 inhibitors, because amantadine binds at both high and
low pH, despite its higher potency at elevated pH.78 A high resolution (1.6 Å) X-ray
structure76 of drug free A/M2TM (PDB: 3LBW) that was recently solved reveals not only
packing of the viral channel interior pore, but more importantly uncovers well-organized
21

water clusters in the channel. This water-His37 box like structure was suggested to play
an important role in A/M2 proton conductance mechanism by delocalizing protons over
the entire region.76 This high resolution structure offers a new starting point for the next
generation of anti-flu drug design.
a)

c)

b)

d)

Figure 1.14 | Structures of A/M2TM used for M2 inhibitor design. a) X-ray structure,
PDB: 3BKD. b) X-ray structure, PDB: 3C9J. c) SSNMR structure, PDB: 2KQT. d) X-ray
structure, PDB: 3LBW.
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All previous reported A/M2 inhibitors share the same structural similarity: a positively
charged amino or amino derivative (guanidine, etc) group attached to a large hydrophobic
aliphatic scaffold. A variety of amantadine analogues with more hydrophobic and bulkier
positively charged groups have several-fold greater potencies against most forms of the
virus that lack the S31N mutation.4,

5

The large variety of amines that can be

accommodated in the site argues against a highly specific interaction between the amine
and the channel.58 This conclusion is consistent with the amantadine-complexed AM2TM structure (PDB: 3C9J), in which the electron density map fits better with the
positively charged amantadine amine pointing down toward His37, but the distance is too
far (6.8 Å) for effective hydrogen bonding between the imidazoles and the amine (or
ammonium group). Overlaying the SSNMR structure of amantadine complexed
A/M2TM (PDB: 2KQT) with the high resolution X-ray crystal structure of drug free
A/M2TM (PDB: 3LBW) generates a model of wt M2 with the crystal waters in the entry
cluster (Figure 1.15). In this model, amantadine is within hydrogen bonding distance with
the crystal waters which suggests amantadine inhibiting M2 by not only physically
blocking the channel, but also altering the pKas of the His37 residue79 such that it can no
longer be protonated at physiological pH.
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Figure 1.15 | Overlaying A/M2TM structures of SSNMR structure (PDB: 2KQT) and Xray structure (PDB: 3LBW).

The pore lining residues of wt A/M2 in the drug binding site are V27, A30, S31 and G34
that forms a hydrophobic pore. In the SSNMR structure of amantadine complexed
A/M2TM (PDB: 2KQT), V27 constrains the drug binding site in the N-terminal with the
pore dimension ~4 Å, and the channel expands to the widest at G34 with an inner
diameter of ~8 Å (Figure 1.16). In the channel axis, the drug binding site consists of two
α-helix turns of A/M2 backbone with the distance of ~ 9 Å (the distance of one turn αhelix is 5.4 Å, the tilt angle of the helix is 30o, thus the distance in the channel axis is 5.4
Å*2*cos30o = 9.4 Å). The drug binding site dimension in the channel axis can be further
extended to 11 Å if the water clusters above His37 are displaced. This suggests the A/M2
drug binding site has enough room to accomendate molecules larger than
amantadine/rimantadine.
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Figure 1. 16 | A/M2 drug binding site dimension analysis

For the inhibitor to fit inside the channel, it has to meet two criteria: hydrophobic match
and Shape complementary. These are the guidelines for A/M2 inhibitor drug design.

The general procedure of A/M2 inhibitor discovery (Figure 1.17) starts from a rational
drug design based on the hit compounds identified from high throughput screening or a
de novo structural based design. The inhibitors designed are next synthesized and assayed
in A/M2 specific electrophysiology assay. The structure and activity relationship (SAR)
correlation results from the assay are used as guidelines for the next round of structure
based rational design using the same scaffold, or selection of structurally diverse
compounds that meet the criteria of SAR results. The inhibitors designed or selected are
subjected to the next round of electrophysiology assays. The most potent inhibitors are
further characterized both in plaque reduction assay and in biophysical assays such as
CD, NMR, etc to gain insights about how inhibitor binding affects the conformational
25

change of A/M2. The ultimate goal is to identify drug candidates that can be further
pursued in animal test and clinical trials.

Figure 1. 17 | A/M2 inhibitor discovery scheme.
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Chapter 2
Aim, focus and perspective of influenza virus M2 channel inhibitor
development
2.1 Aim and focus of A/M2 inhibitor development
Studying the mechanism of proton conductance through A/M2 and how drug binding
affects A/M2 dynamics is the first step towards structure-based design of M2 inhibitors.
The knowledge learned through structural and functional studies of A/M2 drug binding
can be used to guide rational design of potent A/M2 inhibitors targeting not only wild
type (wt), but more importantly pharmacologically relevant drug resistant mutants.

Structural studies of membrane protein are often challenging due to the difficulties
associated

with

production,

assay,

functional

reconstitution,

and

structural

characterization of this class of proteins. Production of large quantities (tens to hundreds
of milligrams) of A/M2 protein and its fragments in high purity (>98%) are required for
structural and functional studies. This problem was addressed in two ways in this study:
(1) Bacterial expression with controlled protease digestion. This provided both
isotopically labeled A/M2 fragments (19-49 and 19-53) for NMR studies and natural
abundance full length A/M2 for liposome flux assay. (2) Solid phase synthesis. The
optimized protocol was applied for synthesis of selectively labeled (15N, 13C or 15N + 13N)
A/M2 peptides with different lengths for NMR or large scale natural abundance A/M2 for
X-ray crystallography. Once enough material was obtained, the next step is to identify
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reconstitution conditions for NMR studies of A/M2. A wild range of common detergents
and detergent/lipid combinations were screened using circular dichrorism (CD)
spectroscopy or

15

N-1H HSQC NMR to identify conditions that stabilize M2TM in a

native like conformation in solution. It was found that n- dodecylphosphatidylcholine
(DPC), n-tetradecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate (C14-betaine) and ndodecyl-α-D-maltoside (DM) gave high quality of

15

N-1H HSQC spectra, highlighting

their promise for M2 structural determination by NMR.

Structural studies of drug-complexed A/M2 raised controversy about the mode of action,
specifically whether the drug inhibits the M2 function by directly blocking the channel or
allosterically modulating a conformational change of M2. From the drug design point of
view, it is imperative to solve this discrepancy so that medicinal chemists can focus on
the correct drug binding site. In collaboration with Dr. Mei Hong (Iowa State University),
we resolved the controversy using REDOR solid state NMR experiments using deuterium
labeled amantadine and M2TM with selective isotope labeled residues at both of the
above proposed drug binding sites.1 As shown in Chapter 3, this study showed that the
primary high affinity site was located at the N-terminal lumen, occupied by a single
amantadine; a secondary low affinity site at the C-terminal helices interface was only
detected with excess amantadine. Moreover, the pore binding model is further supported
by a large body of functional data.2-4
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Even though the N-terminal lumen was confirmed as a pharmacologically relevant drug
binding site, the orientation of the amine from drug inside the channel was not
determined. Extensive computational investigations have been carried out to define the
mechanism of amantadine/rimantadine action as well as orientation of the amine,
including molecular dynamics simulations,5-8 rigid-body docking,9, 10 and small molecule
probe mapping.11, 12 Since these studies used a variety of different M2 structures/models
as starting points with varying protonation states, it is not surprising that no consensus
has yet emerged. A recent molecular dynamic simulation study by Khurana et al5 found
that the orientation of the amine were not the same under different protonation states of
His37: the amine was almost equally distributed up and down at low protonation, while it
preferentially pointed towards His 37 when His37 was more solvated at greater
protonation. Clearly, there is a need to experimentally determine the precise location of
drug in the site. Depending on whether the amine points towards the N or C-terminus, the
mechanism by which drug binding inhibits this proton channel is different. These results
will facilitate the optimization of existing drugs. In Chapter 4, this question has been
addressed using both M2TM reconstituted in lipid bilayers as well as DPC micelles. 13C2

H rotational-echo double-resonance (REDOR) NMR experiments of 13C-labeled M2TM

and methyl-deuterated rimantadine in lipid bilayers showed that the polar amine points to
the C-terminus of the channel, with the methyl group located close to Gly34. Specific 2Hlabeling of the drugs permitted assignment of drug-protein cross peaks in solution NMR
experiments of A/M2TM(22-46) in dodecylphosphatidylcholine (DPC) micelles,
indicating that amantadine and rimantadine bind to the pore in the same fashion as the
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bilayer-bound M2TM. These results strongly suggest that adamantane drugs inhibit
A/M2 function by direct physical occlusion of the pore and perturb the pKa of the proton
sensing His37 through water mediated hydrogen bonding.

A major effort in this dissertation is devoted to structure based rational design of A/M2
inhibitors presented in Chapter 5, 6, 7, 8 and 9. Guided by the X-ray crystal structures of
M2TM and pore binding model, a series of spiran amines have been designed,
synthesized and assayed. Highly potent inhibitors were identified that are not only active
against the wt A/M2, but also against the drug resistant mutants V27A and L26F.

2.2 Two controversial A/M2 drug binding sites
Two studies published in 2008 raised a controversy about the A/M2 drug binding site
among the public.13-15 From the drug discovery standpoint, it is imperative to validate
which site is the pharmacological relevant drug binding site. Before planning experiments
to solve the issue, it is necessary to closely examine the two structures to see whether
either one of the structures agree with existing functional assay data, models built based
on experimental data and biophysical assays. The top and side view of the two drug
bound forms of A/M2 TM structures and their sequence are shown in Figure 2.1.
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a)

c)

b)

d)

e)
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Figure 2.1 | Structures of drug-bound transmembrane domain of A/M2. a) Side view of
X-ray structure of AM2(25-46)-G34A with amantadine14 (PDB: 3C9J). b) Side view of
solution NMR structure of AM2(18-60) with rimantadine13 (PDB: 2RLF). c) Top view
(N to C terminal) of X-ray structure of AM2(25-46)-G34A with amantadine. d) Top view
of solution NMR structure of AM2(18-60) with rimantadine. e) Sequences of
transmembrane A/M2 domains used for structural determination.

These two structures are similar in terms of both showing left handed four-helix bundles
with the same pore lining residues. The differences are dramatic and summarized in table
2.1. The striking difference, which has raised public debate, is where the drug binds. In
the X-ray structure,14 the electron density inside the channel matches that of amantadine,
and fits better with amino group pointing down toward the C-terminus. The amino head
group is too far from other polar groups to form any specific interaction (hydrogen
bonding, electrostatic, etc.).

But due to the low resolution of 3.5 Å, one cannot

definitively assign the structure of amantadine. On the other hand, the solution NMR
structure shows four rimantadines per A/M2 channel sitting in between the helices with
the positively charge ammonium group forming electrostatic interaction

with D44

residues.13
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Table 2.1 | Comparison of X-ray and solution NMR structures of drug-bounded A/M2 TM

X-ray structure

Solution NMR structure

(PDB code: 3C9J)

(PDB code: 2RLF)
Left-handed four helix bundle

Similarities

Pore lining residues are V27, A30, S31, G34, His37 and W41
Shorter sequence: BrF-AM2(25-46) G34A

Longer sequence: AM2(18-60)
Condition: pH 7.5 in 1,2-dihexanoyl-sn-

Condition: pH 5.3 in octyl glucoside (OG) micelle
glycerophosphatidylcholine (DHPC) micelle
2eq Amantadine
213eq Rimantadine

Differences

~35o tilt angle

~23o tilt angle

C-terminal wide open with W41 ~9.5 Å

C-terminal closed with W41 ~1.4 Å

Helix crossing point: L26

Helix crossing point: I33
Drug binding site: Rimantadine at the interface of

Drug binding site: Amantadine inside the channel
helices
Binding stoichiometry: 1 drug per tetramer
Binding stoichiometry: 4 drug per tetramer

Neither of the two structures were determined in a viral membrane mimetic environment
under physiological conditions;16 and both were solved in micelles. It has been well
documented that detergents play an essential role in membrane protein solubilization and
can modulate protein structure due to hydrophobic mismatch.17 So differences between
these two structures were not unexpected. The question is which structure recaptures
A/M2’s native conformation. Several aspects of the solution NMR structure seem to be
the result of experimental artifacts. (1) Rimantadine, being an amphiphilic molecule,
would strongly prefer locating at the interface of detergent/aqueous face.18 Moreover, the
electrostatic interaction with D44 was found to be non-essential, since the D44A mutant
remains amantadine sensitive and was fully inhibited by amantadine.2 A/M2 has also
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been shown to accommodate inhibitors with a wide variety of bulky amine head groups,
which argues against specific interaction between the inhibitor and the protein.19, 20 (2)
The helices are nearly parallel to the membrane normal, which results in a tightly packed
bundle pore that is too small to accommodate rimantadine. This contradicts the function
of A/M2 as a proton selective channel, which has to undergo a conformational change.
But the tight packing the helices might prevent the transition of cation-π interaction
between protonated His37 and Trp41 indole ring.21 (3) The C-terminal amphiphilic helix
aggregated into a bundle and partitioned into the aqueous phase. This is not consistent
with the electron paramagnetic resonance (EPR)22 experiments which showed that the Cterminal helix was membrane associated and nearly parallel to the membrane surface in
lipid bilayers. It is unclear whether it is the dynamics of M2 that result in the different
orientations of the C-terminal helix. It is worth noting that the activities of penta-Ala
A/M2 mutant (F47A, F8A, I51A, Y52A and F55A) in oocyte cells showed no difference
from those of wt A/M2 in terms of surface expression level, proton conductance rate, and
drug binding, 3 suggesting the C-terminal helix does not contribute to A/M2 function. So
despite the lack of the C-terminal helix in the X-ray crystal structure construct (25-46),
the TM domain alone is sufficient to form functional tetramer that is conducive to drug
binding.23 Thus A/M2TM (22-46) is a valid model to study M2 structure and function.

2.3 Identification of the pharmacologically relevant A/M2 drug binding site
In order to definitely assign the drug binding site, the critical experiment is to detect the
drug-protein intermolecular nuclear Overhauser effect (NOE) signals by NMR. In doing
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that, we first need to identify experimental conditions that allow for reconstitution of
A/M2 fragments into a native-like conformation. The longer sequences A/M2TMC (2262) and A/M2TMC (18-60) gave good dispersion and the correct number of accountable
peaks in the

1

H-15N HSQC spectra when reconstituted in LPPG24 and DHPC13

respectively, indicating conformational homogeneity. However, under both conditions,
A/M2TMC did not show or failed to be amenable to drug binding, indicating a nonnative like conformation. Thus, a broader detergent/lipid screening is needed to identify
the right conditions for reconstituting A/M2TMC into a native-like structure. Instead, we
focus on the TM helix of M2-A/M2 (22-46), previously shown to be necessary and
sufficient for tetramerization, proton channel formation, and drug binding3. In chapter 3,
in collaboration with Dr. Mei Hong in Iowa State University, we showed by solid-state
NMR (ssNMR) spectroscopy that two amantadine- binding sites exist in A/M2TM in
phospholipid bilayers using distance measurements between

13

C-labeled A/M2TM (22-

46) and 2H-labeled amantadine (Amt).1 The high affinity site, occupied by a single
amantadine, is located in the N-terminal channel lumen, surrounded by residues mutated
in amantadine-resistant viruses, consistent with the X-ray structure. The second, lowaffinity, site was observed on the C-terminal protein surface as shown in the solution
NMR structure, but only when the drug reaches high concentrations in the bilayer. The
tilt angle and dynamics of the drug are distinct in the two sites, as shown by
2

HNMR.These results indicate that amantadine physically occludes the M2 channel and

rules out the allosteric inhibition mechanism proposed based on the exterior drug binding
site. A recent magic angle solid state NMR study investigated rimantadine binding to
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A/M2

(18-60)

in

both

1-hexadecanoyl-2--(9Z-octadecenoyl)-sn-glycero-3-

phosphocholine (POPC) and 1,2-diphytanoyl-sn-glycero-3-phosphocholine (DPhPC)
bilayers. The large chemical shift induced upon drug binding mapped across the entire
transmembrane region indicating drug binding by conformational selection, instead of
allosteric inhibition as proposed.25

In chapter 4, the dynamics and orientation of amine-containing drugs in the pore of the
A/M2TM was further investigated by solution NMR. The orientation of the polar amine
inside the channel is important as it reveals the mechanism of drug inhibition, whether it
physically occludes the channel or it perturbs of pKas of His37 by water mediated
hydrogen bonding (Figure 2.2). Using
experiments (REDOR) of

13

13

C-2H rotational-echo double-resonance NMR

C-labeled A/M2TM (22-46) and methyl deuterated

rimantadine, it was found that the polar amine pointed to the C-terminus of the channel,
near Gly34, thus supporting the hypothesis that the drug forms hydrogen bonds with
water molecules associated with His37. Drug titration of A/M2TM (22-46) in
dodecylphosphatidylcholine (DPC) micelles monitored by 1D proton NMR revealed that
drug bind in the pore at a stoichiometry of one drug per channel. Moreover, drug binding
causes significant chemical shift perturbations of the protein, consistent with those
observed for A/M2TM (22-46) and A/M2 (18-60) in phospholipid bilayers, but distinct
from the A/M2(18-60) structure in 1,2-diheptanoyl-sn-glycero-3-phosphatidylcholine
(DHPC) micelles. These data suggest that the structure of the cytoplasmic helix Cterminal to the transmembrane domain adopts a non-native conformation in DHPC
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micelles, which may have indirectly altered the conformational and drug binding
properties of the protein.
a)

b)

Figure 2.2 | Docked conformations of amantadine inside the pore of A/M2TM tetramer
with up or down amine orientations. A/M2TM structure was taken from the high
resolution X-ray crystal structure. (PDB code: 3LBW).

Additional evidence supporting a pore binding model includes drug binding
stoichiometry measurements in different lipid/detergent compositions and sample
preparation conditions. Trp41 fluorescence changes upon drug titration with full length
M2 reconstituted in N,N-Dimethyldodecylamine N-oxide (LDAO) micelles revealed 1:1
drug per A/M2 tetramer binding.26 Surface plasmon resonance (SPR)27 and isothermal
titration calorimetry (ITC)3 measurements in liposomes, which are better mimics of the
lipid bilayer viral environment, both showed one drug per tetramer binding
stoichiometry. The critical residue D44, as proposed in the allosteric binding mechanism,
turned out to be not essential for A/M2 inhibition, as the D44A mutant was completely
inhibited by amantadine in a dose dependent manner in two electrode voltage clamp
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(TEV) assays.4 Taken together with our NMR distance measurement, we can conclud that
amantadine inhibits A/M2 by binding inside the channel.

2.4 Synthesis of A/M2 fragments for structural studies
Throughout the course of structural studies of M2, tens to hundreds of milligram
quantities of M2 peptides are needed. Solid phase synthesis of peptides and proteins has
the advantage over biological expression in terms of large scale production and selective
incorporation of isotopically labeled or unnatural amino acids in any desired position.28
However, solid phase synthesis of peptides, especially hydrophobic membrane segments,
often gives truncated products that are difficult to separate. The major problems of
hydrophobic membrane peptide segments synthesis include aggregation of elongating
peptide chains among themselves or with the resin matrix, incomplete deprotection,
racemization and side reactions such as aspartimide formation (Figure 2.3). Initial trial
synthesis of the M2 transmembrane domain (22-46) using the traditional Fmoc chemistry
on rink amide resin at room temperature gave low crude yields (<30%), Yields slightly
improved to 45% with double coupling at each step. Impurities, which eluted as shoulder
peaks of the desired peptide, were difficult to separate and often required two or even
three rounds of HPLC purification. The synthesis was optimized in several aspects: (1)
Hydrophilic PEG based Chemmatrix rink amide resin or ester based Clear rink amide
resin was chosen instead of the hydrophobic polystyrene based resin. This minimizes
aggregation between growing peptide chains and the resin beads. (2) The synthesis (both
coupling and deprotection) was performed at elevated temperature (75 oC) using either
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microwave irradiation or conventional heating, both were equally effective.29 The
synthesis was performed on a semi-automated Quest synthesizer with 5 mins of coupling
and deprotection at 75 oC. Up to 12 peptides can be synthesized in parallel. (3) 5%
piperazine + 0.1 M HOBt instead of 20% piperidine was used to deprotect Fmoc group.
This is to suppress a major side reaction of aspartimide formation30, 31 between Asp44
and Arg45. Using optimized conditions described above, the crude purity of A/M2TM
(22-46) was dramatically increased to ~85% with only single coupling and deprotection
steps. No significant shoulder peaks were detected (Figure 2.4 a). One round of HPLC
purification gave the final peptide at >98% purity. Subsequently, these conditions were
used for synthesis of 41 residue long A/M2TMC (21-61) that includes both the
transmemrbane domain and the C-terminal amphiphilic membrane interacting helix. The
synthesis of this longer fragment was initially found to be challenging due to the
complication of broad shoulder peaks. Subsequently, all three Arginines (Arg 45, 53 and
61) and the residues immediately following (Asp 44, Tyr52 and Lys60) were double
coupled, and this protocol gave A/M2TMC (21-61) with ~75% crude purity (Figure 2.4
b).
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Figure 2. 3 Mechanism of aspartimide side reactions.

a) HPLC trace of crude A/M2TM (22-46)
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b) HPLC trace of crude A/M2TMC (21-61)

Figure 2.4 | HPLC traces of M2 peptide fragments synthesized using the optimized solid
phase synthesis protocol. The peptide was cleaved from the resin using 95% TFA, 2.5%
TIS, 2.5% H2O. Crude peptides were dissolved in 50% B’ (59.9% isopropanol, 30%
acetonitrile, 10% H2O, and 0.1% TFA) and 50% A (99.9% H2O, 0.1% TFA) and purified
by preparative C4 reverse phase HPLC with a linear gradient of 70% B’ to 85% B’.
A/M2TM and A/M2TMC eluted at 83% and 78% B’ respectively. Purity and identify of
the peptide was confirmed by analytical HPLC and MALDI-MS.

2.5 Structure-based design of A/M2 inhibitors
A/M2 is a challenging drug target, partially due to the lack of structural information until
very recently.13, 14, 32, 33 More importantly, it is difficult to assay because the A/M2 proton
conductance function can only be monitored in a lipid bilayer environment. The
challenge to prepare large quantities of uniformly sized liposomes limits high throughput
screening of small molecule libraries in vitro. Instead, researchers working on influenza
antiviral development rely on virus induced cytopathic effect (CPE) assay,34, 35 which is
not A/M2 target specific and makes the structure and activity relationship studies
difficult. Nevertheless, there has been a substantial progress in developing in vitro A/M2
target specific high throughput assay.36
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Since most current circulating influenza viruses carry drug resistant mutations in the
A/M2 transmembrane region (like S31N, V27A and L26F),37, 38 it is urgent to develop
potent broad spectrum antivirals that are capable of targeting all influenza strains. There
are two general approaches to identifying the initial hits: high throughput screening and
structure-based rational design. High throughput screening with influenza A virus failed
to identify hits that were active against A/M2 mutants,34, 39-41 despite the fact that several
hits demonstrated inhibition against amantadine resistant viruses, but their action was
distinct from A/M2 inhibition.42 In contrast, rational design based on an adamantane
scaffold yielded a series of potent inhibitors with reduced cell toxicity. Whether these
inhibitors are active against A/M2 mutants has yet to be determined.19 We started with 2[3-azaspiro(5,5)undecanol]-2-imidazoline (BL-174), initially discovered through a highthroughput screen based on the ability of inhibitors to reverse toxicity associated with M2
channels expressed in the yeast Saccharomyces cerevisiae membranes.39 It is one of the
few examples of nonadamantane-based M2 inhibitors reported in the literature. The spiro
structure is unique, as the nearly perpendicular cyclohexane ring configuration fits the
cylinder shape A/M2 channel better than planer molecules. In chapter 5, the first
generation spiro amine compound library was synthesized and 3-azaspiro[5,5]undecane
hydrochloride (M2WJ10) was found to be the one of the most potent wt A/M2 inhibitor
so far (IC50 = 0.92 ± 0.11 μM)43 (Figure 2.5). Structure and activity relationship (SAR)
studies found that the simple amine is the favored head group, and hydrophobicity is
critical for high affinity binding as active inhibitors all had LogP > 1.5. In chapter 6,
further modifications to extend the piperidine in M2WJ10 to cyclohexane amine gave
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spiro[5.5]undecan-3-aminium chloride (M2WJ34),44 which was active against the wt
A/M2, but more importantly for the first time showed moderate inhibition against A/M2V27A mutant (IC50 = 84.9 ± 13.6 μM). Mutation of the bulky V27 to smaller alanine
residue appears to create a larger binding pocket which favors binding a more extended
molecule. Following this rational, in chapter 7, a series of ring expanded spiran amines
were designed and synthesized, and all had improved potency against A/M2-V27A
mutant compared with M2WJ34. A spiroadamantane inhibitor (M2WJ206) designed to
occupy the extra space created by the V27A mutation was found to be highly potent
against wt, V27A and L26F mutants, and this compound is currently undergoing tests in
animals. In chapter 8, introducing silicon in the quaternary spiro center increases both the
size and hydrophobicity of the inhibitor, and the silaspiran amines were indeed more
potent than their carbon counterparts. Finally, guided by structural and activity
relationship study results provided above, a library of scaffold and head group diverse
compounds were selected and assayed in two electrode voltage clamp assay in chapter 9.
The aim is to identify novel scaffolds and head groups that can be further optimized in
order to target the S31N mutant. It has been found that not only amine, but also hydroxyl,
aminooxyl, guanidine, amidine compounds are active against the A/M2 proton channel.
Moreover, A/M2 proton channel is able to accommodate a wide range of structural
variation in the apolar scaffold.
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Figure 2.5 | Structures of spiran amines

2.6 Perspective
To aid rational drug design, we first need high-resolution A/M2 mutant structures,
especially S31N. But due to the dynamic and conformational heterogeneity, neither NMR
nor crystallization efforts to solve the A/M2-S31N structure have been so far successful.
To identify the optimal detergents to stabilize the S31N mutant, we screened commonly
used detergents using circular dichrorism (CD) and 1H-15N TROSY-HSQC assay. Initial
results indicated that C14-betaine gave the best results, as judged by amide NH peak
dispersion, number of peaks and intensity. With this optimized reconstitution condition,
we are now pursuing to solve the A/M2TM-S31N structure by NMR. In terms of X-ray
crystallization, since there is no available small molecule drug to stabilize the S31N
tetramer, tethering the monomer together to form a covalent tetramer would presumably
stabilize the complex. Moreover, in meso cubic phase crystallization is another option
that has been successful in crystallizing a number of membrane proteins, such as
bacteriorhodopsin, cobalamin transporter, light harvesting complex etc.45 High resolution
structural information will not only clarify the drug resistant mechanism of the S31N
mutant, but also will guide the inhibitor design.
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Structure of the Amantadine Binding Site of Influenza M2 Proton
Channels In Lipid Bilayers
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3.1 Abstract
The M2 protein of influenza A virus is a membrane-spanning tetrameric proton channel
targeted by the antiviral drugs amantadine and rimantadine 1. Resistance to these drugs
has compromised their effectiveness against many influenza strains, including pandemic
H1N1. A recent crystal structure of M2(22-46) showed electron densities attributed to a
single amantadine in the N-terminal half of the pore 2, suggesting a physical occlusion
mechanism for inhibition. However, a solution NMR structure of M2(18-60) showed four
rimantadines bound to the C-terminal lipid-facing surface of the helices 3, suggesting an
allosteric mechanism. Here we show by solid-state NMR spectroscopy that two
amantadine-binding sites exist in M2 in phospholipid bilayers. The high-affinity site,
occupied by a single amantadine, is located in the N-terminal channel lumen, surrounded
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by residues mutated in amantadine-resistant viruses. Quantification of the protein –
amantadine distances resulted in a 0.3 Å-resolution structure of the high-affinity binding
site. The second, low-affinity, site was observed on the C-terminal protein surface, but
only when the drug reaches high concentrations in the bilayer. The orientation and
dynamics of the drug are distinct in the two sites, as shown by 2H NMR. These results
indicate that amantadine physically occludes the M2 channel, thus paving the way for
developing new antiviral drugs against influenza viruses. The study demonstrates the
ability of solid-state NMR to elucidate small-molecule interactions with membrane
proteins and determine high-resolution structures of their complexes.

3.2 Maintext
The M2 protein of influenza A viruses is a modular, multifunctional protein that plays
important roles in the acidification and uncoating of the endosome-entrapped virus and in
viral assembly and budding

1,4

. Its proton-conducting activity is mediated by a single

transmembrane (TM) domain that forms a four-helix bundle, which acts as a pHactivated proton channel. The TM domain alone is sufficient for tetramerization

5,6

and

for amantadine-sensitive proton conductivity in vesicles and cell membranes 7,8.

The recent low pH crystal structure of micelle-solubilized M2(22-46) shows a single
molecule of amantadine (Amt) in the N-terminal pore lumen, consistent with the known
stoichiometry of binding 8 and the location of resistant mutations, including Leu 26, Val
27, Ala 30, Ser 31, and Gly 34

9-11

. However, the low-pH state of the protein is only
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transiently populated in acidifying endosomes, whereas the drug first binds with higher
affinity to the protein near neutral pH 9. Thus, determining the structure of the drugcomplexed M2 protein at neutral pH is important for understanding its mechanism of
inhibition. The solution NMR structure of micelle-solubilized M2(18-60) at pH 7.5 failed
to show strong nuclear Overhauser effects (NOEs) between the drug and pore-lining
residues, but it would have been difficult to observe NOEs between the fast-relaxing
pore-lining residues and unlabeled rimantadine undergoing restricted motion in the pore.
Weak NOEs were observed between residues on the protein surface and the drug, which,
however, comprised 13% of the detergent in which the protein was dissolved (200-fold
excess over protein tetramers). We thus turned to solid-state NMR (SSNMR), which
allows for investigation of the dynamics and contacts of drug molecules bound at variable
concentrations to membrane proteins in phospholipid bilayers, which are far better
mimics of biological membranes than are micelles.

Rotational-echo double-resonance (REDOR) NMR is a powerful method to measure subnanometer inter-atomic distances with up to 0.1-Å accuracy 12. The M2 peptide (residues
22-46), reconstituted into DMPC vesicles at pH 7.5 under fully tetrameric conditions
contained uniformly 13C-labeled residues whose

13

6,13

,

C chemical shifts were assigned from

2D correlation spectra (Supplementary Fig. 1). Amantadine was perdeuterated, thus
enabling 13C{2H} REDOR distance measurements.
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To select for the highest-affinity binding site, we first measured the REDOR spectra of
Amt-complexed M2 at an Amt/peptide molar ratio (Amt/P) of 1:4 (one drug per
tetramer). At this stoichiometric concentration, Amt binds only to the luminal site: Fig. 1a
shows
14

13

C{2H} REDOR spectra without (S0) and with (S) multiple 2H dephasing pulses

. The Ser31 C signal is strongly dephased by the deuterons ( S S0  0.76  0.03 at 10.1

ms), indicating that Amt binds near Ser 31. In contrast, the Asp44 C signal in the


peripheral site is unaffected. A double-quantum-filtered REDOR experiment that
removed all lipid signals confirmed the lack of Asp 44 dephasing (Supplementary Fig. 2).

To search for additional, lower-affinity, binding sites, we increased the Amt
concentration to Amt P  4 : 4 , making the drug 7% of the amphiphiles composing the
bilayer, which approaches the large excess of drug in the solution NMR experiments.

 Asp44 C signal is also dephased ( S S  0.86  0.02 at 10.1 ms), but to a
Now the
0
lesser extent than Ser31 C (Fig. 1b). Thus, when free amantadine is a major component


of the membrane, Amt contacts the C-terminus of the protein as in the solution NMR
structure,

3

but without displacing the drug in the luminal site. Consistently, Amt

deuterons also dephased other residues in the luminal site, particularly Val27 C

and

Gly34 C (Fig. 1c, d), but more weakly than Ser 31. This Ser 31-proximal binding is
consistent with the large chemical shift perturbation of Ser 31 by Amt 15.
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Figure 1| Drug-protein proximities from 13C{2H} REDOR spectra of Amt-bound M2
in DMPC bilayers at two Amt/P ratios. Control (S0), dephased (S, red), and difference
(S) spectra at specified mixing times are shown. a. Ser31, Ile32, Asp44-labeled (SID)
M2 at the stoichiometric ratio of Amt P 1: 4 . b. SID-M2 at the 4-fold excess ratio of
Amt P  4 : 4 . Ser31 C is dephased under both conditions but Asp44 C is dephased
only when Amt is in excess. c-d. Leu26, Val27, Ala29, and Gly34-labeled (LVAG) M2
at Amt P  4 : 4 . c. Gly34 C region. d. Val27 C1 region.



2



H NMR provided exquisite details on the orientation and dynamics of amantadine,

whose unique symmetry and rigidity simplify analysis. Amantadine is a rigid amphiphile
with a polar amine and a hydrophobic adamantane centered around a 3-fold axis, Z M .
Three axial C-D bonds are parallel to Z M while twelve equatorial C-D bonds are at 70°

 protein-free
or 110° ( PM ) from Z M (Fig. 2d). Amantadine partitions strongly into
DMPC vesicles and exhibit2H quadrupolar splittings of 36 and 123 kHz with a 4:1


intensity
ratioat 243 K (Fig. 2a). These splittings indicate fast anisotropic rotation of the
molecule around Z M , which scales the couplings from the rigid-limit value of 125 kHz
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by 3cos 2 PM 1 2 , giving 40 kHz for the twelve equatorial bonds and 125 kHz for
the three axial bonds. Wobbling of the Z M axis by ~6° likely accounts for the additional



motional averaging. As the temperature increased to 303 K, the couplings decreased

maintaining the same 1:3 frequency ratio and 4:1 intensity
twofold (18 and 58 kHz) while
ratio. The ±0.46 scaling factor indicates Amt rotates rapidly around the normal ( n ) of the
liquid-crystalline bilayer in addition to its own axis, with Z M tilted by 37˚ or 80˚ from n



(Fig. 2e) 16.





When a stoichiometric amount ( Amt P 1: 4 ) of protein is present, the Amt spectrum at
243 K resembles the lipid-only spectrum, but the couplings remain unchanged from 243


to 303 K across the membrane
phase transition (Fig. 2b), indicating sequestration of the
drug from the lipids. The constant scaling factor (0.93) compared to pure rotation around

Z M indicates that the first equivalent of Amt rotates rapidly around n in a slightly tilted



orientation (~13˚) between Z M and n (Fig. 2d). An isotropic peak grows at high

temperature, indicating a small fraction (~12% at 303 K) of Amt either near 54.7˚ from


 or undergoing
the membrane normal
large-angle tumbling in the channel. Finally, a weak
18-kHz splitting is observed at 303 K that matches the lipid-only coupling at this
temperature. The spectrum is consistent with a 9:1 combination of the 283 K M2-bound
spectrum without the 18-kHz splitting and the 303 K lipid-bound spectrum, suggesting
that 10% of the drug partitions into the bilayer at 303 K.
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To confirm that the lumen-bound drug persists under drug excess and to probe for
additional binding sites, we measured the 2H spectra under 4-fold excess Amt over the
tetramer (corresponding to 12% of the lipid concentration). Fig. 2c shows that the
spectroscopic signatures of the lumen-bound drug persists, but the 303 K spectrum is now
the 1:3 combination of the stoichiometric spectrum (Fig. 2b) and the lipid-bound
spectrum (Fig. 2a). No additional bound species was detected. Since the 4-fold symmetry
of the channel requires four peripheral sites for each luminal site, the 9:1 intensity ratio of
the 303 K stoichiometric spectrum suggests that Amt has at least a 40-fold greater affinity
for the channel lumen than the peripheral site.

Figure 2| 2H NMR spectra of d15-Amt in DMPC bilayers as a function of
temperature and Amt/P. a. No M2. The calculated spectrum for 303 K reproduces the
1:3 frequency ratio and 4:1 intensity ratio of the two splittings. b. Amt P 1: 4 . The sum
60



spectrum reproduces the 303 K spectrum by 1:9 combination of the lipid-bound 303 K
spectrum and peptide-bound 283 K spectrum (not shown). c. Amt P  4 : 4 . The sum
spectrum uses a 1:3 combination of the M2-bound spectrum (II) and lipid-bound
spectrum (I). d. Amt orientation in the M2 channel. e. One of the two possible Amt
orientations in the lipid bilayer.

These 2H NMR and distance data indicate that M2 has a single high-affinity site for
amantadine, located in the channel lumen centered at Ser 31. In this site, Amt is nearly
aligned with the channel axis, but given sufficient thermal energy a small fraction of drug
is also able to undergo nearly isotropic motion, as suggested by molecular dynamics
simulations

17,18

. Excess Amt adopts a significantly tilted orientation in the membrane,

with or without the protein. The peripherally bound rimantadines in the solution NMR
structure are tilted by 80˚ 3, precisely one of the two possible orientations found for the
lipid-associated drug. Since the same peripheral site is detected here in the TM peptide,
its existence is independent of the protein length or the membrane environment; it is the
result of excess drugs in the micelles and lipid bilayers.

To determine the sub-angstrom resolution structure of the high-affinity binding site, we
quantified the M2-Amt distances using an alternative REDOR experiment containing
multiple

13

C pulses and one 2H pulse, thus minimizing 2H pulse imperfections and

yielding REDOR intensities closely following the universal curve 19 (Supplementary Fig.
3). The experiment yielded significantly faster REDOR dephasing (Fig. 3) while
confirming the relative dephasing of different sites in Fig. 1.
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Due to the 4-fold symmetry of the tetramer, we parameterized the REDOR simulations in
terms of the distance R of each peptide carbon from the channel axis and the distance Z
of each carbon plane from the Amt center (Fig. 3c). We considered the twelve deuterons
in the two equatorial planes with rotational averaging and neglected the three axial
deuterons due to poor inversion of their broad 2H spectra. A series of REDOR curves
were calculated for R of 2.7–6.2 Å and various Z values for each R, capturing the
geometry of previous M2 structural models, (Fig. 3d-f). The curves are quite sensitive to
geometry. The Ser31 C pore radius is most tightly constrained, to 5.7–6.3 Å. Larger R
would not give sufficient dephasing even when Z  0 while smaller R would shift the
drug up or down the channel too much to comply with the observed intensities of Val27
C1 and Gly34 C. The best-fit Z places
 Ser31 C in the middle of the two planes of
deuterons.
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Figure 3| M2-Amt distance quantification. a-b. 13C{2H} REDOR spectra of Amtbound M2 ( Amt P  4 : 4 ) obtained by the single-2H-pulse REDOR. a. SID-M2 at 4.2
ms mixing. b. LVAG-M2 at 6.1 ms mixing. c-f. REDOR simulations. c. Definition of the
pore radius R and height difference Z from the center of Amt. d. Ser31 C simulation. e.
Val27 C1 simulation. f. Gly34 C simulation.

We computed an ensemble of structures using these protein-drug distances and previous
SSNMR constraints. The structures cluster tightly with a heavy-atom root-mean-square
deviation (RMSD) of 0.3 Å (Fig. 4). The four helices are kinked at Gly 34, with the
helical axis tilted by 30˚ for the N-terminal segment and 19˚ for the C-terminal segment,
consistent with 15N SSNMR orientational constraints 20. The narrowest points of the pore
lie at the N-terminal Val 27 and C-terminal His 37/Trp 41, which are responsible for pH
sensing and proton conduction

21

. Amantadine fits snugly into the N-terminal lumen,
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surrounded by residues whose mutation confers resistance 9. The surrounding backbone
amides and Ser31 hydroxyl group engage in intra-helical hydrogen bonding, imparting a
hydrophobic character to the site. The luminal binding indicates that M2 inhibition is by
physical occlusion, interrupting water-wires and perturbing the protonation equilibrium
of His37

22

. The N-terminal location is consistent with the fact that Amt inhibits only

when added to M2-expressing cells from the outward-facing N-terminal side 9. Moreover,
the V27 vestibule is too small to permit drug dissociation without a 1–2 Å radial
expansion, consistent with the very slow association and dissociation of the drug
compared to a diffusion-controlled process 9. Finally, the drug is most likely oriented
with the adamantane packed against the hydrophobic Val27 sidechains and the polar
amine towards the cavity near His 37 residues, whose pKa’s are affected by Amt binding
22

.

Figure 4| SSNMR structure of Amt-bound M2 in lipid bilayers. a. Side view showing
Ser 31, Val 27, Gly 34, His 37, Trp 41, and Amt in the high-affinity luminal site. Ser31
C lies in the mid-plane between the two rings of deuterons. The instantaneous
orientation of Amt, which is slightly tilted from the channel axis, is shown. The timeaveraged Amt orientation is parallel to the channel axis. b. Top view showing the Ser 31
and Val 27 pore radii. This ribbon diagram was generated using the program Insight II.
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The present SSNMR structure has significant differences from previous proposed
structures of the Amt-M2 complex

2,3

. While the drug location is very similar to that of

the low-pH crystal structure, the shape of the binding site differs dramatically (3.4-Å C
RMSD between the structures). In the crystal structure, the helices splay far apart near the
C-terminus (Fig. 5b), to minimize electrostatic repulsions among the protonated His 37.
In the high-pH SSNMR structure, the helices close off the bottom of the site, fully
sequestering the drug and explaining the improved affinity at higher pH (Fig. 5a). The
backbone of the SSNMR structure is more similar to the high-pH solution NMR
structure, with comparable distances involving Val27 C, Ser31 C, and Gly34 C
(Supplementary Fig. S5). Thus, the drug may have been present in the lumen in the
solution NMR sample but not observable without isotopic labeling. Alternatively it
might have been truly absent from the lumen due to reduced affinity to the micelle-bound
and structurally plastic protein

23-25

. The current high-resolution structure also revises an

earlier SSNMR chemical-shift-constrained M2 model, where the lack of protein-drug
distances resulted in a large N-terminal vestibule, which would yield a highly solventaccessible low-affinity drug (Supplementary Fig. S6-S7).
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Figure 5| Comparison of the high-pH SSNMR structure of Amt-bound M2 in lipid
bilayers with the low-pH crystal structure of Amt-bound M2. a. Side view of the
high-pH SSNMR structure, showing Amt to be enclosed by Val 27 at the top and His 37
at the bottom. b. Side view of the low-pH crystal structure 2. The helices are splayed far
apart near the C-terminus. c. C-terminal view of the high-pH structure, showing a wellsequestered drug. d. C-terminal view of the low-pH structure, showing a more solventaccessible drug. The figure was generated using the program PyMOL.
What is the significance of the peripheral site? Since it is occupied only at drug/lipid or
drug/detergent ratios above 7 mol%, the protein-drug interactions at this site must be
weak, and largely a consequence of the high local concentration and preference of the
drug for the membrane-water interface

16

. The peripheral site may in some way be

related to the partial inhibition of M2 by polyamines in the absence of sodium ions 26.
Since amantadine undergoes significant motion in the N-terminal lumen, its structure
appears to be not fully optimized to fit the M2 channel. Thus, other drugs may be
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designed to access the most conserved regions of the pore and evade drug resistance.
Indeed, a potent and structurally distinct class of inhibitors has been recently reported that
binds the same site 27. Solid-state NMR spectroscopy, especially the multi-deuteron 13C2

H distance strategy, opens a new avenue for structure elucidation of drug-complexed

membrane proteins in lipid bilayers, yielding distances with longer range and higher
accuracy than NOE measurements in solution.

3.3 Methods Summary
The

13

C-labeled wild-type Udorn M2(22-46) peptide was synthesized by solid-phase

methods and reconstituted into DMPC bilayers at pH 7.5 by detergent dialysis
fully tetramerized protein in the liposomes 6.

13

25

, giving

C{2H} REDOR experiments were

conducted on a 9.4-Tesla wide-bore NMR spectrometer (Bruker Biospin) using a 4 mm
1

H/13C/2H MAS probe. The distances were measured at 243 K, where the peptide was

immobilized

28

while Amt was uniaxially mobile. Static 2H spectra were measured on a

14.1-Tesla SSNMR spectrometer.

An ensemble of 17 lowest-energy SSNMR structures was computed using 24 (6x4) longrange

13

C-2H distances, four inter-helical distances among Trp41 indole rings

(15x4) backbone amide orientational constraints

20

13

, 60

, two sidechain rotamer constraints

29

,

and idealized covalent geometry. For comparison, the previous solution NMR M2
structure ensemble was constrained by 12 inter-helical NOEs and 18 amide residual
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dipolar couplings for the TM region 3. The structure ensemble has been deposited in the
Protein Databank (ID: 2KQT) and the BMRB (ID: 16612).

3.4 METHODS
Sample

preparation.

The

wild-type

Udorn

SSDPLVVAASIIGILHLILWILDRL was synthesized with

M2(22-46)
13

sequence

C, 15N-labeled amino acids

at Leu 26, Val 27, Ala 29 and Gly 34 in one sample (LVAG), and Ser 31, Ile 32, and Asp
44 in another sample (SID). The peptide was reconstituted into DMPC vesicles by
detergent dialysis using octyl--D-glucopyranoside. The peptide/lipid molar ratios were
1:8 for all 2H NMR experiments and 1:8 or 1:15 for the REDOR experiments. A
phosphate buffer (pH 7.5) was used for lipid vesicle preparation and throughout detergent
dialysis. The dialyzed proteoliposome solutions were centrifuged at 150,000 g to obtain
~40% hydrated membrane pellets. Amantadine was directly titrated into the membrane
pellet to the desired amount.

Solid-state NMR spectroscopy. A triple-resonance 1H/13C/2H magic-angle-spinning
(MAS) probe was used for the 13C-2H REDOR experiments and a 1H/13C/15N probe was
used for 2D correlation experiments for resonance assignment. The 2H pulse length in the
REDOR experiments was 6.2 s, and 13C and 15N pulse lengths were 5-6 s.

13

C-2H REDOR experiments were carried out at MAS frequencies of 4250 Hz or 4750

Hz. A REDOR pulse sequence containing a single selective

13

C pulse and multiple
68

composite 2H pulses was used to obtain clear qualitative dephasing at long mixing times,
since the selective 13C pulse suppressed the 13C-13C scalar coupling and gave rise to long
13

C T2 relaxation times. However, the use of multiple 2H pulses is known to slow down

dipolar dephasing by the cumulative effects of imperfect inversion of the broad 2H
quadrupolar spectra
multiple

13

30

. Thus, a second version of REDOR experiment consisting of

C non-selective pulses and a single composite 2H pulse was carried out to

obtain quantitative dephasing values at shorter mixing times. Distance quantification was
possible because the multiple heteronuclear couplings commute and the uniaxial rotation
of amantadine removes the effects of 2H-2H homonuclear couplings. Perdeuteration
speeded up

13

C-2H REDOR dephasing by ~ 15 -fold compared to a single

13

C-2H pair.

The inversion efficiency of the deuterons in the single-2H-pulse REDOR experiment was
70% based on measurements 
of the model compound

13

C, 2H-labeled alanine

(Supplementary Fig. 3).

REDOR distance simulations. Using a motionally averaged model, we calculated
REDOR curves for various published M2 models (Supplementary Fig. S4-6), with pore
radii R of 2.7 – 6.2 Å. For each R, several REDOR curves with different Z values were
calculated. The best-fit Z values for a specific R were compared with the carbon plane
separations in the structural model. Plane separations that are inconsistent with the
differences in Z values exclude the structural model. The Ser31 C pore radius is
constrained by the M2-drug distances to be 5.7 – 6.3 Å. Once amantadine is confined
within 1 Å vertical distance of the Ser31 C plane, the Val27 C1 and Gly34 C pore
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radii are jointly constrained by the Val27 C1 – Gly34 C plane separation, which is 10.5
± 1.0 Å in all M2 structures so far. We found that neither RV nor RG can exceed 6.0 Å,
as it would lead to overly small plane separations.





In the final refined SSNMR structure, Val27 C1 is fit by RV  3.8 Å with ZV  5.3 Å ,
indicating that the Val27 C1 plane is 5.3 Å above the center of amantadine. Gly34 C is


fit by RG  4.9 Å with a distance of 5.0 Å below the amantadine center.

 Structure calculation and refinement.

The process of generating a helix that is

consistent with the protein-drug distances, backbone N-H orientational constraints, and
sidechain rotameric conformations, was carried out in two phases. In the first phase, we
constructed an ideal helix with the sequence SSDPLVVAASIIGILHLILWILDRL whose
/ angles were set to (-65˚, -42˚). The helix was then split at the Gly34-Ile35 bond and
reconnected using a rigid-body optimization procedure that maximized agreement with
the SSNMR 15N-1H dipolar couplings 20 and the internal geometry at that bond. Rotamer
preferences were taken from the high-resolution X-ray structure of M2 (PDB ID: 3BKD).
25 In the second phase we refined our model to maximize agreement with the

13

C-2H

REDOR distances (Supplementary Table S2) and the backbone 15N-1H dipolar couplings
(Supplementary Table S3). To do this, we combined an inverse kinematics algorithm
with a Monte Carlo/Simulated Annealing (MC/SA) minimization procedure that would
gradually relax the backbone of the helix subject to REDOR distance constraints and the
N-H dipolar couplings. Rotamer preferences were also changed to maximize agreement
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with the χ1 angle constraints (Supplementary Table S4).

The MC/SA minimization

procedure was used to generate an ensemble with a maximum heavy-atom RMSD of 0.3
Ǻ between any two models. Since the REDOR distances provided excellent constraints
between the drug and M2, we positioned the amantadine molecule near Ser 31 without
the need for further minimization. Fig. 5 was created using the PyMOL Molecular
Graphics System.

Supplementary information is linked to the online version of the paper at
www.nature/com/nature.
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(A) Chemical shift assignment of amantadine-bound M2 in DMPC bilayers.

Supplementary Figure S1. 2D 13C-13C and 15N-13C correlation spectra of amantadinebound M2(22-46) in DMPC bilayers for chemical shift assignment. (a) 2D DARR
spectrum of LVAG-M2 (L26, Val27, A29, and Gly34 labels) with 40 ms mixing. (b) 2D
DARR spectrum of SID-M2 (S31, I32 and D44 labels) with 40 ms mixing. (c) 2D 15N13
C correlation spectrum of LVAG-M2. (d) 2D 15N-13C correlation spectrum of SID-M2.
All spectra were measured at 243 K under 7 kHz MAS.
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Supplementary Table S1. 13C and 15N isotropic chemical shifts of amantadine-bound
M2(22-46) in DMPC bilayers. 13C chemical shifts are referenced to -Gly 13CO (176.4
ppm) on the TMS scale and 15N chemical shifts are referenced to 15N-acetylvaline (122.0
ppm) on the NH3 scale.
Residue
L26

Val27

A29

Site
N
C’
C
C
C
C
C
N
C’
C
C
C
C
N
C’
C
C

 (ppm)
117.5
176.3
55.8
39.5
25.1
24.2
21.2
119.8
178.3s, 177.5w
61.4s, 64.2w
29.6
21.2
19.3
121.6
177.0
53.4
16.2

Residue
Ser31

I32

Gly34

D44

Site
N
C’
C
C
N
C’
C
C
C1
C2
C
N
C’
C
N
C’
C
C

 (ppm)
120.8s, 114.1w
172.8
61.0
59.5
122.8
175.6
64.0
35.9
28.2
15.2
12.4
110.2
175.1
44.9
118.7
175.7
55.6
42.4
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(B) Additional 13C-2H REDOR spectra, REDOR simulation details and model
compound result

Supplementary Figure S2. Double-quantum filtered 13C{2H} REDOR spectra of
amantadine-bound M2 in DMPC bilayers. As shown before 1, the experiment
incorporates a SPC5 dipolar recoupling sequence 2 before the REDOR period to generate
13 13
C- C double-quantum coherences, which suppress all natural abundance 13C signals of
the lipids in the spectra. The experiments were carried out at 243 K under 4750 Hz MAS.
(a) SID-M2 spectra at Amt/P = 1:4, corresponding to a stoichiometric amount of Amt per
channel. The D44 C signal shows no dephasing. (b) SID-M2 spectra at Amt/P = 4:4,
corresponding to 4-fold excess Amt to channel. D44 C is now dephased to a small
extent, indicating that the excess amantadine binds to the C-terminus near D44. Ser31
C is dephased significantly at both amantadine concentrations, thus it is the highaffinity binding site.
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13

C-2H REDOR simulations. The dephasing of a 13C spin in the peptide by the
recoupled dipolar fields of 12 equatorial deuterons on the amantadine molecule was
simulated in detail by considering the uniaxial rotation of amantadine. The coupling of
13
C to 15 deuterons increases the second moment (i.e. the sum of the squares) of the 13C2
H dipolar couplings 15-fold compared to a single 13C-2H spin pair, thus speeding up the
dephasing by a factor of 15  3.9 .
The three axial deuterons have a three times wider spectrum, which makes their inversion
significantly incomplete under the 2H 90˚ pulse length of 6.2 s. Thus, they were

neglected in the simulations.
The inversion efficiency of the 12 deuterons was about 70%, as determined by
measurements on Ala-CD3 (Supplementary Figure S3), which has a very similar
motionally narrowed 2H spectrum to amantadine.
The geometry of the 12 equatorial amantadine deuterons is as follows. Six deuterons are
located on one ring of 2.20 Å radius centered on the C-N bond axis. The other six
deuterons lie on two rings of 2.48 Å radius that are so close (separated by only 0.37 Å)
that they were combined into one ring. The planes of the two rings are separated by 2.10
Å along the C-N axis.
The orientation-dependent 13C-2H REDOR frequency ( CD ) under MAS is

CD ,,r  CD r



2
 sin2sin  ,


(1)

where  is the polar angle between the C-D vector and the rotor axis and  is the
azimuthal angle of the internuclear vector around the rotor axis. The coupling constant
CD depends on the13C-2H distance r according to:

  
1
CD r  2 0 C 3 D  2 9.3 kHz
3
4
r
r 1Å








(2)



The CD values were calculated for ,  and r values that correspond to various locations
of the deuterons on each ring, which are sampled at 10˚ steps around the channel axis.

Since each ring undergoes uniaxial rotation, the REDOR frequencies were then averaged
to give CD .
For 13C coupled to an I = 1 spin of a deuteron, the 2I + 1 = 3 allowed values of the zcomponent of the deuterium spin angular momentum result in three equally spaced
 spectral lines of equal intensity, at 0 and ± CD , for each orientation of the C-D vector.
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Thus, the single spin-pair
channel orientation is:

13

C-2H REDOR time signal after N rotor periods, t r , for one

S

S0 single spin pair  1 2cosCDNt r  3.


(3)

For M deuterons, the REDOR time signal is the product of the single-spin-pair signals,



S

1
S0 M spin pairs  M  M
m1 1 2cosCD,m Nt r  .
3





(4)

Due to the fast rotation of the amantadine molecule around the C-N axis, all six deuterons
on each ring have the same motionally averaged 13C-2H dipolar coupling. Thus, the

A
B
motionally averaged REDOR frequencies for each ring, CD
and CD
, are multiplied to
13
give the total REDOR signal experienced by each peptide C:

S S0 12 amantadine deuterons 









 
6 
6
A
B
1
2cos

Nt

1
2cos

Nt
CD r 
CD r 

 


312 
1

(5)

This REDOR signal is finally powder averaged for all channel orientations relative to the
rotor axis. Powder averaging was performed in a molecule- (peptide-) fixed frame, by
sweeping the rotor-axis orientation over the surface of a unit sphere and by rotation
around the rotor axis, each in 10˚ steps.
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Supplementary Figure S3. 13C-2H REDOR data of 13C, 3,3,3-2Hlabeled alanine for
determining the amplitude scaling of the single-2H-pulse REDOR experiment.
(a) The REDOR pulse sequence contains a single 2H composite  pulse (90˚90˚90˚) of
18.6 s in the middle of the mixing period, and multiple 13C  pulses of 10 s spaced half
a rotor period apart. The phase cycles are: 1= +x +x +y +y –x –x –y –y; 2 = 1, 1 +90˚,
1 +180˚, 1 +270˚; 3= R, R+90˚, R+180˚, R+270˚, where R is a 32-step cycle of (1
+90˚, 1 +180˚, 1 +270˚, 1); The receiver phase 4= Q, Q, Q, Q, -Q, -Q, -Q, -Q, where
Q = +x –x +y –y –x +x –y +y.
(b) Representative REDOR control (S0) and dephased (S) spectra of 13C, 3,3,3-2H
labeled alanine diluted in unlabeled alanine at a 1:9 ratio. The spectra were measured at a
MAS frequency of 4.250 kHz. The C signal experiences significant dephasing to the
three intramolecular methyl deuterons, whereas the C signal mostly (90%) results from
2
H-unlabeled alanine without any significant dephasing.
(c) REDOR S/S0 values (circles) and simulations (solid lines). Black line is the
SIMPSON simulation 3 for an ideal -function 2H pulse, which completely inverts the 2H
quadrupolar spectra. The motionally averaged 13C - 2H dipolar coupling is 364 Hz for
each of the three 13C-2H spin pairs based on the crystal structure C–H distance of
2.04 Å 4. The simulation curves have been corrected for the natural abundance 13C
intensity. The time point for the first REDOR minimum from the simulation is very
similar to that of the experimental data, verifying that this single 2H-pulse REDOR
experiment does not slow down dipolar evolution 5. The effects of incomplete inversion
of the 2H spectrum and the imperfection of the 2H pulse is manifested as a 70% scaling of
the theoretical maximum dephasing to the measured dephasing. This scaling factor is
used for all simulated M2-amantadine REDOR time signals.
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(C) REDOR simulations for various M2 structural models

Supplementary Figure S4. Simulations of Val27 C1, Ser31 C and Gly34 C 13C{2H}
REDOR data using the pore sizes of the low-pH crystal structure of amantadine-bound
M2(22-46) (PDB code: 3C9J) 6. Val27 C1 has a best-fit ZV of –6 Å while the Gly34 C
best-fit ZG is 3.5 Å. Ser31 C has a best-fit Z of 2 Å or –2 Å. Either ZS value agrees only
marginally with the Val27 C1 – Ser31 C plane separation (4.8 Å) and the Ser31 C Gly34 C plane separation (4.6 Å) in the model. Thus, the low-pH structure of Amtbound M2 in detergent is different, as expected, from the high-pH SSNMR structure of
bound M2 in lipid bilayers.
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Supplementary Figure S5. Simulations of Val27 C1, Ser31 C and Gly34 C 13C{2H}
REDOR data using the pore sizes of the solution NMR structure of DHPC micelle-bound
M2(18-60) (PDB code: 2RLF) 7. The two Val27 C carbons have similar R values in this
structural model. The 19.5-ppm Val27 C signal in the REDOR spectra has been recently
stereospecifically assigned to C1 8. To be complete, the pore radii of both C1 and C2
in the solution NMR structure were used in the REDOR simulations. For the C2 radius
of 3.6 Å, the best-fit ZV of -5.7 Å ± 0.5 Å combined with the Gly 34 best-fit ZG of 5.0 ±
0.5 Å gives a Val27 C2-Gly34 C height difference of 10.7 Å, which is inconsistent
with the C2-C plane separation of 12.2 Å in the structure model. If Val27 C1 is
considered, then its best-fit ZV of -5.5 Å indicates a height difference of 10.5 Å from
Gly34 C, which agrees well with the Val27 C1 – Gly34 C plane separation of 10.7 Å
in the structure. However, the Ser31 C best-fit ZS of either 1 Å or -1 Å does not agree
well with the height of the Ser31 C in the structure model, which is equidistant between
Val27 C1 and Gly34 C. Thus, the solution NMR structure is not fully consistent with
the M2-Amt distances.
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Supplementary Figure S6. Simulations of Val27 C1, Ser31 C and Gly34 C 13C{2H}
REDOR data using the pore sizes of the DLPC bilayer-bound M2(22-46) structure (PDB
code: 2KAD) obtained from SSNMR 9. The best-fit ZV, using the Val27 C1 pore radius
of 6.2 Å in the structure, is -3.5 Å. The best-fit ZG for Gly34 C is 4.5 ± 0.5 Å. The
resulting Val27-Gly34 height difference of 8.0 Å is significantly smaller than the 9.5 Å
plane separation in the model. Thus, this model is not consistent with the M2-amantadine
distance results.
The DMPC-bound M2(22-46) structure model (PDB: 1NYJ) obtained from orientedsample SSNMR experiments 10 is similar to the 2KAD model. Thus it is also not
compatible with the REDOR distance constraints. In the 1NYJ model, the Val27 C1
pore radius is even larger (7.3 Å), which would result in an even shorter ZV.
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Supplementary Figure S7. Comparison of SSNMR structures of M2 in lipid bilayers
determined with and without protein-amantadine distances. a. Current structure
restrained by protein-drug distances (PDB: 2KQT). The side view shows the closest
contact between amantadine and Ser 31 (magenta). The N-terminal top view shows that
the drug is tightly enclosed in the protein. b. Structural model restrained by 13C, 15N
chemical shifts and three inter-helical distances but no protein-drug distances (PDB:
2KAD). The drug location in the picture is hypothetical 9. The N-terminal view shows a
more solvent-accessible binding pocket. The ribbon diagrams were generated using
Insight II and the space-filling models were generated using PyMOL.
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Supplementary Table S2.
Planes
V27 C1 – S31 C
S31 C - G34 C
V27 C1 – G34 C
Carbons
V27 C1
S31 C
G34 C

13

C-2H M2-Amt distances from REDOR measurements.

Plane separations (Å)
5.3 Å
5.0 Å
10.3 Å
Pore radius (Å)
3.8 Å
5.9 Å
4.9 Å

Uncertainty
± 0.5 Å
± 0.5 Å
± 1.0 Å
Uncertainty
± 0.5 Å
-0.2 Å, + 0.4 Å
± 0.5 Å
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(D) Computation procedure for the SSNMR structure ensemble of amantadinebound M2 in lipid bilayers
An ideal helix with the sequence SSDPLVVAASIIGILHLILWILDRL was constructed
using standard internal geometry and by setting the () values to (-65˚, -42˚). Side
chain rotamer conformations were taken from the high-resolution M2 crystal structure
(PDB ID: 3BKD). The ideal helix was then split at the Gly34-Ile35 amide bond to
generate two separate helices. Each helix fragment was then transformed to the global
frame of reference such that the helical axes were coincident with the global Z axis. The
Gly34-Ile35 bond was then rebuilt using a rigid-body optimization procedure composed
of a harmonic potential to optimize the internal geometry between Gly34-Ile35, and a
harmonic potential to optimize the fit to the 15N-1H dipolar couplings from SSNMR 11.
To simplify coordinate transformation, Gly34 C was set as at the origin. The rigid-body
optimization procedure resulted in a helix that agreed with the N-H bond orientations to
within ±10˚ of the previous SSNMR results.
To maximize agreement with the 15N orientational constraints further, an inverse
kinematics algorithm (IKA) was used to gradually relax the backbone 12. To reduce largescale movements between the N-terminal and C-terminal segments of the helix, the
wriggling algorithm was used to construct a set of suitably local dihedral-angle moves
along the protein chain without distorting the internal bond lengths and bond angles. The
stochastic nature of this algorithm allowed us to easily integrate in a Monte
Carlo/simulated annealing (MC/SA) minimization strategy. Thus, small random
perturbations to the () angles (up to ±1º) were introduced along the backbone of the
helix subject to the following potential:
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The temperature was initially set to 106 K and decreased by 10% every 100 steps until a
temperature of 25 K was reached. The constants (CI-CIV) were obtained through a trialand-error process. Some side chain rotamers were changed to maximize agreement with
the radial distances (Supplementary Table 2). An ensemble of models was obtained by
selecting the top scoring model after one round of MC/SA minimization and refining
again with the IKA. The constant CIII was set to 50 kcal/mol-radian2. Since the radial
distance provided excellent restraints between the drug and M2, we were able to position
the amantadine molecule near S31 without the need for further minimization.
A brief description for each of the terms in the above potential energy function is
provided below:
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1) Radial potential—used to improve the fit between the distance belonging to atoms in
Supplementary Table S2 and the channel axis (i.e., the global Z axis). The constant CI
was set to 1000 kcal/mol-Ǻ2.
2) Dipolar angle potential—used to improve the fit with the 15N dipolar coupling data
measured by SSNMR (PDB ID: 2H95) (Supplementary Table S3) 11. The angle θ is
measured between the channel axis and the bond vector formed between the amide
backbone nitrogen and the corresponding amide hydrogen. The constant C II was set to
1000 kcal/mol-radians2.
3) Dihedral potential—used to maintain the helical geometry by forcing the dihedral
angles to stay in an acceptable region of Ramachandran space. The constant C III was set
to 100 kcal/mol-radians2. The starting dihedral angle value was set as the target value.
4) Distance potential—used to maintain the helical geometry by forcing the hydrogen
bond distances between the backbone of the ith carbonyl-oxygen and i+4th nitrogen to
remain close to the starting value. This potential was also used to restrain the Trp41
distance in Supplementary Table S4. The constant CIV was set to 100 kcal/mol-Ǻ2.
5) Lennard-Jones potential—the parameters for this potential were taken directly from
the CHARMM22 force field parameter file in XPLOR-NIH 13. Interactions between the
ith and i+4th bonded neighbor interactions were not considered and non-bonded cutoffs
were not utilized. After each pass of the local sampling algorithm, a C4 operation about
the channel axis was performed to generate the four equivalent chains before calculating
the energy.
Supplementary Table S3. N-H vector angles with respect to the channel axis used to
constrain the current structure. The angles are based on 15N SSNMR data of M2 in
DMPC bilayers at high pH with amantadine bound (PDB: 2H95) 11.
Residue Angle (º) Residue Angle (º)
V27
17.2
H37
NA
V28
40.1
L38
12.0
A29
43.5
I39
31.5
A30
29.8
L40
32.7
S31
26.4
W41
9.74
I32
44.1
I42
15.5
I33
36.1
L43
43.0
G34
15.5
D44
17.2
I35
31.5
R45
40.1
L36
32.1
L46
43.5
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Supplementary Table S4. Additional restraints for M2 structure calculation.
Residue
V27
V28
Residue
W41 5-19F (Hz3)

 angles
+158˚ or –158˚
+158˚ or –158˚
Diagonal distance
16.5 Å

Uncertainty
±4˚
±4˚
Uncertainty
±0.8 Å

(E) Synthesis of perdeuterated amantadine
All chemicals were purchased from commercial vendors and used without further
purification unless otherwise noted. 1-adamantane-d15-carboxylic acid was purchased
from C/D/N isotopes Inc. 13C NMR spectra were recorded on a DMX-360 NMR
spectrometer. Chemical shifts are reported in parts per million (ppm) and referenced to
the residual solvent (CD3OD) signal at 49.15 ppm. The following abbreviations were
used in reporting the NMR spectra: s: singlet, p: pentet.
All reactions were carried out under a N2 atmosphere unless otherwise stated. HPLC
grade solvents were used for all reactions. Column chromatography was performed using
silica gel (230-400 mesh). Low-resolution mass spectra were obtained using an ESI
technique on 3200 Q Trap LC/MS/MS system (Applied Biosystem).

Scheme 1: 1-aminoadamantane-d15-hydrochloride 14.
Diphenylphosphorylazide (DPPA) (1.29 ml, 6 mmol) and triethylamine (0.84ml, 6mmol)
were added to a solution of 1-adamantane-d15-carboxylic acid (0.98 g, 5 mmol) in 10 ml
CH2Cl2 at ambient temperature. The reaction was stirred for 2 hours. An additional 10 ml
CH2Cl2 and 10 ml H2O were added to the reaction mixture, the organic layer was
separated and washed sequentially with H2O, saturated NaHCO3 and brine and dried over
MgSO4. Solvent was removed by rotary evaporation and t-BuOH (50 ml) was added. The
solution was heated to reflux under N2 atmosphere for 5 hours. Excess t-BuOH was
removed in vacuo and the residue was treated with 50% TFA/CH2Cl2 at ambient
temperature for 2 hours. N2 was purged through the mixture to remove excess TFA and
CH2Cl2 to give yellow oil. 4M HCl in dioxane (3 ml) was added and the mixture was
added dropwise to cold diethyl ether. A white solid was collected by centrifugation and
subsequent decanting of the ether supernatant. Further flash column chromatography
purification gave 1-aminoadamanta-d15-hydrochloride as a white power (0.83g, Yield:
82%). 13C NMR (90 MHz, CD3OD) gave signals at 52.62 ppm (s), 40.51 ppm (p, J =
89

18.9 Hz), 35.11 ppm (p, J = 20.7 Hz), and 29.47 ppm (t, J = 21.6 Hz). The calculated
mass for C10H2ND15 (M + H)+ is 167.3, and the measured value by ESI-MS was 167.2.
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(F) Complete set of 2H spectra of perdeuterated amantadine in lipid bilayers.

Supplementary Figure S8. Variable-temperature 2H spectra of perdeuterated
amantadine in DMPC bilayers. a. Without any M2. b. With M2 at Amt P 1: 4 . c. With
M2 at Amt P  4 : 4 . The spectra were measured from 243 K to 313 K.
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Chapter 4
Specific Binding of Adamantane Drugs and Direction of their Polar
Amines in the Pore of the Influenza M2 Transmembrane Domain in
Lipid Bilayers and Dodecylphosphocholine Micelles Determined by
NMR Spectroscopy
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4.1 Abstract
The transmembrane domain of the influenza M2 protein (M2TM) forms a tetrameric
proton channel important for the virus lifecycle. The proton-channel activity is inhibited
by amine-containing adamantyl drugs amantadine and rimantadine, which have been
shown to bind specifically to the pore of M2TM near Ser31. However, whether the polar
amine points to the N- or C-terminus of the channel has not been determined so far.
Elucidating the polar group direction will shed light on the mechanism by which drug
binding inhibits this proton channel and will facilitate rational design of new inhibitors.
In this study, we determine the polar amine direction using M2TM reconstituted in lipid
bilayers as well as DPC micelles.

13

C-2H rotational-echo double-resonance NMR
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experiments of

13

C-labeled M2TM and methyl-deuterated rimantadine in lipid bilayers

showed that the polar amine pointed to the C-terminus of the channel, with the methyl
group close to Gly34. Solution NMR experiments of M2TM in dodecylphosphocholine
(DPC) micelles indicate that drug binding causes significant chemical shift perturbations
of the protein that are very similar to those seen for M2TM and M2(18-60) bound to lipid
bilayers. Specific 2H-labeling of the drugs permitted the assignment of drug-protein
cross peaks, which indicate that amantadine and rimantadine bind to the pore in the same
fashion as for bilayer-bound M2TM. These results strongly suggest that adamantyl
inhibition of M2TM is achieved not only by direct physical occlusion of the pore but also
by perturbing the equilibrium constant of the proton-sensing residue His37. The
reproduction of the pharmacologically relevant specific pore-binding site in DPC
micelles, which was not possible with another detergent, DHPC, underscores the
significant influence of the detergent environment on the functional structure of
membrane proteins.

4.2 Introduction
The M2 protein of the influenza A virus is a membrane-spanning tetrameric proton
channel responsible for a number of functions, including the acidification of the virion
with concomitant uncoating of the viral RNA,1,2 inhibition of autophagosome-lysosome
fusion,3 filamentous virus formation and viral membrane budding/scission.4-6 This
essential protein is the target of the adamantane class of anti-influenza drugs, amantadine
(Amt) and rimantadine (Rmt). M2 has a modular structure7 containing: 1) a short N-
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terminal region that is important for the protein’s incorporation into the virion;8 2) a
transmembrane (TM) helix required for tetramerization, drug-binding and proton channel
formation;7 3) an amphiphilic cytoplasmic helix important for filamentous virion
formation, budding and ESCRT-independent vesicle membrane scission;4-6 and 4) a Cterminal tail that interacts with the matrix protein, M1.9

Mutagenesis and electrophysiological measurements of full-length M2 in oocytes showed
that drug-resistant mutations occur at pore-lining residues (Leu26, Val27, Ala30, Ser31,
Gly34) of the N-terminal portion of the TM helix.10-13 These residues line the Amtbinding site, as seen in the crystal structure of Amt-bound M2TM.14 Solid-state NMR
(SSNMR) distance measurements between

13

C-labeled M2TM and 2H-labeled Amt in

lipid bilayers15 showed Amt bound to this site when the drug was present at a
stoichiometric concentration relative to the number of tetramers. However, when Amt
was in excess to the channels and formed a significant fraction of the lipid bilayer (>5
mol% of the phospholipids), it also showed dipolar interactions with Asp44 on the
surface of the four-helix bundle.15 This peripheral interaction had previously been seen in
the solution NMR structure of M2(18-60) in mixed micelles consisting of 7.5 : 1
DHPC/Rmt, which was equivalent to a 200-fold excess of drug relative to tetramers.16
The pharmacological relevance of the two sites was addressed by a series of
electrophysiological studies10-12 that assessed the drug sensitivities of reverse-engineered
viruses in which either the peripheral site or the pore site was mutated. These studies and
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other functional assays17 supported the high-affinity binding site within the pore to be the
pharmacologically relevant binding site.

There are several possible mechanisms of M2 inhibition by Amt and Rmt in the pore.
First, the location of the drug physically occludes the pore, as in the classical mechanism
of channel blockers. Second, the M2 transmembrane domain is structurally plastic,
switching between multiple conformational states during proton conduction as well as
triggered by other environmental factors.14,18-23 Any drug that locks the protein into a
single form will inhibit the structural transitions required for conduction, particularly if
the drug-stabilized conformational state is a non-conducting resting state. Indeed,
channel-blockers have been known to be able to act in part via conformational
selection,24,25 Finally, drug-binding was observed to strongly perturb the acid dissociation
constants (pKa’s) of the proton-sensing His37 residues,26,27 through a mechanism that has
not yet been fully understood.

To elucidate the mechanism with which Amt and Rmt perturb the His37 pKa, it is
important to determine the direction of the polar moiety of these drugs. Both Amt and
Rmt contain a hydrophobic adamantyl cage connected to a polar moiety, which is an
amine in Amt and ethylamine in Rmt. Perturbation of the His37 pKa can be understood if
the polar group points down toward the C-terminus of the channel rather than up toward
the N-terminus.28 However, the amine direction of these drugs has not been directly
determined. In a number of computational studies, energetically reasonable solutions with
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the amine either up or down were both found, furthermore the amine direction varied
with pH and mutation of the pore-lining residues.29-34 Experimental efforts to determine
the amine direction are also inconclusive: the crystal structure of the Amt-bound M2TM
did not have sufficient resolution (3.5 Å) to unambiguously define the amine direction,
although the C-terminus-facing direction was favored.14 The recent high-resolution
SSNMR study based on cage-perdeuterated Amt (d15-Amt) did not probe the amine
direction.15 Therefore, the polar group direction of the adamantyl drugs in the pore
remains an open question; its elucidation will be important for the design of secondgeneration compounds against drug-resistant variants of M2.

The purpose of this study is two fold. First, we determine the polar group direction of the
adamantyl drugs in the pore using solid-state NMR

13

C-2H dipolar coupling

measurements in lipid bilayers. We use methyl-deuterated Rmt as the probe for the amine
direction of the drugs in the pore, and 2H quadrupolar spectra of cage-perdeuterated Rmt
(d15-Rmt) to determine the tilt angle of Rmt in the pore as well as in the lipid bilayer.
Second, these solid-state NMR measurements were complemented by isotope-edited
solution NMR experiments that show that M2TM exhibits the same specific drug-binding
site in DPC micelles as in lipid bilayers. The parallel solution and solid-state NMR
experiments were motivated by the fact that the previous solution NMR study of M2(1860) in DHPC micelles16 did not observe a pore-bound drug. By comparing the NMR
spectra of M2TM in micelles and in native-like lipid bilayers, we wish to address whether
detergent micelles in general perturb the pore binding site,35 or whether it is the specific
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combination of the longer M2 construct with the DHPC micelle in the previous solution
NMR study16 that abolished the pore binding site. The choice of the TM constructs for
this study, rather than the longer construct containing both the TM helix and the
cytoplasmic helix, is based on the increasing body of evidence that the cytoplasmic helix
is not required for Amt-sensitive proton channel activities. First, electrophysiological
measurements of M2TM in oocytes7 with careful quantification of the surface expression
level of the peptide showed that the single-channel conductivity of M2TM is within a
factor of two of that of the full length protein, which revised the conclusions of an earlier
study.36 Several liposome assays also showed that M2TM conductance was 50-100% that
of the full-length protein or the cytoplasmic-helix-containing construct.7,37 Second,
numerous biophysical studies showed that M2TM was both necessary and sufficient for
tetramerization

in

detergent

micelles,14,38

and

the

thermodynamics

of

tetramerization7,20,39-45 reproduces the unusual pKa of the essential His37 in the fulllength protein.7,27 Third, a large number of low-resolution biophysical studies, including
fluorescence,41 isothermal titration calorimetry,7 and surface plasmon resonance46
demonstrated that M2TM is capable of binding adamantyl drugs, and drug binding
inhibits proton translocation through M2TM channels in vesicles.7,27

Instead of mediating proton conductance, the latest reports make it now clear that the
cytoplasmic helix mediates budding and release of the virus from infected cells.4-6
Simultaneous mutation of five hydrophobic residues (F47, F48, I51, Y52, and F55) in
this helix gave rise to viruses that are defective in budding but fully capable of proton
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conductance as the wild-type protein.5 Site-directed spin-labeling EPR47 and oriented
solid-state NMR data48 showed that the cytoplasmic helix is oriented parallel to and
packed closely with the plane of the bilayer, stabilized by hydrophobic interactions
between residues on one face of the cytoplasmic helix and the lipid bilayer. These
findings revise the separate water-soluble helical bundle structure reported earlier by
solution NMR.16

4.3 Materials and Methods
The M2 transmembrane domain spans roughly from residue 22 to residue 46. We used
two slightly different M2TM constructs in this study: M2TM(22-46) by chemical
synthesis and M2TM(19-49) by recombinant expression.

Optimized synthesis procedure for M2TM(22-46)
Due to the requirements for a large number of isotopically labeled peptides and the
hydrophobic nature of M2TM, we developed an optimized procedure that delivered crude
peptide with >80% purity of the desired peptides based on HPLC peak integration.
Problems encountered in obtaining high-yields and purity included aspartamide
formation at residue 44 and slow coupling near the center of the chain. M2TM(22-46)
with uniformly

13

C,

15

N-labeled V27, A30 and G34 (VAG-M2TM) was synthesized

using Fmoc chemistry at elevated temperature (75˚C for both coupling and deprotection)
in a semi-automated Quest synthesizer using Rink Amide Chemmatrix resin (Matrix
Innovation Inc, Canada). Coupling reagent were 5 eq amino acid, 5 eq HCTU, 10 eq
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DIEA in NMP for 5 mins coupling. 5% piperazine and 0.1 M HOBt in DMF were used as
the deprotection solution in order to minimize aspartamide formation. The peptide was
cleaved from the resin using 95% TFA, 2.5% Tris, 2.5% H2O and precipitated from ether
after removal of TFA. Ether was decanted after centrifugation and the peptide was
washed with cold ether again. The final peptide was dissolved in 50% B’ (59.9%
isopropanol, 30% acetonitrile, 10% H2O, and 0.1% TFA) and 50% A (99.9% H2O, 0.1%
TFA) and purified by preparative C4 reverse phase HPLC with a linear gradient of 70%
B’ to 85% B’. The peptide was eluted at 78% B’. The purity and identify of the peptide
was confirmed by analytical HPLC (>98% purity) and MALDI-MS. Calculated MS:
2782.38, Observed MS: 2782.90.

Expression of 15N-labeled and 15N, 13C-labeled M2TM(19-49)
Uniformly

15

N-labeled or

15

N,

13

C double labeled M2TM(19-49) for solution NMR

experiments were obtained by expressing the full-length protein in minimal medium
enriched with 1 g/L

15

N NH4Cl or 1g/L

15

N NH4Cl and 4g/L

13

C glucose7. The protein

was reconstituted in octylglucopyranoside (OG) micelles and digested with TPCK-treated
trypsin (Thermo Fisher), following a modification of the method described previously40
and in the Supporting Information. The peptide was purified to homogeneity by reverse
phase HPLC, and its purity and identity confirmed by analytical HPLC, MALDI-MS, and
high resolution ESI-MS. Analytical data are provided in the Supporting Information.

Synthesis of two deuterated rimantadine compounds
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1-adamantane-d15-carboxylic acid was purchased from C/D/N isotopes Inc. CD3Li in
diethyl ether was purchased from Sigma-Aldrich. 1D 1H and

13

C NMR spectra were

recorded on a DMX-360 NMR spectrometer. Chemical shifts are reported in parts per
million (ppm) and referenced to the residual solvent (CD3OD or CDCl3) signals. The
following abbreviations were used in reporting the NMR spectra: s: singlet, t: triplet, m:
multiplet, p: pentet. All reactions were carried out under a N2 atmosphere unless
otherwise stated. HPLC grade solvents were used for all reactions. Column
chromatography was performed using silica gel (230-400 mesh). ESI mass spectra were
obtained on a 3200 Q Trap LC/MS/MS system (Applied Biosystem).

Synthesis of CD3-rimantadine
Intermediate I (Scheme 1): A solution of 0.5 M CD3Li (44ml, 22mmol) in diethyl ether
was added dropwise to an ice-bath cooled solution of 1-adamantane carboxylic acid (1.8
g, 10 mmol) in diethyl ether (50 ml) with stirring. The mixture was stirred at 0˚C for 30
minutes, and then continued at ambient temperature for 4 hrs. The reaction mixture was
slowly poured into a vigorously stirring solution of 1N HCl (100 ml) in ice water bath.
Ether (50 ml) was added to the solution and the layers were separated, the aqueous layer
was further extracted three times with diethyl ether. The combined ether layers were
extracted with aqueous NaHCO3 and dried with MgSO4. The solvent was removed under
reduced pressure and the crude product was purified by silica gel flash column
chromatography (5-10% ethyl acetate/hexane) to give intermediate I as a white solid
(1.57 g, Yield: 88%). 1H NMR (360 MHz, CDCl3) δ 2.06 (br s, 3H), 1.79-1.65 (m, 12H);
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13

C NMR (90 MHz, CDCl3) δ 214.21, 46.63, 38.40, 36.73, 28.12; The calculated mass

for C12H15OD3 (M + H)+ is 182.3, Found 182.5.

A solution of Intermediate I (181 mg, 1 mmol), NH2OH•HCl (208.5 mg, 3 mmol) and
CH3COONa (328.1 mg, 4 mmol) in anhydrous EtOH (5 ml) was heated to reflux for 2
hrs. The solvent was removed under reduced pressure and the residue was dissolved in
CH2Cl2 and extracted with H2O twice. The organic layer was dried with MgSO4 and the
solvent was removed under reduced pressure to give the oxime intermediate. Without
further purification, the oxime was dissolved in anhydrous THF (10 ml) and cooled to
0˚C with an ice-water bath. LiAlH4 (0.4 g, 10.5 mmol) was added portion-wise to the
stirring mixture. The solution was warmed to ambient temperature and heated to reflux
for 4 hrs. The reaction was quenched by sequential addition of 0.4 ml H2O, 0.4 ml 15%
NaOH solution and 1.2 ml H2O. The resulting slurry was filtered and the solvent was
removed by rotary-evaporation under reduced pressure. 4 M HCl in 1,4-dioxane (1 ml)
was added to the oily residue and the solvent was removed again under reduced pressure
to give a white solid crude product, which was subsequently purified by silica gel flash
column chromatography (10-20% CH3OH/CH2Cl2) to yield CD3-rimantadine as a yellow
solid (164 mg, Yield: 75%). 1H NMR (360 MHz, CD3OD) δ 2.86 (br s, 1H), 2.03 (br s,
3H), 1.74-1.60 (m, 12H);

13

C NMR (90 MHz, CD3OD) δ 57.90, 38.74, 37.65, 35.29,

29.30; The calculated mass for C12H19ND3 (M + H)+ is 183.3, Found 183.7. (The

13

C

NMR experiment did not use 2H decoupling, so the signal of the CD3 carbon was not
detected due to splitting by deuterons.)
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Synthesis of d15-Rimantadine
The synthesis procedure of d15-rimantadine was the same as described above except
starting with 1-adamantane-d15-carboxylic acid and CH3Li.
Intermediate II: 1H NMR (360 MHz, CDCl3) δ 2.09 (s, 3H); 13C NMR (90 MHz, CDCl3)
δ 214.16 (s), 46.04 (s), 37.50 (p, J = 18.0 Hz), 35.40 (p, J = 18.0 Hz), 27.12 (t, J = 18.9
Hz), 24.34 (s); The calculated mass for C12H4OD15 (M + H)+ is 194.3, Found 194.3.
D15-rimantadine: 1H NMR (360 MHz, CD3OD) δ 2.91 (s, 3H), 1.26 (s, 3H); 13C NMR (90
MHz, CD3OD) δ 58.06 (s), 37.63 (p, J = 18.0 Hz), 36.37 (p, J = 18.0 Hz), 34.89 (s),
28.27 (t, J = 18.9 Hz), 13.65 (s); The calculated mass for C12H7ND15 (M + H)+ is 195.3,
Found 195.8.

Scheme 1. Synthetic scheme for CD3-rimantadine and d15-rimantadine

Solution NMR spectroscopy
Solution NMR spectra were recorded at 313 K on a Varian INOVA 500 MHz
spectrometer with a conventional probe, and 600 MHz and 900 MHz spectrometers
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equipped with cryogenic 1H{13C,

15

N}-triple resonance probes.

15

N TROSY-HSQC,

13

C

HSQC, 2D H(N)CA, 2D (H)C(C)H-TOCSY spectra49 were collected for backbone and
sidechain resonance assignment of

15

N,

13

C-labeled VAG-M2TM. 2D (13C)-NOESY

spectra with a 200 ms mixing time were acquired to identify 1H1H NOE between the
peptide and Amt or Rmt. Spectra were processed with the program NMRPipe.50 Prior to
Fourier transformation, time domain data were multiplied by sine square bell window
functions shifted by 90˚ and zero-filled once. 1H chemical shifts were referenced to the
residual water signal while

13

C and

15

N chemical shifts were indirectly referenced to

DSS.

Membrane-bound M2TM samples for solid-state NMR
Residue-specifically labeled M2TM(22-46) for SSNMR experiments was synthesized by
PrimmBiotech (Cambridge, MA) and purified to >95% purity. Uniformly

13

C,

15

N-

labeled amino acids were incorporated at residues Val27, Ser31, Gly34 and Asp44
(VSGD-M2TM). Unlabeled peptides were used for static

2

H quadrupolar echo

experiments that detect Rmt dynamics and orientation. M2TM(22-46) was reconstituted
into 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) vesicles by OG dialysis.51
The final peptide/lipid molar ratio was 1 : 8. A pH 7.5 phosphate buffer (10 mM
Na2HPO4/NaH2PO4, 1 mM EDTA, 0.1 mM NaN3) was used to prepare the lipid vesicle
solutions. The protein-lipid solutions were dialyzed at 4°C for three days with 5-6 buffer
changes to remove the detergent. Protein-lipid precipitates usually formed after one day
of dialysis. The proteoliposome mixtures were centrifuged at 150,000 g to obtain ~40%
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hydrated membrane pellets for SSNMR experiments. d15-Rmt or CD3-Rmt was dissolved
in water and directly titrated into the membrane pellet in the MAS rotor. For

13

C-2H

REDOR experiments, CD3-Rmt was added at a ratio of 1 drug/tetramer or 5
drugs/tetramer, which corresponded to drug/lipid molar ratios of 1 : 60 or 1 : 12,
respectively. For static 2H lineshape experiments, d15-Rmt was added to unlabeled
M2TM at 1 drug/tetramer and 4 drugs/tetramer ratios. Excess water after the addition of
Rmt was evaporated by placing the rotor uncapped in a dessicator at room temperature
for several hours.

Solid-state NMR spectroscopy
Static 2H quadrupolar echo experiments were carried out on a 14.1 T wide-bore solidstate NMR spectrometer (Bruker Biospin) operating at a 2H Larmor frequency of 92.12
MHz using a double-resonance 4 mm 1H/2H probe. The quadrupolar-echo sequence
involved a pre-echo delay of 40-50 s, a post-echo delay that was 8 s shorter, and a 2H
90˚ pulse length of 3.8 s. The time signal was left-shifted appropriately to capture the
echo maximum to give Fourier-transformed spectra with flat baselines. The spectra were
measured from 243 K to 303 K. The number of scans ranged from 30,000 to 150,000.

13

C-detected and 2H-dephased REDOR experiments were carried out using a triple-

resonance 4 mm 1H/13C/2H magic-angle-spinning (MAS) probe on a 9.4 T wide-bore
SSNMR spectrometer (Bruker Biospin) operating at a 13C resonance frequency of 100.71
MHz and a 2H frequency of 61.48 MHz. The samples were spun under 4250 Hz MAS at
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243 K, where the protein was immobile but the drug remained dynamic. The REDOR
experiment involved a single selective

13

C 180˚-pulse in the center of the mixing period

and multiple 2H 180˚ pulses (pulse length 12.4 s) every half a rotor period apart. This
version of the REDOR experiment removes

13

C-13C scalar coupling and thus gives long

13

C T2 relaxation times, which allows the detection of dephasing effects at long mixing

times. An alternative REDOR version containing a single 2H composite 90˚90˚90˚ pulse
and multiple 13C hard 180˚ pulses was also conducted at one mixing time to confirm the
dipolar dephasing (data not shown). Although the second experiment produces
quantitative dephasing,15 the complex dynamics of the rotating methyl attached to a
uniaxially diffusing adamantyl cage prohibits distance quantification from the dephasing
curve, thus we did not attempt to measure multiple REDOR time points using the latter
REDOR experiment.

Static 2H lineshapes of d15-Rmt were simulated using MATLAB and the software
EXPRESS.52 For each molecular orientation of Rmt, a 4 : 1 area ratio of two couplings
with a 1 : 3 splitting ratio was always maintained to represent the equatorial and axial
deuterons of the adamantyl cage. Since the effect of uniaxial diffusion on the quadrupolar
coupling is known analytically, the coupling values were directly inputted into the
EXPRESS program to generate the Pake patterns. Fitting the measured spectrum yielded
the ratio between different orientations of Rmt in the channel pore versus in the bilayer.

4.4 Results and Discussion
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Amt and Rmt binding to M2TM in DPC micelles
We measured the location of Amt and Rmt in the M2TM channel in DPC micelles using
solution NMR. To evaluate the effect of drug-binding on the structure of the M2TM
tetramer, we first examined uniformly

15

N-labeled and

13

C,

15

N-labled M2TM(19-49),

which was prepared by controlled proteolysis of the native, full-length protein expressed
in bacteria. We explored the spectroscopic properties of M2TM(19-49) in DPC micelles,
because the tetramerization, affinity, and stoichiometry of binding of drugs to various
fragments of M2 had been extensively evaluated in this detergent micelle.7,40,41 Thus, it
was possible to choose conditions where M2TM(19-49) was predominantly tetrameric. In
addition to Amt and Rmt, we also examined a spiro-piperidine inhibitor, WJ10, which
had been shown to bind to M2TM strongly and perturb its conformation in a similar
fashion as the adamantyl drugs.53 Fig. 1a shows the

15

N-1H HSQC spectrum of

M2TM(19-49) in the absence of drug, which showed limited peak dispersion. Addition of
the spiro-piperidine inhibitor53 and Amt (Fig. 1b, Fig. S1) into the sample resulted in the
appearance of a new set of significantly sharper resonances in slow exchange with the
resonances of the unbound species. Confirming the observations of SSNMR,21 drug
binding stabilized a slowly exchanging conformer that is in low abundance in the absence
of the drug (Fig. S2).
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Figure 1. 2D 15N TROSY-HSQC spectra of 1 mM (monomer concentration) M2TM(1949) in the absence (a) and presence (b) of 2.5 mM WJ10. The spectra were measured at
313 K in 100 mM DPC micelle (50 mM sodium phosphate, pH 7.5, in 10% D2O and 90%
H2O) on a cryoprobe-equipped Varian INOVA 600 MHz NMR. Upon drug binding, the
signals became better dispersed in the 1H dimension, and the improved lineshape and
uniformity of the linewidths indicate that the bound protein adopts a well-folded
conformation. Assignments are labeled for the bound protein and inset shows an
expanded view of part of the spectrum. The chemical structure of spiro-piperidine WJ10
(IC50 = 0.92 µM) is shown in the spectrum on the right. For comparison, Amt has an IC50
= 16 µM.53
The drug-bound conformation shows large chemical shift changes of the resonances
throughout the peptide relative to the unbound form. In particular, drug binding perturbed
the chemical shifts of Val27, Ala30 and Gly34 (Fig. S3, S4) as well as the aromatic
resonances of His37 and Trp41 away from their frequencies typically seen in proteins
(Fig. 2, Fig. S5, S2). The changes are especially pronounced in the 1H dimension, in
which the dispersion of the amide 1H chemical shifts increased by 2-fold (Fig. 1),
indicating the formation of a uniquely folded tertiary structure. The increased spectral
dispersion is similar to that seen upon titration of drug into M2TM51,54 or M2(18-60)23 in
phospholipid bilayers, but contrasts with the minimal changes seen when the drug was
titrated into M2(18-60) in DHPC micelles16.
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Having determined conditions that are conducive to specific binding of Amt and Rmt to
the protein in the DPC micelle, we conducted solution NMR titration experiments to test
whether the drugs bind directly to the pore as observed in lipid bilayers by SSNMR. To
more closely match the SSNMR conditions, we used M2TM(22-46) for these
experiments. Fig. 2 shows the 1D titration spectra that confirmed specific binding to the
channel: for example, the H signal of His37 undergoes a large upfield shift in the drugcomplexed state compared to the unbound state. This peak shift is consistent with the
influence of Amt on the His37 tetrad pKa’s observed by solid-state NMR experiments 26.
The titration data are well described by a theoretical curve generated using independently
determined optical titrations in micelles and isothermal titration calorimetry in
phospholipid bilayers.
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Figure 2. Titration of 2 mM M2TM (residues 22-46) by Amt. The intensities of the
major peak of His HD2 at 6.0 ppm are plotted as a function of drug/tetramer molar ratio.
The curve has a well-defined break at a molar ratio of one drug/tetramer. Circles: data at
298 K, pH 8.0, 80 mM DPC, corresponding to a protein : DPC molar ratio of 1:40.
Squares: data at 313 K, pH 7.5, 200 mM DPC (protein : DPC ratio 1:100). Two datasets
are shown to demonstrate that the curves are essentially the same over a range of
temperature, peptide/detergent ratios, and pH. The 313 K spectra are shown in the inset,
and other titration spectra are shown in Fig. S1. The fit curve was generated using the
binding isotherm and best-fit parameters determined previously from a circular dichroism
binding assay (Kd= 16 M, stoichiometry=0.9 drug/tetramer) in which the protein was
reconstituted under the same conditions.66 Assignments of His37 HD2 were based on 2D
1
H NOESY spectra recorded in D2O and aromatic 13C-1H HSQC spectra (unpublished
data).
The specific location of Amt and Rmt in M2TM(22-46) was investigated using 13C-edited
NOESY experiments. Due to the difficulty of conducting half-filtered experiments on
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fast-relaxing proteins in detergent micelles, we opted to measure difference spectra of the
peptides in the presence of deuterated versus protonated drugs. Two sets of experiments
were carried out to detect NOE signals between the drug and

13

C-labeled residues, one

comparing protonated versus perdeuterated Amt, and the other comparing protonated
versus CD3-labeled Rmt. Three residues in the pore binding site - Val27, Ala30 and
Gly34 - were labeled with

13

C and

15

N. Any NOEs from the protonated drugs to these

residues that disappear upon deuteration represent specific drug-protein interactions.
Figure 3 shows

13

C-edited NOESY spectra for protonated and perdeuterated Amt. The

drugs were not 13C-labeled, thus the only cross-peaks associated with the drug must result
from interactions with the

13

C-labeled residues of the protein, and drug-drug NOEs

cannot exist in the spectra. We observed a strong NOE cross-peak at ~0.7 ppm in the
direct dimension and ~1.6 ppm in the indirect dimension, which was assigned to the
γCH3 of Val27 and the C4 methylene protons of Amt (Fig. S6). This cross peak indicates
that the hydrophobic cage of Amt points up to the N-terminus while the polar amine
points down, consistent with the SSNMR result of cage-perdeuterated Amt

15

and the X-

ray structures14 of the complex, in which the sidechain of Val27 forms a hydrophobic lid
of the binding site, interacting with the apolar portion of the drug. It is also consistent
with the fact that Val27 forms closer contacts with the adamantyl cage than Ala30 in both
the crystal and SSNMR structures (Fig. 3D).

To probe the polar group direction of Rmt in the pore, we performed the same 13C-edited
NOESY experiments of the peptide bound to CD3-labeled Rmt versus protonated Rmt.
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Fig. 3B shows a weak NOE cross peak between the β CH3 of Ala30 and Rmt CH3. Taken
together, these NOESY difference experiments indicate that both Amt and Rmt bind in
the channel pore with the amine pointing towards the C-terminus in DPC-bound M2TM
tetramers.

112

Figure 3. Upfield region of 2D 13C-edited 1H NOESY spectra with 200 ms mixing of
13
C, 15N-labeled VAG-M2TM with 2 eq Amt (A) and Rmt (B). The left spectra are those
of protonated drugs, and the middle spectra are from samples containing perdeuterated
Amt and methyl-deuterated Rmt. The right spectra are the difference between the left and
middle spectra. (C) The protons that show NOE cross peaks with M2 are highlighted in
red in the Amt and Rmt structures. Spectra in (A) and (B) were recorded on a 500 MHz
and a 600 MHz spectrometer, respectively. The concentrations were 2 mM peptide, 100
mM DPC, 1 mM Amt or Rmt, and pH 7.5 phosphate buffer as in Fig. 3. The methyl
groups of Val were not stereospecifically assigned. (D) The structure of Amt bound in the
channel pore in the crystal structure of M2TM 14, viewed from the C-terminal end.
Shown in balls are Gly34 C (orange), Val27 sidechains (green), and Ala30 sidechains
(cyan). The hydrophobic adamantyl cage (magenta) interacts extensively with the Val27
sidechains, while the polar group (blue) points to the C-terminus in the crystal structure.
Adamantyl cage orientations of Rmt in DMPC-bilayer-bound M2TM(22-46)
To determine the Rmt orientation and dynamics in M2TM bound to lipid bilayers, which
better represent the virus envelope environment than detergent micelles, we measured the
2

H spectra of d15-Rmt. Rimantadine consists of a rigid adamantyl cage attached to an

ethylamine. Similar to Amt, the adamantyl cage has a three-fold symmetric axis Z M .
Three axial C-D bonds are parallel to Z M while twelve equatorial C-D bonds lie at 70°

 around Z
or 110° from Z M . Fast uniaxial rotation or CN jumps (N ≥ 3) of the cage
M
 of 40 and 125 kHz with a 4 : 1 intensity ratio. If the drug
results in quadrupolar splittings

 
undergoes
additional fast diffusion about the bilayer normal n with a tilt angle
nM from
the molecular axis, then both equatorial and axial couplings will be further scaled by an



order parameter, Smol  3cos2 nM 1 2 .55,56 While the adamantyl cage moiety is





identical between Rmt and Amt, the different polar functionality between the two drugs

the molecular orientation, as we show below.
can affect
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Figure 4 shows the 2H spectra of d15-Rmt under varying drug : channel ratios from 243 K
to 303 K. Three membrane samples were examined: Rmt bound to DMPC bilayers in the
absence of M2TM, in the presence of a stoichiometric number of channels (1
drug/tetramer), and in 4-fold excess of the number of channels (4 drugs/tetramer). At 243
K, all three samples exhibited quadrupolar splittings of ~35 kHz and ~120 kHz,
consistent with the frequency ratio expected when the adamantyl cage uniaxially rotates
around its own molecular axis. The slight reduction of the splittings from 40 and 125 kHz
( Smol  0.9) indicate that Z M is tilted by 13˚ from the bilayer normal. These 243 K
spectra of Rmt are identical to the spectra of d15-Amt at the same temperature.15





Figure 4. Static 2H quadrupolar echo spectra of d15-Rmt for determining the tilt angle of
the adamantyl cage in M2TM (residues 22-46) channels versus lipid bilayers. (a) d15-Rmt
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bound to DMPC bilayers without the protein. (b) d15-Rmt bound to M2TM in DMPC
bilayers at a ratio of 1 drug/tetramer. (c) d15-Rmt bound to M2TM at a ratio of 4
drugs/tetramer. (d) One of the two degenerate orientations of d15-Rmt in lipid bilayers at
303 K. (e) Orientation of d15-Rmt in M2TM channels at 303 K.
When the membranes warmed to the liquid-crystalline phase at 303 K, the 2H spectra
differed for the three samples. The lipid-only sample showed two splittings of 11.4 kHz
and 35 kHz, which corresponded to a Smol of ±0.28, indicating that the adamantyl cage
is tilted from the bilayer normal by 44˚ (or 67˚) at physiological temperature (Fig. 4d).


Simulation of the 303 K spectrum
confirmed the intensity and frequency ratios of the
underlying Pake patterns that represent the equatorial and axial deuterons (Fig. 5a). The
44˚ tilt angle of lipid-bound Rmt is significantly larger than the 37˚ found for Amt.15 We
hypothesize that the larger tilt angle is due to the bifurcated ethylamine structure, which
may orient differently from the amine in Amt in order to better position the polar group to
the negatively charged phosphate groups on the membrane surface.

When a stoichiometric amount of M2 tetramers was present, the 303 K spectrum changed
qualitatively from the lipid-only sample: the 36 kHz splitting of the equatorial deuterons
at 243 K persisted to 303 K across the membrane phase transition, and dominated the
spectral intensity (Fig. 4b). The persistence of this large coupling at high temperature is
similar to what was observed for Amt15 and indicates that a significant fraction of Rmt
cannot deviate from the upright orientation due to confinement by the channel (Fig. 4e),
and the drug is well isolated from the disordered liquid-crystalline membrane. In addition
to the 36-kHz splitting, a 13.3 kHz splitting and an isotropic peak were detected in the
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stoichiometric spectrum at 303 K. The former corresponds to Smol=0.33 or nM =42˚,
which can be attributed to Rmt in the lipid bilayer, since the amphipathic drug has

 that the splitting
affinity to both the lipids and the aqueous pore of the
channel. The fact
is 2 kHz larger than the 11.4 kHz value seen in the lipid-only sample (Fig. 4a) translates
to only a 2˚ reduction in the tilt angle, because the order parameter has the highest
angular sensitivity at 45˚. The isotropic peak, which was also observed for Amt,15 may
result from randomly tumbling drug that has escaped into the inter-bilayer aqueous phase,
or from pore-bound drug tilted at the magic angle (54.7˚) from the channel axis. The
fractions of the three components were found by simulation (Fig. 5b) to be 63% : 27% :
10% for the 13˚-tilted channel-bound component, the 42˚-tilted lipid-bound component
(13.3 kHz), and the isotropic component. The lipid-bound fraction of 27% is higher than
the 10% fraction for Amt,15 suggesting that Rmt has slightly higher affinity for the
membrane than Amt under the molar ratios used in these solid-state NMR samples.

Figure 5. Simulations of the 2H spectra of d15-Rmt at 303 K. Top row: experimental
spectra reproduced from Fig. 5. Bottom row: simulated spectra. (a) d15-Rmt bound to
DMPC bilayers without M2. Simulation used a 4 : 1 area ratio of the small and large
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couplings, consistent with the number of equatorial and axial deuterons in the adamantyl
cage. (b) d15-Rmt bound to M2 at 1 drug/tetramer. Simulated spectrum used an area ratio
of 63% : 27% : 10% for the 36 kHz, 13.3 kHz, and isotropic components, which represent
the pore bound, lipid bound and isotropic drugs. (c) d15-Rmt bound to M2(22-46) at 4
drugs/tetramer. Simulated spectrum used an area ratio of 13% : 83% : 4% for the 36 kHz,
12.5 kHz and isotropic components.
Fig. 4c shows the 2H spectra when Rmt is in four-fold excess to the M2TM tetramers and
accounting for 8 mol% of the lipid membrane. The 303 K spectrum is now dominated by
a 12.5 kHz splitting and a small 36-kHz component for the equatorial deuterons. Thus,
the excess drug adopts a similarly tilted orientation as the lipid-bound drug in the absence
of the protein, while the drug inside the pore retained the same upright orientation as in
the stoichiometric sample.15 Simulation (Fig. 5c) yielded a ratio of 13% : 83% : 4% for
the 36 kHz, 12.5 kHz and the isotropic components.

Taken together, these 2H spectra indicate that the majority of the first equivalent of Rmt
adopts the same upright orientation in the pore of the channel as Amt. Excess Rmt has a
very tilted orientation of 42-43˚ from the bilayer normal, which is nearly identical to the
44˚ tilt of the drug in the lipids in the absence of the protein. Compared to Amt, Rmt has
a slightly different equilibrium constant between the specific pore-binding site and the
non-specific lipid-binding site, which is likely a result of the slightly different
hydrophobicity and size of the two drugs.

Binding locations and polar group direction of Rmt in the M2TM pore
Protein chemical shift perturbation provides independent evidence of ligand binding sites.
To confirm the binding locations inferred from the 2H spectra, and to compare M2-Rmt
117

interactions with M2-Amt interactions, we measured the

13

C and

15

N chemical shifts of

several key residues in M2TM. Ser31, Val27 and Gly34 defined the center and the
boundaries of the pore binding site for Amt,15,51 while Asp44 probed the interaction of
the drug with the lipid-exposed binding site. Figure 6 shows 2D

15

N-13C correlation

spectra of VSGD-M2TM(22-46) in the absence and presence of Rmt. The drug-free
15

peptide shows two Ser31 peaks and two Gly34
changed with titration of the drug: the downfield
intensity upon Rmt binding. The bound Ser31
unbound peak, while the bound Gly34

15

15

N peaks, whose relative intensities

N peaks of each residue increased in

15

N peak is 6 ppm downfield from the

N peak is 3 ppm downfield from the unbound

peak. These peak displacements are very similar to those observed for Amt-bound
M2TM,15,51 strongly suggesting that Rmt also binds to the N-terminal pore near Ser31.
The fact that the bound Ser31 conformation is already present in the drug-free state
indicates that Rmt shifts the conformational equilibrium of the protein to the bound state,
rather than inducing an entirely new conformation. This observation is consistent with the
concept of conformational selection by ligands, which has been documented for many
globular proteins57 and which has also be reported for M2TM.18 The Val27 C chemical
shift decreased by 2.5 ppm upon Rmt binding. In comparison, the Asp44

15

N chemical

shift did not change between the apo sample and the stoichiometric sample (both at 118.4
ppm), but increased by 1.5 ppm (at 119.9 ppm) in the sample containing excess Rmt.
Thus, only excess drug affects the Asp44 conformation, providing strong evidence that
the first equivalent of drug binds elsewhere from Asp44.
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Figure 6. 2D 15N-13C correlation spectra of Val27, Ser31, Gly34 and Asp44-labeled
M2TM in DMPC bilayers without and with Rmt. (a) The spectrum of drug-free peptide.
(b) The spectrum with 1 drug/tetramer. (c) The spectrum with 5 drugs/tetramer. Ser31
and Gly34 15N chemical shift increases and Val27 C chemical shift decreases upon drug
binding.
13

C{2H} REDOR experiments of CD3-Rmt provided definitive proof of the binding

location of the drug as well as the direction of the amine in the pore. If the ethylamine
points to the N-terminus of the channel, significant REDOR effect is expected for Val27
sidechains, whereas if the amine points to the C-terminus, significant REDOR dephasing
should occur for Gly34. Since the Rmt 2H spectra and the 15N-13C correlation spectra of
the protein with varying drug concentrations both indicate that excess Rmt does not
remove the specific binding site, but only populates both sites, we focused the

13

C{2H}

REDOR experiment on the 5 drugs/tetramer sample. Fig. 7 shows the REDOR control
(S0) and dephased (S) spectra measured with a single

13

C 180˚ pulse and multiple 2H

pulses.58 Val27 C1 exhibited no dephasing at 16.9 ms, and the combined Ser31 and
Val27 C peak at 61.4 ppm also showed no dephasing (S/S0 = 1.02 ± 0.03 at 15.1 ms),
indicating that both 13C-labeled residues are outside the dipolar contact of the deuterated
methyl. In contrast, significant dephasing was observed for Gly34 C, with an S/S0 value
of 0.81 ± 0.04 at 18.8 ms. Thus, the REDOR spectra indicate unambiguously that the
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ethylamine lies near Gly34 and points to the C-terminus of the channel, in the direction of
the His37.

Figure 7. 13C{2H} REDOR spectra of DMPC-bound M2TM with CD3-Rmt at 5
drugs/tetramer. Intensity difference between the control (S0, black) and dephased spectra
(S, red) indicate proximity of the 13C-labeled residues to the deuterated methyl group. (a)
16.9 ms REDOR spectra of Val27 C showing S/S0 = 1.02 ± 0.04. (b) 15.1 ms REDOR
spectra of Ser31 C (S/S0 = 1.02 ± 0.03) and Asp44 C (S/S0 = 0.89 ± 0.03). (c) Gly34
C REDOR spectra at 18.8 ms, with S/S0 = 0.81 ± 0.04. The difference spectrum is
shown in blue. (d) Schematic of rimantadine structure in the pore, with the polar amine
pointing to the C-terminus and the adamantyl cage tilted by 13˚.
Fig. 7b additionally shows moderate dephasing of Asp44 C to 0.89 ± 0.03 at 15.1 ms,
indicating that at a lipid/drug molar ratio of 6.4 : 1, the drug is in dipolar contact with the
surface-exposed Asp44. This finding is consistent with Amt binding to M2(22-46)15 in
lipid bilayers and with the Rmt interaction with M2(18-60) in mixed micelles composed
of 7.5 : 1 DHPC/Rmt.16 Both Rmt and Amt are amphiphilic molecules and partition into
the membrane-water interface of lipid bilayers,59 at approximately the same depth as
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Asp44. Thus, drug binding to Asp44 can be attributed to the high concentrations of the
drugs in the bilayer and the preference of the drugs for the membrane-water interface.
Additional REDOR experiments of the 1 drug/tetramer sample (Fig. 8) exhibited no
significant dephasing for the four residues within experimental uncertainty, which is
expected for Val27, Ser31 and Asp44. The lack of strong dephasing for Gly34 is partly
due to the incomplete occupancy of the drug in the pore, since 27% of the Rmt is in the
bilayer and 10% has vanishing quadrupolar coupling (Fig. 4), thus making ~37% of the
drug unable to cause any dipolar dephasing. In addition, the peptide conformation may be
slightly altered between low and high drug concentrations due to changes in the
membrane viscosity and lateral pressure, such that the height of the CD3 group may be
slightly different between stoichiometric and excess drug concentrations. Previously we
did not observe different REDOR dephasing between the stoichiometric and drug-excess
complexes between d15-Amt and M2TM.15 However, d15-Amt contains a large number of
deuterons distributed over a 2.2 Å vertical distance, which minimized the effects of small
displacements of the drug in the channel. In contrast, the current CD3-Rmt contains only
three deuterons concentrated in a small region of space, thus even subtle changes of the
drug height in the channel could significantly weaken the REDOR dephasing.
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Figure 8. 13C{2H} REDOR spectra of M2TM in DMPC bilayers with CD3-Rmt at 1
drug/tetramer. (a) 15.1 ms REDOR spectra. S/S0 values are 1.2±0.16 for Val27 C1, 1.00
± 0.19 for Ser31 C, and 0.92 ± 0.08 for Asp44 C. (b) 16.9 ms REDOR spectra of
Gly34 C. S/S0 = 0.94 ± 0.07.
Excess drug and other membrane composition changes are known to have significant
effects on the conformational dynamics of M2TM.18,19,56,60 For example, the addition of
cholesterol at lower concentrations than the Rmt amount used here causes significant
changes in the thermodynamic stability44 and the structure21 of the protein. 1H relaxation
NMR data revealed that the uniaxial diffusion of M2TM tetramers in DLPC bilayers was
sped up by excess Amt in the membrane,61 suggesting that the tetramers adopt tighter
conformations due to the indirect influence of the drug on the membrane fluidity. Thus,
the first equivalent of Rmt may be bound deeper in the pore, with the ethylamine outside
the detectable (~5 Å) distance range of Gly34. As excess Rmt partitioned into the
membrane, the tetramers tighten slightly, pushing the drug up in the channel so that the
CD3 group approached Gly34, giving measurable dipolar dephasing.

The downward orientation of the polar amine in the pore confirms that the adamantane
drugs inhibit the M2 proton channel activity not only by steric block and dehydration of
the channel,22 but also by indirect drug-His37 interactions. The C-terminus-pointing
amine would be able to form hydrogen bonds with the clusters of water molecules
His37.38 These water-mediated hydrogen bonds would tend to reduce the His37 pKa, as
shown for Amt-bound M2TM in 15N chemical shift measurements.26 The perturbation of
His37 pKa is relevant to inhibition, because it increases the fraction of the protein in the
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high-pH form and decreases dynamic processes believed to be required for proton
conduction.14,18,62-64 In a new spiro-piperidine inhibitor of M2 with 10-fold higher
potency than Amt, methyl substitution of the amine was found to reduce the potency
significantly, indicating the importance of the polar moiety.53

4.5 Conclusions
Both solid-state and solution NMR results shown here demonstrate that Rmt binds the
M2TM channel in a very similar fashion to Amt. At the stoichiometric drug
concentration, Rmt binds inside the pore with the molecular axis roughly parallel to the
bilayer normal. The polar group points towards the C-terminus, supporting the notion that
the drug inhibits the proton conductance not only by interrupting the water wire leading
to His3730,65 but also by forming water-mediated H-bonds with His37, which perturbed
its pKa. The proximity of the methyl group to the Gly34 backbone also suggests that the
higher affinity of Rmt to M2 than Amt66 may result from better space filling of the drug
in the channel and dehydration of the additional hydrophobic methylene and methyl
groups. This insight suggests that new drugs to target resistant variants of the M2 protein
may involve side groups that similarly access the space near Gly34. The dynamics of
Rmt inside the pore suggests two possible strategies to the design of new M2 inhibitors.
In one strategy, one can design molecules that better fill the channel, leading to molecules
with high potency for not only the wild type but also the drug-resistant mutants V27A
and L26F, as will be reported elsewhere. Alternatively, one can also adopt the strategy of
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retaining the molecular dynamics as a potential mode of entropic stabilization. The new
structural information obtained here has informed both strategies.

This study not only extends the previous structural findings of Amt to Rmt, but also
provides unique information about the polar group direction, which was absent in all
previous high-resolution structures of the M2 protein.1,15 The fundamental similarity of
Rmt and Amt in their binding locations, as well as subtle differences in their lipid
interaction, provide a rare opportunity to examine the entire distribution of bound states,
including the membrane-bound as well as protein-bound states. These data should
provide essential information to test and improve molecular dynamics protocols for
simulating the kinetic steps involved in binding a hydrophobic drug to a membrane
protein receptor.

The fact that Amt binds specifically to the pore of M2TM in DPC micelles in solution
and cause chemical shift changes that are consistent with the effects of drug on
M2TM51,54 and M2(18-60)23 in lipid bilayers, but distinct from the effects of drug on
M2(18-60) in DHPC micelles,16 underscore the importance of the environment to the
functional structure of the protein and the mutual influence that can exist between the
protein and detergent micelles.35 The high-resolution orientational structure of the
cytoplasmic helix recently determined by solid-state NMR in lipid bilayers64 differ
significantly from the structure in DHPC micelles. How exactly the cytoplasmic helix
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affects specific drug binding in the TM pore in a detergent environment remains an open
question for future investigation.
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4.7 Supporting Information
Dynamics and Orientation of Amine-Containing Drugs in the Pore of the M2
Transmembrane Domain of the Influenza A Virus
Sarah D. Cady1, Jun Wang2, Yibing Wu2, William F. DeGrado2*, and Mei Hong1*
Expression and trypsin digestion of U-15N and U-15N

13

C labeled M2TM(19-49) for

detergent screening of solution NMR
BL21(DE3)pLyS E. Coli cells with pET23D(+) plasmids containing the Udorn wt M2
gene were grown in LB agar plates with 100 µg/ml ampicilin at 37oC overnight. A single
colony was picked up from the plate to inoculate 5ml LB supplemented with 100 µg/ml
ampicilin, and was allowed to incubate at 37oC with 200rpm shaking for 8hrs. Next, 0.5
ml of the above cell solution was used to inoculate 50ml of minimal media with 1g/L
15

NH4Cl, 4g/L glucose and 100 µg/ml ampicilin and shake at 37oC overnight (for double

15

N and 13C labeling, the minimal media was supplemented with 1g/L 15NH4Cl, 4g/L 13C

glucose) . The overnight culture was used to inoculate 1 L of minimal media with 1g/L
15

NH4Cl and 100 µg/ml ampicilin. When OD600 reached 0.7-1.0 (normally after 3hrs),

M2 expression was induced with 1 mM IPTG (final concentration). Protein expression
was halted three hours later by centrifugation at 4˚C for 30 min. The cell pellet was
resuspended in 50 ml of 50 mM Tris (pH 8), 40 mM OG, 150 mM NaCl, 0.25 µg/ml
lysozyme, 0.02 µg/ml DNase I and 500 µM PMSF at 0˚C. The mixture was sonicated on
ice for 20 min (20% amplitude, 1 s on 1 s off), followed by further reconstitution using a
homogenizer for 10 mins to make the solution homogeneous. The solution was then
centrifuged at 15,000 g for 30 mins. The supernatant was saved for Ni-NTA column
purification, and the pellet was subjected to another round of reconstitution as described
above. Finally the supernatants from two rounds were combined and incubated with 10
ml Ni-NTA super flow resin (Qiagen) and 20 mM imidazole at room temperature for 30
min with gentle shaking. The column was washed successively with 50 mM Tris (pH 8),
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150 mM NaCl, 40 mM OG, 20% v/v glycerol, then 50 mM Tris (pH 8), 20 mM OG, 20%
v/v glycerol, followed by 50 mM Tris (pH 8), 4 mM OG, 20% v/v glycerol, 20 mM
imidazole. Finally, the M2 protein was eluted with 50 mM Tris (pH 8), 4 mM OG, 20%
v/v glycerol, 300 mM imidazole. The purity of M2 was judged by gel electrophoresis and
HPLC to be >95%. Full length M2 was digested by TPCK-trypsin (Thermo Fisher, cat #
PI-20233, 10mg/ml) in the elution buffer overnight at 37˚C. The resulting solution was
separated by C4 reverse phase HP C with linear gradient of 70% B’ to 95% B’ (Eluent
A: 89.9% H2O + 10% isopropanol + 0.1% TFA; Eluent B: 59.9% isopropanol + 30%
acetonitrile + 10% H2O + 0.1% TFA) to give two major fragments M2(19-49) and
M2(19-53) in 3:2 ratio. ESI-MS of the A/M2(19-49) was found to be 3507.2411,
calculated 3505.8149.
Chemical shift assignment of

15

13

N,

C-V27, A30, G34-labeled M2TM(22-46) in the

absence and presence of Amt and Rmt
Val, Ala and Gly have characteristic

13

C chemical shifts of 62.4  2.9 ppm, 53.2  2.0

ppm, and 45.3  1.3 ppm, respectively, thus the backbone C signals can be
unambiguously assigned in the 13C HSQC spectra. The Val C chemical shift should be
32.7 1.8 ppm, and is also straightforward to assign. The methyl carbon and protons of
Ala are usually shifted upfield by 2.2 ppm and downfield by 0.5 ppm, respectively,
compared to the corresponding atoms of Val, so the assignment of the methyl group is
also clear. The 2D H(N)CA experiment correlates the amide 1H chemical shifts with the
intra-residue and preceding residue

13

C chemical shifts. Since the preceding residues of

V27, A30 and G34 are unlabeled, the H(N)CA experiments only connect the intra-residue
amide 1H and

13

C chemical shifts. The 2D (H)C(C)H TOCSY experiment was used to

extend and confirm the 1H and

13

C assignments within a spin system. The C peak of

G34 was too weak to observe, which may be due to high dynamics, as supported by the
weak signals of G34 in both the

13

C and

15

N HSQC spectra. Nevertheless, G34

assignment was obvious after the other two residues had been assigned and because Gly
15

N resonates in a very unique region of the spectrum (109.7  4.0 ppm). Figure S7A,
131

S7B and S7C show the assignments of M2TM in the apo state and in presence of Amt
and Rmt.
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Figure S1. 2D 15N TROSY-HSQC spectra of 1 mM M2TM(19-49) in the absence (left)
and presence (right) of 5 eq Amt, at 313 K in 50 mM DPC (50 mM sodium phosphate in
10% D2O and 90% H2O). The spectra were measured on a Varian INOVA 600 MHz
(left) and 900 MHz (right) spectrometer equipped with a 1H{13C, 15N}-triple resonance
cryoprobe. Similar to the spectra in Figure 1, upon Amt binding, 1H chemical shift
dispersion increases, and peak shape and linewidths become more uniform, indicating the
drug-protein complex adopts a well-structured conformation.
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Figure S2. Aromatic 13C HSQC spectrum of M2TM(19-49) in the absence of the
inhibitor WJ10 (red, A) shows two conformers for W41, one much stronger than the
other. Addition of WJ10 (blue, B) shifts the equilibrium towards the one less populated in
the apo state. Superposition of the two spectra (C) clearly indicates that there are no
additional new peaks for W41. The assignments of the W41 indole ring were based on
2D 1H NOESY spectra recorded in H2O and D2O (unpublished data). The sample was the
same as described in Figure 1 of the main text.
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A

B

Figure S3. Overlay of 15N TROSY HSQC spectra of VAG-M2TM(22-46) in the absence
(blue) and presence (red) of Amt (A) and Rmt (B) to illustrate the perturbation of the
backbone conformation by drugs. 1H chemical shift changes for all three residues ranged
from 0.2 to 0.5 ppm upon drug binding, showing the drug strongly perturbs pore-lining
residues. Lineshape and intensity analysis shows that drug-bound peaks of the three
residues are more uniform than the unbound peaks, indicating that the bound
conformation is more homogeneous. The spectra were recorded on a 500 MHz and a 600
MHz spectrometer. The peptide was reconstituted at 1 : 100 peptide/DPC, pH 7.5 (50
mM sodium phosphate buffer), 313 K, and 2 mM peptide.
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Figure S4
A

B

Figure S4. Overlay of 13C HSQC spectra of VAG-M2TM(22-46) in the absence (blue)
and presence (red) of Amt (A) and Rmt (B) to illustrate perturbation of the sidechain
conformation by drugs. Chemical shifts are very similar for all peaks of the two bound
forms, suggesting similar geometry of the complexes. The peptide was reconstituted at
1 : 100 peptide/DPC, pH 7.5 (50 mM sodium phosphate buffer), 313 K, and 2 mM
peptide.
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A

B

Figure S5. Titration of 2 mM M2TM (residues 22-46) by Amt at 298 K, pH 8.0, 80 mM
DPC (A) and at 313 K, pH 7.5, 200 mM DPC (B). Assignments of His37 HD2 were
based on 2D 1H-1H NOESY spectra recorded in D2O and aromatic 13C-1H HSQC spectra
(unpublished data). Two datasets are shown to demonstrate that the curves are essentially
the same over a range of temperature, peptide/detergent ratios, and pH.
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Figure S6. Amantadine remains bound in the pore in the presence of a large excess of
drug, as assessed from intermolecular NOEs detected in the difference spectrum. The
upfield region of the 2D (13C)-edited NOESY spectrum (200 ms mixing time) of M2TM
with 20 eq protonated Amt (left) and deuterated Amt (middle) at 313 K gave rise to a
difference spectrum (right) that shows the same intermolecular NOEs between Val27 and
the drug as when the drug was present at much lower molar excess (Figure 3).
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A

B
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C

Figure S7. Chemical shift assignment of VAG-M2TM(22-46) in DPC micelles. (A) In
the absence of drug. (B) Bound with Amt. (C) Bound with Rmt. The peptide was
reconstituted at 1 : 100 peptide/DPC, pH 7.5 (50 mM sodium phosphate buffer in 10%
D2O, 90% H2O), 313 K, 2 mM peptide (monomer concentration), and 1 mM Amt or Rmt.
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5.1 ABSTRACT
Amantadine has been used for decades as an inhibitor of the influenza A virus M2 protein
(AM2) in the prophylaxis and treatment of influenza A infections, but its clinical use has
been limited by its central nervous system (CNS) side effects as well as emerging drugresistant strains of the virus. With the goal of searching for new classes of M2 inhibitors,
a structure-activity relation study based on 2-[3-azaspiro(5,5)undecanol]-2-imidazoline
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(BL-1743) was initiated. The first generation BL-1743 series of compounds has been
synthesized and tested by two-electrode voltage-clamp (TEV) assays. The most active
compound from this library, 3-azaspiro[5,5]undecane hydrochloride (9), showed an IC50
as low as 0.92±0.11 M against AM2, more than an order of magnitude more potent than
amantadine (IC50=16 M). 15N and 13C solid-state NMR was employed to determine the
effect of compound 9 on the structure and dynamics of the transmembrane domain of
AM2 (AM2-TM) in phospholipid bilayers. Compared to amantadine, spiro-piperidine 9
1) induces a more homogeneous conformation of the peptide, 2) reduces the dynamic
disorder of the G34-I35 backbone near the water-filled central cavity of the helical
bundle, and 3) influences the dynamics and magnetic environment of more residues
within the transmembrane helices. These data suggest that spiro-piperidine 9 binds more
extensively with the AM2 channel, thus leading to stronger inhibitory potency.

5.2 Introduction
The influenza virus, especially the H5N1 strain of influenza A, is a serious threat to
human health. The outbreak of highly pathogenic H5N1 avian influenza virus in 1997 and
2004/5 caused the death of millions of chickens and had a very high mortality rate among
the limited number of infected humans. These cases cause great concern about the
transmission of avian virus mutants among humans. The spread of influenza virus is
mainly due to two factors: antigenic drift and antigenic shift.1 Antigenic drift due to point
mutations of the virus’ negative-strand RNAs generates slightly modified antigens on the
142

virus surface, while antigenic shift causes reassortment of RNAs between viruses that
infect avian populations and viruses that infect humans. The latter is a more serious
problem since it produces more radically different antigenic determinants, for which there
is little pre-existing immunity. Thus there is a great need for anti-influenza therapeutics.
Currently there are two classes of small-molecule drugs in use to treat influenza virus
infection 2: amantadine and rimantadine (Figure 1), which target the virus’ M2 proton
channel, and Tamiflu (oseltamivir), which targets the virus surface protein neuraminidase.

The AM2 proton channel plays an important role in viral replication by facilitating
uncoating of the virus after its endocytosis into the host cells. The low pH of the
endosome activates the AM2 channel, thus allowing proton flux into the viral interior.
This acidification dissociates the viral RNA from its bound matrix proteins,3 a process
that is required to release the viral genetic material to the cytoplasm for replication.4 In a
later stage of viral replication, the M2 protein also equilibrates the pH gradient between
the Golgi lumen and the cytoplasm, thus preventing premature conformational changes of
hemagglutinin.5,

6

AM2 is a homo-tetrameric, type III integral membrane protein

containing a small N-terminal periplasmic domain (23 residues), a single transmembrane
domain (20 residues), and a C-terminal cytoplasmic tail (53 residues).7

Structural studies of membrane proteins such as AM2 are often hampered by the
difficulties associated with the production, functional characterization, and structure
determination of this class of proteins. Structural analysis of AM2 has the additional
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challenge of pH-induced changes in the TM region. Recently one of our groups solved the
structures of the AM2 TM domain (22-46) both with (pH 5.3) and without (pH 7.3)
bound amantadine using X-ray crystallography.8 In the crystal structure of amantadineM2TM complex, one drug binds each M2 tetramer in the pore, and the drug is surrounded
by residues whose mutations cause amantadine resistance. This finding is consistent with
the

stoichiometry

previously

inferred

from

fluorescence

titrations9

and

electrophysiological measurements,10 which showed the binding of one drug per tetramer
with a Hill coefficient of 1.0. Moreover, the amantadine and rimantadine sensitivity of
AM2 channels expressed either in Xenopus oocytes or in mammalian cells revealed the
drug-binding region in the TM domain to encompass residues V27, A30, S31, and G34.
No mutations C-terminal to residue G34 have been found to be amantadine resistant,
except H37 and W41, which are functionally important for the channel activity. These
results are less consistent with the solution NMR structure of AM2(18-60) at higher pH
(7.5), solved in the presence of 40 mM rimantadine.11 The solution NMR structure
showed four rimantadine molecules per AM2 tetramer channel bound on the outside of
the helices toward the cytoplasmic side of the membrane, with the basic amine group of
rimantadine interacting with D44. The authors suggested that rimantadine indirectly
inhibits the channel by stabilizing the closed form of AM2, and that drug-resistant
mutants escape inhibition by stabilizing the open state of the channel. However, this
allosteric inhibition mechanism is not consistent with recent electrophysiological
measurements of the amantadine-resistant mutations of AM2.12 Furthermore, mutations
to the side chains that form the proposed surface site remained amantadine sensitive.8
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Taken together, these data strongly suggest that the drug-binding site that is responsible
for inhibition is located in the channel pore.

Figure 1. Crystal structure of the amantadine-bound AM2-TM complex (PDB accession
code: 3BKD). 8
Amantadine targets AM2 by blocking the acidification of virus entrapped in endosomes.13
Unfortunately the use of amantadine-related drugs is limited by central nervous system
(CNS) side effects and the rapid emergence of drug-resistant viruses such as L26F,
V27A, A30T and S31N.14-16 Extensive structure-activity relationship (SAR) studies of
adamantyl derivatives

2, 17-25

have been evaluated, leading to a series of potent

adamantane analogs active against H2N2 and H3N2 viruses.

However, few other

molecular scaffolds have been explored, which led us to search for novel scaffolds that
might provide new avenues for developing antagonists of AM2. The spirene guanidine
analog, 2-[3-azaspiro(5,5)undecanol]-2-imidazoline (BL-1743) (Figure 2), was previously
discovered through a high-throughput screen based on the ability of inhibitors to reverse
the toxicity associated with M2 channels expressed in the yeast Saccharomyces cerevisiae
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membranes.26 It is one of the few examples of non-adamantane-based M2 inhibitors
reported in the literature.27-29

Figure 2. The chemical structures of AM2 channel inhibitors.

The M2 channel, due to its proton conductance properties, disrupts the electrochemical
potential across the yeast cell membrane when expressed in high copy numbers. This
disruption results in retarded growth rate and eventually yeast cell death. The mechanism
of AM2 channel inhibition by BL-1743 was further characterized by electrophysiological
methods.30 BL-1743 is also able to inhibit the AM2 channel expressed in Xenopus
oocytes, as determined using the two-electrode voltage clamp (TEV) technique. It was
found that the majority of M2 sequences isolated from influenza viruses resistant to
amantadine were also resistant to BL-1743, which suggests that BL-1743 binds
competitively with amantadine. Interestingly, the kinetics of channel inhibition by BL1743 were more rapid, showing a fast onset of inhibition as well as a reasonably rapid
reversal of inhibition following removal of the compound.30,

31

This behavior contrasts

with that of amantadine, whose second-order rate constant for the onset of inhibition is
much slower than the diffusion-controlled rate, and whose off-rate is essentially
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irreversible on the minute to hour time scale of the experiment. The Hill coefficient for
inhibition was 1.0, which is consistent with the binding ratio of one BL-1743 per AM2
tetramer. Given the structural difference between BL-1743 and the amantadine class of
compounds, and the lack of any published SAR studies for analogs of BL-17423, we have
begun to explore this scaffold.

The goals of this study are to: 1) explore the structure-activity relationship of BL-1743; 2)
determine the binding specificity; 3) characterize the effects of the most potent inhibitor
on the conformation and dynamics of AM2-TM in the lipid bilayer using solid-state NMR
(SSNMR) spectroscopy. SSNMR is ideally suited to atomic-level structural analysis of
membrane proteins and their ligands in lipid bilayers, since it does not require long-range
order nor fast isotropic mobility. Previously, SSNMR has been used to investigate the
orientation, dynamics, and conformation of key residues of the influenza M2 protein; 32-35
however, it is only recently beginning to be used to investigate drug-M2 interactions in
lipid bilayers.36, 37 We report herein the synthesis of our first generation BL-1743 series of
inhibitors. Binding of the most potent compound, 3-azaspiro[5,5]undecane hydrochloride
(9) to AM2 was characterized by 2D

13

C and

15

N NMR correlation experiments and

linewidth analysis.

5.3 Results and Discussion
5.3.1 Structure-activity relationship (SAR) study of BL-1743
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The activity of the inhibitors were measured using the TEV technique with full length
Udorn AM2 protein in the Xenopus oocytes membrane.38 All inhibitors were initially
tested at 100 M; those that inhibited the AM2 channel activity by more than 70% (less
than 30% remaining activity) were chosen for measurement of their IC50.

Synthesis of BL-1743 started with reduction of commercially available 3,3pentamethylene

glutarimide

with

LiAlH4

in

refluxing

THF

to

give

3-

azaspiro[5,5]undecane hydrochloride (9) in 75% yield after treatment with HCl/ether.
Subsequent nucleophilic substitution of 2-methylthio-2-imidazoline with 9 furnished the
model compound BL-1743.39 Reductive amination of 9 with different aldehydes using
NaBH(OAc)3/HCO2H in dichloroethane40 gave 1-8 with yields of 65% to 95%. The
results showed that replacements of the imidazoline ring of BL-1743 with either
hydrophobic substitutions or heterocycles lacking hydrogen-bond donors (HBD) led to
complete loss of potency at 100 M, as AM2 still retained >90% activity after inhibition.
In contrast, inhibitors 7 and 8 with the imidazole headgroup retain moderate inhibition.
This suggests that a hydrogen-bond donor may be necessary for the inhibitory activity.
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Scheme 1. Synthesis of BL-1743 and N-substituted azaspiro[5,5]undecane 1-8.
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Table 1. AM2 channel proton conductivity after applying 100 M inhibitors with cyclic
hydrophobic and heterocyclic head groups.

As a positive control, the AM2 channel showed 6% remaining activity after 100 M
amantadine inhibition. The IC50 of amantadine was determined to be 16 M.
a
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Interestingly, the simple piperidine lacking the imidazoline group altogether, spiropiperidine 9 (3-azaspiro[5,5]undecane hydrochloride), had an IC50 of 0.92 ± 0.11 M
(n = 6), representing a more than 45-fold increase in potency relative to BL-1743. Thus,
the bulky imidazoline head group does not contribute to the affinity of BL-1743 to AM2.
To determine whether the secondary amine is important for the activity of spiropiperidine 9, it was converted to the corresponding N-methyl piperidine 10 by reductive
amination.

This

modification

decreased

the

activity

approximately

20-fold

(IC50 = 20.6±2.14 M; n = 6), indicating that the polar secondary amine might be
functionally important for inhibitor binding. To assess the potential role of charge, spiropiperidine 9 was modified to the corresponding unsubstituted guanidine (11), urea (12),
thiourea (13), and sulfonamide (14). Synthesis of 11, 12, 13 were achieved using standard
procedure by treatment of 9 with 1,3-diBoc-2-methyl-2-thiopseudourea, trimethylsilyl
isocyanate, and trityl thioisocyanate respectively, followed by hydrolysis or acid
deprotection (Scheme 2). The sulfonamide 14 was prepared using the literature reported
sulfamoylating

agent,

N-(tert-Butoxycarbonyl)-N-[4-(dimethylazaniumylidene)-1,4-

dihydropyridin-1-ylsulfonyl]azanide.41

The guanidine compound 11 had a potency

similar to the parent BL-1743, indicating that the cyclic ring in the imidazoline was not
essential for activity.

The urea 12 and thiourea 13, by contrast, were not active.

Interestingly, however, the sulfonamide 14 had a potency similar to BL-1743, indicating
that a positively charged group was not a prerequisite for activity. Taken together, our
results show that the most potent compound in this series was the simple piperidine, and
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conversion of the secondary amine in 9 to tertiary amines decreased the potency.
Furthermore, while compound 9 is likely to be charged at neutral pH, overall positive
charge does not appear to be a prerequisite for activity, as long as appropriately placed
polar groups were included as in 14.

In our amantadine-complexed AM2-TM structure, the electron density map fits better
with the positively charged amantadine amine pointing down towards H37, but the
distance is too far (6.8 Å) for effective hydrogen bonding between the imidazoles and the
amine (or ammonium group). However, more recent and higher-resolution AM2-TM
crystal structures have shown two layers of well organized H2O above H37 (unpublished
result). Thus, it is possible that the polar HBD group at the end of the inhibitor
contributes to potency by forming hydrogen bonds with structural H2O molecules, while
hydrophobic substituents at the same position would lead to energetically unfavorable
dehydration of polar residues in the channel. This hypothesis might explain the reduced
binding affinity of inhibitor 10 with methyl substitution. Similar structure-activity
relations were also found in adamantane analogs, where methylation and ethylation of the
amine group of all heterocycles caused a reduction of anti-influenza A virus activity 17, 1922, 25

.
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Scheme 2. Synthesis of methylated inhibitor 10, guanidine (11), urea (12), thiourea (13),
and sulfonamide (14).
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Table 2. AM2 channel activities after applying 100 M inhibitors with HBD acyclic head
groups.

Spiro amines with different fused ring sizes have also been synthesized to determine
which one best fits the AM2 channel. Reduction of 8-azaspiro [4,5] decane-7, 9-dione by
LiAlH4 gave 8-azaspiro [4,5]decane hydrochloride 15 after treatment with HCl/ether. 2azaspiro[4,5]decan-3-one was reduced and acidified to give 2-azaspiro[4,5]decane

154

hydrochloride (16) under the same condition. Ketal (17) and dithiene (18) versions of the
spiro-piperidine 9 were synthesized by polyphosphoric acid catalyzed condensation.42
Compared to 9, the contraction of the bottom cyclohexane ring to cyclopentane (15) led
to a significant loss of activity (IC50 = 8.14±0.18 M). Similarly, contraction of the
piperidine ring to a pyrolidine (16) was also found to be unfavorable. These comparisons
showed that the spiro[5,5] undecane was the most active. The ketal (17) and dithiene (18)
retain the spiro 6-membered ring of spiro-piperidine 9, but have increased hydrophilicity
compared to 9 (clogP = 3.38). The introduction of a ketal in 17 completely abolished the
binding affinity (IC50>100 M), while dithiene 18 retained moderate binding
(IC50 = 37.6±2.67 M). Presumably this finding reflects the energetics of dehydration of
17, which has a clogP of -0.30 as compared to that of 18 (clogP = 1.28).

To further test the role of the spiro system, the 6,6-fused decahydroisoquinoline (cis/trans
mixture and trans isomer) was also tested and found to be less active than the
corresponding spiro[5,5]undecane scaffold based inhibitors.

Two 4,4-disubstituted

piperidines (19 and 20) were also synthesized and found to be no more advantageous than
the corresponding spiro-piperidine. Thus, the [5,5] spiro ring system appeared to provide
the greatest activity.
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Scheme 3. Synthesis spiro-amines 15, 16, 17 and 18 with different ring sizes and
substitutions.

Table 3. AM2 channel activities after applying 100 M inhibitors of 3-azaspiro
[5,5]undecane analogs.
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Scheme 4. Synthesis 4,4-disubstituted piperidines.

Table 4. Potency of decahydroisoquinoline and 4,4-disubstituted acyclic piperidines.

5.3.2 Structural basis for activity
The most active compound, spiro-piperidine 9, was selected for docking experiments
with AM2-TM. The minimum energy conformation of 9 was docked into the previously
published high resolution AM2-TM structure (PDB code: 3BKD). As would be expected,
the optimized docking conformation showed spiro-piperdine 9 located inside the channel
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with the amine group pointing either up or down the channel. The amine group of 9 could
be hydrated in both orientations, but in neither case a specific interaction was formed
between the amine and the AM2-TM protein.

(a)

(b)

(c)

Figure 3. Docked conformation of spiro-piperidine 9 in AM2-TM channel (Only three of
four helices are shown to enhance viewing of the inhibitor). a) Crystal structure of the
amantadine-AM2 complex (PDB: 3BKD). Minimized conformation of spiro-piperidine 9
inside the AM2 channel with the amine group pointing down (b) and up (c). Docking
experiments are performed using Autodoc. Side chains of drug-surrounding residues V27,
A30, S31, G34 and functionally essential residues H37 and W41 are shown.

When overlaying the optimized docking conformation of the 9-AM2-TM complex with
the X-ray crystal structure of amantadine-bound AM2-TM, we found that spiro-piperidine
9 and amantadine occupied approximately the same region in the channel, spanning
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residues 27-34. A new structure was generated when overlaying the bottom cyclohexane
ring of spiro-piperidie 9 with amantadine. Interestingly this hybrid molecule was recently
reported in the literature to have highly potent anti-influenza activity, being 12-fold more
active than amantadine and 2-fold more active than rimantadine when tested in virus
infection assays. It is interesting to note that spiro-piperidine 9 is also 10 to 20-fold more
active than amantadine 20. Thus, it is likely that the bulky, hydrophobic adamantyl group
of the spiro adamantane compound is not required for potent activity.

Figure 4. Conformational analysis of spiro-piperidine 9. 3D conformations of amantadine
and spiro-piperidine 9 are minimized using MOPAC in Chem3D. Models are generated
in Pymol.
5.3.3 Solid-state NMR characterization of AM2-TM bound to spiro-piperidine 9
To investigate the interaction between AM2-TM and spiro-piperidine 9 as well as the
effect of the drug on the peptide structure, we measured the 15N and 13C SSNMR spectra
of bilayer-bound AM2-TM peptide complexed to the drug. The

15

N cross-polarization

(CP) spectra of the peptide were measured at both 313 K and 243 K. The low-temperature
spectra report the conformation and conformational distribution of AM2-TM, while the
high-temperature spectra reflect the dynamics of the peptide channel. AM2-TM (22-46)
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was bound to DLPC bilayers at a peptide : lipid molar ratio of 1 : 15, where the peptide is
known to form tetramers based on previous
Figure 5a compares the low-temperature

15

19

F spin diffusion NMR experiments.43

N spectra of the apo, amantadine-bound and

spiro-piperidine 9-bound AM2-TM. The spiro-piperidine-bound peptide shows
significantly narrower linewidths for all four labeled sites (L26, A29, G34, and I35) than
either the apo or the amantadine-bound peptide. Since at low temperature all
conformations are present, the narrower linewidths suggest that spiro-piperidine binding
induces more homogeneous conformation of AM2-TM. To verify this possibility, we
carried out

15

N spin-echo measurements at 243 K. Residues L26, A29 and the upfield

G34 peak (G34a) show very similar 15N T2 values of 10 – 11 ms for both the amantadinebound peptide and the spiro-piperidine-bound peptide, confirming that the line narrowing
by spiro-piperidine 9 indeed results from reduced conformational heterogeneity of these
residues. However, the downfield G34 peak (G34b) increased its 15N T2 from 12 ms to 15
ms while the I35

15

N T2 increased from 13 ms to 22 ms in the presence of 9. These

significant T2 increases indicate that the G34-I35 junction of the peptide is more
immobilized by spiro-piperidine 9 than by amantadine, thus part of the line narrowing for
these two sites is due to the reduction of dynamic disorder.
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Figure 5. 15N CP-MAS spectra of LAGI-AM2-TM in DLPC bilayers at (a) 243 K and (b)
313 K. Three states of the peptide are compared: apo (bottom), bound to amantadine
(middle row), and bound to spiro-piperidine 9 (top row).
2D

15

N-13C correlation spectra in Figure 6 confirm the increased conformational

homogeneity of AM2-TM upon spiro-piperidine binding. The most significant line
narrowing is found at I35 and L26, whereas more modest line narrowing is observed at
A29 and G34 (Table 5). The line narrowing of L26 is interesting, because this residue is
at the edge of the binding pocket of amantadine based on the crystal structure.8 Indeed,
amantadine-bound AM2-TM did not show narrower L26

15

N linewidth than apo AM2-

TM. This suggests that the bulkier spiro-piperidine 9 has a larger rigidifying effect that
extends over a larger area of the AM2 channel. Similarly, based on the 15N linewidth, I35
exhibits little conformational ordering by amantadine but is significantly ordered by
spiro-piperidine 9. Taken together, the data indicate that spiro-piperidine 9, compared to
amantadine, induces a more homogeneous structure of AM2-TM from L26 to I35.
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Figure 6. 2D 15N-13C spectra of LAGI AM2-TM in DLPC bilayers at 243 K. (a) Apo
peptide. (b) Amantadine-bound peptide. (c) Spiro-piperidine 9 bound peptide. (d) 1D 15N
cross sections of G34. Note the separation of two G34 peaks in the spiro-piperidinebound sample.

The

15

N spectra in Figures 5 and 6 also show that the G34 chemical shifts are very

sensitive to the state of AM2-TM. The apo peptide shows a broad G34

15

indicating a distribution of conformations. Upon amantadine binding this broad

N peak,

15

N peak

is partly resolved into two peaks with similar heights. Spiro-piperidine 9 shifts the
conformational equilibrium to predominantly the downfield

15

N conformer (G34b, 110.3

ppm), which also becomes narrower, indicating reduced conformational heterogeneity.

Table 5. 15N chemical shifts (N) and full width at half maximum (1/2) of LGAI AM2TM in DLPC bilayers at 243 K.
Apo

Amantadine-bound

Spiro-piperidine 9 bound

N (ppm)

1/2 (Hz)

N (ppm)

1/2 (Hz)

N (ppm)

1/2 (Hz)

L26

117.7

340

117.5

340

117.5

210

A29

120.9

200

121.7

210

121.2

170

G34a

107.1

270

106.3

240

106.6

280
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G34b
I35

In addition to

-

-

109.7

230

110.3

140

122.3

280

124.6

270

124.8
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15

N chemical shifts, we measured the

13

C chemical shifts of the peptide

using the 2D INADEQUATE experiment. Figure 7 shows the 2D spectra of AM2-TM in
the three states. The main linewidth reduction is found for L26 sidechain C and C
peaks, which became much better resolved in the spiro-piperidine-bound sample (Figure
7b). In addition, the other L26 C peak (24 ppm) is shifted downfield compared to the
apo and amantadine-bound peptide (Figure 7c). A recent study by London et al. 44 and our
own studies of Val and Leu sidechains in protein NMR structures found that methyl

13

C

chemical shifts are sensitive to protein sidechain conformation. Thus, these L26 chemical
shift changes suggest perturbation and ordering of the L26 sidechain by spiro-piperidine
9.
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Figure 7. (a) 2D 13C-13C INADEQUATE spectrum of spiro-piperidine-bound AM2-TM
at 243 K. (b) The L26 C/Cregion of apo, amantadine-bound, and spiro-piperidinebound peptide. (c) 1D cross sections at 1 = 49 ppm shows the line narrowing and
chemical shift changes induced by the two drugs.

In the liquid-crystalline phase of DLPC lipids, it is known that the apo and amantadinebound AM2-TM undergoes fast (> 120 kHz) uniaxial rotational diffusion around the
membrane normal

32

. This is also observed for the spiro-piperidine-bound peptide based

on 15N spectra measured as a function of temperature (Figure 8). The lowest (243 K) and
highest (313 K) temperatures give the greatest intensities, whereas at intermediate
temperatures of 263 – 293 K most 15N signals are suppressed. This trend is characteristic
of molecular motion, which interferes with 1H decoupling and 1H-15N CP when the
motional rates are comparable to the 1H-15N dipolar couplings. When the motions are
much slower or faster than the dipolar interaction, rigid-limit or motionally averaged
spectra with high intensities are obtained.

Figure 8b and c plot the intensities of the four

15

N peaks at different temperatures

quantitatively. The L26, A29 and G34a intensities show the aforementioned minimum at
intermediate temperature. In contrast, I35 and G34b do not exhibit intensity recovery at
high temperature, indicating that these two residues are still in the intermediate motional
regime at 313 K. Thus, the two G34 conformations have different dynamics, with the
G34b conformer being more immobilized than G34a. The intermediate motion of G34b
and I35 at 313 K is also consistent with their longer

15

N T2 values at low temperature,
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indicating that this region of the peptide is more immobilized by spiro-piperidine 9 than
are other residues.

Figure 8. (a) Variable-temperature 15N CP-MAS spectra of LAGI AM2-TM in DLPC
bilayers from 243 K to 313 K. (b) I35 and G34 intensities as a function of temperature.
G34a: 106.6 ppm. G34b: 110 ppm. Note the recovery of the G34a intensity at 313 K, in
contrast to G34b and I35. (c) L26 and A29 15N intensities as a function of temperature.

5.4 Conclusion
In summary, a class of spirene-based AM2 inhibitors was identified from this study. The
most potent compound from this series, 3-azaspiro[5,5]undecane hydrochloride (9),
showed an IC50 of 0.92±0.11 M, which is more than an order of magnitude more potent
than amantadine. Solid-state NMR data indicate that compound 9 interacts with AM2165

TM differently from amantadine: it affects a longer stretch of the transmembrane helix,
induces a more homogeneous conformation of the peptide, and immobilizes the G34-I35
region. These structural findings make compound 9 an attractive molecule for atomiclevel structural investigation of drug-complexed AM2-TM. It is well known that the apoform of AM2-TM has extensive conformational and dynamic disorder in lipid bilayers 32,
36, 45

and detergents.11 Amantadine was previously found to accelerate the peptide motion,

which enhances the NMR spectral resolution at ambient temperature.36 However, the low
temperature 15N spectra shown here indicate that substantial conformational heterogeneity
remains in the amantadine-bound AM2-TM. Spiro-piperidine 9 significantly reduces this
conformational heterogeneity, and immobilizes the G34-I35 region of the peptide, which
is a hot spot of conformational change in response to environments. These favorable
properties make spiro-piperidine a promising compound for examining the structure of
M2-channel complex in lipid bilayers. Continuing synthetic studies have been initiated to
generate more diversity based on the spirene scaffold, with the aim of discovering
inhibitors to target AM2 mutants, predominantly S31N.

5.5 Experimental details
In Vitro cRNA Transcription, Heterologous Expression and Electrophysiological
Recordings
The cDNA encoding to the influenza virus A/Udorn/72 AM2 protein was inserted into
pGEMHJ (a gift from N.Dascal Tel-Aviv University, Israel) for the expression on
Xenopus oocytes. Plasmid was linearized with HindIII, and capped cRNA was transcribed
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in vitro using T7 RNA polymerase (mMessage mMachine; Ambion, Austin, TX). The
quality of transcripts was assessed by agarose gel electrophoresis and ethidium bromide
staining and analytical UV spectroscopy. Stage V-VI Xenopus laevis oocytes were
prepared as described previously.46 Oocytes were injected with 5-10 ng of cRNA in 50
nl/oocyte, and assayed 2-3 days later. Two electrode voltage clamp recordings were
carried out using TEV-200 (Dagan, Minneapolis, MN) connected to DIGIDATA 1440A
and pCLAMP10 (Axon Instruments, Foster City, CA). Oocytes were superfused with
Barth’s solution containing 88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 0.3 mM NaNO3,
0.71 mM CaCl2, 0.82 mM MgCl2 and 15 mM HEPES for pH 8.5 or 15 mM MES for pH
5.5. Currents were recorded at -20 mV. Dose-inhibition curves were usually constructed
by applying 1-3 concentrations per oocyte of antagonist mixed in recording pH5.5 Barth’s
solution, and currents were normalized to the steady-state current obtained with pH5.5
Barth solution alone. Data were analyzed using the ORIGIN 8.0 software (OriginLab,
Northampton, MA).

Preparation of M2 membrane samples for solid-state NMR
13

C and

15

N-labeled AM2-TM (22-46) of the Udorn strain

47

(SSDPL VVAASII

GILHLIL WILDRL) was synthesized by PrimmBiotech (Cambridge, MA) and purified to
>95%.

13

C and

15

N-labeled amino acids were placed at L26, A29, G34 and I35 in one

sample and V27, A30, I33 and L38 in another sample.
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AM2-TM was reconstituted into 1, 2-dilauroyl-sn-glycero-3-phosphatidylcholine (DLPC)
or 1,2-dimyristoyl-sn-glycero-3-phosphatidylcholine (DMPC) bilayers by detergent
dialysis as described before.43,

48

The peptide structure and dynamics have been

extensively characterized in both bilayers.32, 36 AM2-TM was first dissolved in octyl--Dglucopyranoside (OG) solution, then mixed with the lipid vesicle solution at pH 7.5. OG
was then removed by dialysis for 3 days. The peptide-lipid suspension was
ultracentrifuged to obtain the membrane pellet. The peptide: lipid molar ratio was 1 : 15.
3-azaspiro [5,5]undecane was added to the membrane by either direct titration to the
pellet at a peptide : drug molar ratio of 1 : 2, or through a 10 mM solution before
ultracentrifugation. For the latter, the percent spiro-piperidine 9 remaining in the
supernatant was quantified by 1H solution NMR to be 60%, giving a peptide: drug molar
ratio of 1: 8 in the membrane pellet.

Solid-state NMR spectroscopy
SSNMR experiments were carried out on Bruker wide-bore AVANCE and DSX
spectrometers at 14.1 Tesla and 9.4 Tesla (Karlsruhe, Germany) using 4 mm magic-anglespinning (MAS) probes. Radio-frequency pulse lengths were typically 5 s for
15

N and 3.5-4.0 s for 1H. 1H TPPM

49

or SPINAL

50

13

C and

decoupling field strengths of 60 –

70 kHz were applied. 13C and 15N chemical shifts were referenced, respectively, to the Gly C’ signal at 176.49 ppm on the TMS scale and the

15

N signal of N-acetyl-valine at

122.0 ppm on the liquid ammonia scale. 2D 13C-13C correlation was carried out using the
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INADEQUATE sequence

51, 52

which better resolves sidechain methyl signals than the

standard spin diffusion experiments. 2D

15

N-13C correlation was carried out using an

HSQC-type sequence53 incorporating a REDOR train for

15

N-13C coherence transfer.54

The 2D spectra were measured at 243 K to freeze the peptide motion.

The numbers of scans for the 1D

15

N CP spectra of the apo-, amantadine-bound and

spiro-piperidine-bound AM2-TM were 3,000-6,000 at low temperatures (< 263 K) and
30,000-40,000 at high temperatures (> 263 K). For the 2D

15

N-13C correlation spectra,

352 scans were coadded per t1 slice and a maximum t1 evolution time of 8.8 ms was used,
resulting in a measuring time of 21 hours for each experiment. For the 2D

13

C-13C

INADEQUATE spectra, the number of scans per t1 slice was 192 and the maximum t1
evolution time was 6.4 ms. The measuring time was 20 hours for each experiment.

Chemical synthesis
All chemicals were purchased from commercial vendors and used without further
purification unless otherwise noted. 3, 3-Pentamethylene glutarimide was purchased from
Bosche, NJ. 1H NMR and

13

C NMR spectra were recorded on a DMX-360 NMR

spectrometer. Chemical shifts are reported in parts per million referenced with respect to
residual solvent (CHCl3 = 7.26 ppm and DMSO-d6 = 2.50 ppm) or from internal standard
tetramethylsilane (TMS = 0.00 ppm). The following abbreviations were used in reporting
spectra: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of
doublets. All reactions were carried out under N2 atmosphere, unless otherwise stated.
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HPLC grade solvents were used for all the reactions. Column chromatography was
performed using silica gel (230-400 mesh). Low-resolution mass spectra were obtained
on an LC platform from Micromass using ESI technique.

3-azaspiro[5,5]undecane chloride (9)
To a solution of the LiAlH4 (0.38 g, 10 mmol) in THF (20 mL) at 0oC was added 3,3pentamethylene glutarimide (0.36 g, 2 mmol) in THF (10 mL) dropwise under a nitrogen
atmosphere. The reaction was allowed to warm to RT over 30 min, then refluxed
overnight. The solution was cooled to 0oC, and quenched with H2O (0.38 mL), 15%
NaOH (0.38 mL), and H2O (1.14 mL) sequentially. The resulting slurry was filtered. The
filtrate was diluted with CH2Cl2, washed with brine, dried over MgSO4, filtered,
concentrated

in

vacuo

and

purified

by

flash

chromatography

to

give

3-

azaspiro[5,5]undecane as a yellow oil. The hydrochloride salt was prepared by passing
HCl gas into the ether solution of 3-azaspiro[5,5]undecane at 0oC, followed by decanting
the ether supernatant. The final white solid (0.28 g, 75% yield) was dried in vacuo. 1H
NMR (360 MHz, CDCl3)  9.29 (br s, 2H), 3.14 (t, J = 5.87 Hz, 4H), 1.74 (t, J = 5.87 Hz,
4H), 1.43 (m, 10H);

13

C NMR (90 MHz, CDCl3)  39.93, 35.85, 32.76, 30.60, 26.53,

21.37; ESI-MS: Calculated for C10H20ClN (M -Cl)+ 154.2, Found: 154.5.

3-(4,5-dihydro-1H-imidazol-2-yl)-3-azaspiro[5,5]undecane hydroiodide (BL-1743)
3-Azaspiro[5,5]undecane (0.38 g, 2 mmol) and 2-methylthio-2-imidazoline hydroiodide
(0.44 g, 1.8 mmol) was refluxing in CH3OH overnight, concentrated in vacuo and
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purified by flash chromatography to give yellow oil (0.26 g, 65% yield). 1H NMR (360
MHz, CDCl3)  8.27 (br s, 2H), 3.72 (s, 4H), 3.39 (t, J = 5.83 Hz, 4H), 1.50 (t, J = 5.94
Hz, 4H), 1.47-1.44 (m, 10H); 13C NMR (90 MHz, CDCl3)  159.48, 43.39, 42.73, 36.02,
35.26, 30.83, 26.65, 21.61. 21.49; ESI-MS: Calculated for C13H24IN3 (M -I)+ 222.3,
Found: 222.5.

3-(cyclopropylmethyl)-3-azaspiro[5,5]undecane (1)
To a solution of 3-azaspiro[5,5]undecane (0.34 g, 2.2 mmol), cyclopropanecarbaldehyde
(0.14 g, 2 mmol) and NaBH(OAc)3 (0.64 g, 3 mmol) in dichloroethane (10 mL) were
added AcOH (0.12 mL, 2 mmol), the resulting suspension was stirred overnight,
quenched with NaHCO3 and extracted with CH2Cl2 twice, the combined organic layer
was washed with brine, and dried with MgSO4. The solution was filtered, concentrated in
vacuo and purified by flash chromatography.

The compound was converted to the

hydrochloride by passing HCl gas into the ether solution of 3-(cyclopropylmethyl)-3azoniaspiro[5,5]undecane at 0oC, followed by decanting the ether supernatant, the final
white solid (0.39 g, 80% yield) was dried in vacuo. 1H NMR (360 MHz, CDCl3)  2.45 (t,
J=5.66 Hz, 4H), 2.23 (d, J=6.51 Hz 2H), 1.49 (t, J= 5.66 Hz, 4H), 1.48-1.40 (m, 6H),
1.38-1.30 (m, 4H), 0.92-0.82 (m, 1H), 0.52-0.47 (m, 2H), 0.11-0.17 (m, 2H);

13

C NMR

(90 MHz, CDCl3)  64.55, 49.67, 36.47, 35.46, 31.00, 27.12, 21.73, 8.74, 4.19; ESI-MS:
Calculated for C14H25N (M +H)+ 208.4, Found: 208.4.
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3-(cyclopentylmethyl)-3-azaspiro[5,5]undecane (2)
This compound was prepared by the same procedure as described for the synthesis of 1.
95% yield. 1H NMR (360 MHz, CDCl3)  2.35 (t, J= 5.56Hz, 4H), 2.25 (d, J=7.08 Hz,
2H), 2.06-2.02 (m, 1H), 1.76-1.73 (m, 2H), 1.58-1.52 (m, 4H), 1.45 (t, J= 5.56 Hz, 4H),
1.43-1.39 (m, 6H), 1.39-1.31 (m, 4H), 1.20-1.14 (m, 2H); 13C NMR (90 MHz, CDCl3) 
65.52, 49.93, 37.80, 36.51, 35.47, 32.08, 31.00, 27.14, 25.44, 21.74; ESI-MS: Calculated
for C16H29N (M +H)+ 236.4, Found: 236.6.

3-(thiophen-3-ylmethyl)-3-azaspiro[5,5]undecane (3)
This compound was prepared by the same procedure as described for the synthesis of 1.
92% yield. 1H NMR (360 MHz, CDCl3)  7.24 (d, J= 4.88Hz, 1H), 7.09 (s, 1H), 7.04 (d,
J= 4.88Hz, 1H), 3.35 (s, 2H), 2.37 (t, J=5.52Hz, 4H), 1.46 (t, J= 5.52 Hz, 4H), 1.37-1.34
(m, 6H), 1.30-1.26 (m, 4H); 13C NMR (90 MHz, CDCl3)  129.02, 125.39, 123.11, 58.14,
49.37, 36.77, 36.35, 30.92, 27.08, 21.72; ESI-MS: Calculated for C15H23NS (M +H)+
250.4, Found: 250.4.

3-((1-methyl-1H-pyrazol-4-yl)methyl)-3-azaspiro[5,5]undecane (4)
This compound was prepared by the same procedure as described for the synthesis of 1.
82% yield. 1H NMR (360 MHz, CDCl3)  7.93 (s, 1H), 7.28 (s, 1H), 3.87 (s, 3H), 3.41 (s,
2H), 2.38 (t, J=5.38Hz, 4H), 1.46 (t, J= 5.38 Hz, 4H), 1.39-1.34 (m, 6H), 1.30-1.24 (m,
4H);

13

C NMR (90 MHz, CDCl3)  141.15, 140.30, 130.18, 52.93, 48.97, 39.03, 36.29,
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35.45, 30.90, 27.05, 21.70; ESI-MS: Calculated for C15H25N3 (M +H)+ 248.4, Found:
248.6.

3-(3-azaspiro[5,5]undecan-3-ylmethyl)-5-methylisoxazole (5)
This compound was prepared by the same procedure as described for the synthesis of 1.
75% yield. 1H NMR (360 MHz, CDCl3)  6.00 (s, 1H), 3.54 (s, 2H), 2.41 (t, J=5.73, 4H),
2.39 (s, 3H), 1.46 (t, J= 5.73 Hz, 4H), 1.39-1.35 (m, 6H), 1.30-1.25 (m, 4H);

13

C NMR

(90 MHz, CDCl3)  169.41, 161.90, 102.05, 53.94, 49.49, 36.74, 30.75, 27.05, 21.68,
12.47; ESI-MS: Calculated for C15H24N2O (M +H)+ 249.4, Found: 249.6.

3-(pyridin-2-ylmethyl)-3-azaspiro[5,5]undecane (6)
This compound was prepared by the same procedure as described for the synthesis of 1.
84% yield. 1H NMR (360 MHz, CDCl3)  8.56 (d, J = 4.8 Hz, 1H), 7.63 (td, J = 7.6, 1.6
Hz, 1H), 7.40 (d, J = 7.2 Hz, 1H), 7.15-7.13 (m, 1H), 3.65 (s, 2H), 2.44 (t, J=5.58 Hz,
4H), 1.48 (t, J= 5.58Hz, 4H), 1.39-1.36 (m, 6H), 1.30-1.25 (m, 4H); 13C NMR (90 MHz,
CDCl3)  149.36, 136.47, 130.58, 123.42, 122.03, 65.32, 49.79, 36.44, 35.46, 30.87,
27.10, 21.72; ESI-MS: Calculated for C16H24N2 (M +H)+ 245.4, Found: 245.6.

3-((1H-imidazol-4-yl)methyl)-3-azaspiro[5.5]undecane (7)
The same procedure as described for synthesis 1. 68% yield. 1H NMR (360 MHz,
CD3OD) δ 8.97 (s, 1H), 7.81 (s, 1H), 4.56 (s, 2H), 3.34 (br s, 4H), 1.77 (br s, 4H), 1.54173

1.48 (m, 10H);

13

C NMR (90 MHz, CDCl3)  137.47, 124.34, 123.60, 50.18, 49.86,

34.31, 31.21, 27.58, 22.50; ESI-MS: Calculated for C14H23N3 (M +H)+ 234.4, Found:
234.6.

3-((1H-imidazol-2-yl)methyl)-3-azaspiro[5.5]undecane (8)
This compound was prepared by the same procedure as described for the synthesis of 1.
65% yield. 1H NMR (360 MHz, CD3OD)  7.51 (s, 2H), 4.55 (s, 2H), 3.22 (t, J=5.94Hz
4H), 1.74 (t, J=6.01Hz, 4H), 1.47-1.45 (m, 10H); 13C NMR (90 MHz, CDCl3)  123.49,
51.45, 50.37, 34.64, 31.16, 27.62, 22.51; ESI-MS: Calculated for C14H23N3 (M +H)+
234.4, Found: 234.6.

3-methyl-3-azoniaspiro[5,5]undecane chloride (10)
To a solution of 3-azaspiro[5,5]undecane (0.38 g, 2 mmol), formaldehyde (0.15 g 5
mmol) and NaBH(OAc)3 (0.42 g, 2 mmol) in dichloroethane (10 mL) were added AcOH
(0.12 g, 2 mmol); the resulting suspension was stirred overnight, diluted with NaHCO3
extracted with CH2Cl2 twice, washed with brine, and dried with MgSO4. The solution
was filtered, concentrated in vacuo and purified by flash chromatography. The
hydrochloride salt was prepared by passing HCl gas into the ether solution of 3-methyl-3azoniaspiro[5,5]undecane at 0oC, followed by decanting the ether supernatant, the final
white solid (0.33 g, 80% yield) was dried in vacuo. 1H NMR (360 MHz, CDCl3)  3.353.31 (m, 2H), 2.83-2.79 (m, 2H), 2.75 (d, J=4.89Hz, 3H), 2.10-2.00 (m, 2H), 1.77-1.74
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(m, 2H), 1.45-1.39 (m, 10H);

13

C NMR (90 MHz, CDCl3)  50.56, 43.69, 39.69, 32.91,

31.43, 26.49, 21.55; ESI-MS: Calculated for C11H22ClN (M -Cl)+ 168.4, Found: 168.6.

3-azaspiro[5,5]undecane-3-carboximidamide (11)
3-azaspiro[5,5]undecane (0.38 g, 2 mmol), HgCl2 (0.54 g, 2 mmol) and 1,3-bis(tertbutoxycarbonyl)-2-methyl-2-thiopseudourea (0.58 g, 2 mmol) were stirred in DMF (10
mL) under N2 atmosphere for 24 hr, H2O was added, and the white precipitate was
removed by filtration. The precipitate was washed with CH2Cl2 twice, the combined
filtrate was extracted with CH2Cl2, washed with brine, dried with MgSO4, concentrated in
vacuo and purified by flash column. The Boc protecting group was removed by 20%
TFA/CH2Cl2 for 2 hr at RT. Excess TFA was removed by passing N2 through the solution
to give yellow solid which was subsequently purified by flash column (0.28 g, 71% over
two steps). 1H NMR (360 MHz, CD3CN)  5.11 (br s 2H), 3.12 (t, J = 5.74 Hz, 4H), 1.57
(t, J = 5.74 Hz, 4H), 1.46-1.35 (m, 10H); 13C NMR (90 MHz, CD3CN)  157.20, 41.78,
35.64, 35.06, 26.48, 21.26, 20.94; ESI-MS: Calculated for C11H21N3 (M+H)+ 196.3,
Found: 196.3.

3-azaspiro[5,5]undecane-3-carboxamide (12)
Triethylamine (0.42 mL, 3 mmol) was added to 3-azaspiro[5,5]undecane (0.38 g, 2 mmol)
in CH2Cl2 (10 mL) at 0oC, then trimethylsilyl isocyanate (0.35 g, 3 mmol) was added
dropwise to the solution under N2. The solution was allowed to warm to RT and stirred
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for 7 hr. H2O was added and the solution was extracted with CHCl3 twice, the combined
organic layer was dried with MgSO4, filtered, concentrated in vacuo and purified by flash
column to give a white powder (0.32 g, 82% yield). 1H NMR (360 MHz, CD3CN)  5.23
(br s, 2H), 3.31 (t, J = 5.87 Hz, 4H), 1.46-1.36 (m, 14H); 13C NMR (90 MHz, CD3CN) 
160.23, 41.09, 37.21, 36.95, 27.87. 22.57, 21.83; ESI-MS: Calculated for C11H20N2O (MH)- 195.3, Found: 195.1.

3-azaspiro[5,5]undecane-3-carbothioamide (13)
3-azaspiro[5,5]undecane (0.38 g, 2 mmol) and trityl isothiocyanate (0.54 g, 1.8 mmol)
was stirred in THF at RT for 8 hr until the disappearance of trityl isothiocyanate (based
on TLC), then the mixture was concentrated in vacuo and purified by flash column
(hexane/CHCl3=1:1 to CHCl3) to give a white foam. This was followed by deprotection
of trityl group using 20% TFA/CH2Cl2 for 2 hr at RT. TFA was removed by passing N2
through the solution to give yellow solid which was subsequently purified by flash
column (0.29 g, 76% yield over two steps). 1H NMR (360 MHz, CD3CN)  6.04 (br s 2H),
3.70 (t, J=5.76Hz, 4H), 1.48-1.37 (m, 14H), 1.46-1.36 (m, 14H);

13

C NMR (90 MHz,

CD3CN)  181.49, 45.25, 37.46, 37.08, 32.16, 27.89, 22.73; ESI-MS: Calculated for
C11H20N2S (M+Na)+ 236.4, Found: 236.8.

3-azaspiro[5,5]undecane-3-sulfonamide (14)
The sulfamoylating agent, N-(tert-Butoxycarbonyl)-N-[4-(dimethylazaniumylidene)-1,4176

dihydropyridin-1-ylsulfonyl]azanide, was synthesized according to literature protocols.41
3-azaspiro[5,5]undecane (0.38 g, 2 mmol) and the sulfamoylating agent (0.602 g, 2 mmol)
were stirred in CH2Cl2 (10 mL) at RT overnight. Solvent was removed by rotary
evaporation and the residue was purified by flash column to give tert-butyl 3azaspiro[5,5]undecan-3-ylsulfonylcarbamate. The Boc protecting group was removed by
20% TFA/CH2Cl2 for 2 hr at RT. Excess TFA was removed by passing N2 through the
solution to give yellow solid which was subsequently purified by flash column (0.29 g,
62% yield for 3 steps). 1H NMR (360 MHz, CD3CN)  5.01 (br s 2H), 3.03 (t, J = 5.78
Hz, 4H), 1.53 (t, J = 5.78 Hz, 4H), 1.46-1.35 (m, 10H);

13

C NMR (90 MHz, CD3CN) 

41.78, 35.62, 35.06, 26.41, 21.06, 20.84; ESI-MS: Calculated for C10H20N2O2S (M+H)+
233.3, Found: 233.1.

8-azoniaspiro[4,5]decane chloride (15)
Synthesis of 15 was accomplished following the same procedure as described for 9. 72%
yield. 1H NMR (360 MHz, CDCl3)  2.80 (t, J=5.62, 4H), 1.61 (t, J=5.62Hz, 4H), 1.431.40 (m, 8H); 13C NMR (90 MHz, CDCl3)  44.18, 41.43, 38.70, 35.45, 24.46; ESI-MS:
Calculated for C9H18ClN (M-Cl)+ 140.4, Found: 140.6.

2-azoniaspiro[4,5]decane chloride (16)
Synthesis of 16 was accomplished following the same procedure as described for 9. 85%
yield. 1H NMR (360 MHz, CDCl3)  9.67 (br s, 2H), 3.39 (Quintet, J=7.10 Hz, 2H), 3.07
177

(t, J=5.75Hz, 2H), 1.85 (t, J=7.49Hz, 2H), 1.52-1.46 (m, 10H);

13

C NMR (90 MHz,

CDCl3)  54.68, 43.97, 43.05, 35.86, 35.44, 25.72, 23.47; ESI-MS: Calculated for
C9H18ClN (M-Cl)+ 140.4, Found: 140.2.

1,5-dioxa-9-azaspiro[5,5]undecane (17)
4-Piperidone hydrochloride (0.31 g, 2 mmol), 1,3-propanediol (0.76 g, 10 mmol) and
phosphoric acid (0.5 g) were stirred at 65oC for 6 hr. Saturated Na2CO3 was added and
the solution was extracted with CHCl3 twice; the combined CHCl3 was washed with DI
H2O, dried over Mg2SO4, and concentrated in vacuo to give yellow oil. (0.23 g, 73%
yield). 1H NMR (360 MHz, CDCl3)  3.91 (t, J=5.62, 4H), 2.86 (t, J=5.58, 4H), 2.50 (s br,
1H), 1.84 (t, J=5.58Hz, 4H), 1.73 (quintet, J=3.56, 2H);

13

C NMR (90 MHz, CDCl3) 

108.62, 59.41, 43.26, 34.55, 25.87; ESI-MS: Calculated for C8H15NO2 (M+H)+ 158.2,
Found: 158.5.

1,5-dithia-9-azaspiro[5,5]undecane (18)
Synthesis of 18 was accomplished using the same procedure as described for 9. 75% yield.
1

H NMR (360 MHz, CDCl3)  2.96 (t, J=5.39, 4H), 2.83 (t, J=5.39, 4H), 2.06-1.97 (m,

6H), 1.56 (s, 1H); 13C NMR (90 MHz, CDCl3)  48.97, 42.49, 38.87, 26.20, 25.87; ESIMS: Calculated for C8H15NS2 (M+H)+ 190.3, Found: 190.4.

4,4-dimethylpiperidinium chloride (19)
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Synthesis of 19 was accomplished using the same procedure as described for 9. 87% yield.
1

H NMR (360 MHz, CDCl3)  9.37 (br s, 2H), 3.15 (t, J=5.97, 4H), 1.68 (t, J=5.97, 4H),

1.04 (s, 6H), 1.56 (s, 1H); 13C NMR (90 MHz, CDCl3)  40.64, 35.21, 28.29, 27.64; ESIMS: Calculated for C7H16ClN (M-Cl)+ 114.4, Found: 114.6.

4-ethyl-4-methylpiperidinium chloride (20)
Synthesis of 20 was accomplished using the same procedure as described for 9. 82% yield.
1

H NMR (360 MHz, CDCl3)  9.38 (br s, 2H), 3.19-3.09 (m, 4H), 1.77-1.73 (m, 2H),

1.71-1.62 (m, 2H), 1.37 (q, J=7.34Hz, 2H), 0.97 (s, 3H), 0.85 (t, J=7.45Hz, 2H);

13

C

NMR (90 MHz, CDCl3)  40.37, 33.41, 33.24, 30.70, 22.88, 7.52; ESI-MS: Calculated
for C8H18ClN (M-Cl)+ 128.2, Found: 128.4.
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6.1 ABSTRACT

The A/M2 proton channel of influenza A virus is a target for the anti-influenza drugs
amantadine and rimantadine, whose effectiveness was diminished by the appearance of
naturally occurring point mutants in the A/M2 channel pore, among which the most
common are S31N, V27A and L26F. We have synthesized and characterized the
properties of a series of compounds, originally derived from the A/M2 inhibitor BL-1743.
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A lead compound emerging from these investigations, spiro[5.5]undecan-3-amine, is an
effective inhibitor of wild type A/M2 channels and L26F and V27A mutant ion channels
in vitro, and also inhibits replication of recombinant mutant viruses bearing these
mutations in plaque reduction assays. Differences in the inhibition kinetics between BL1743, known to bind inside the A/M2 channel pore, and amantadine were exploited to
demonstrate competition between these compounds; consistent with the conclusion that
amantadine binds inside the channel pore. Inhibition by all of these compounds was
shown to be voltage-independent, suggesting that their charged groups within the Nterminal half of the pore, prior to the selectivity filter that defines the region over which
the transmembrane potential occurs. These findings not only help define the location and
mechanism of binding of M2 channel-blocking drugs, but also demonstrate the feasibility
of discovering new inhibitors that target this binding site in a number of amantadineresistant mutants.

6.2 INTRODUCTION
Influenza A virus is a continuing cause of mortality and morbidity on an annual basis (1)
and thus presents an important target for pharmaceutical investigation. Two classes of
anti-influenza agents are available for human use: adamantane derivatives amantadine
and rimantadine which target the virus A/M2 ion channel and oseltamivir and zanamivir,
which targets the viral surface protein neuroaminidase (2). The use of amantadine and
rimantadine is limited by the wide distribution of drug resistant virus variants, including
the recently isolated influenza A (H1N1) virus (3-5).
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The A/M2 protein of the influenza A virus forms a pH-gated proton channel that is
essential for virus replication (6). The mature channel consists of four identical subunits
of 96 amino acids, each subunit is a type III integral membrane protein (Nout, Cin) (7);.
The highly conserved H37xxxW41 motif located in the single transmembrane domain of
the protein is responsible for its channel activity and proton selectivity (7, 8). The activity
of wild type (wt) A/M2 channels is known to be efficiently inhibited by amantadine, BL1743 and its derivative azaspiro[5,5] undecane (spiro piperidine 20, Table 1) (Figure 1)
(2, 9, 10). Naturally occurring point mutations of the pore lining residues located outside
of the H37xxxW41 motif, such as L26F, V27A, A30T, S31N and G34E result in the
formation of amantadine-insensitive influenza A virus phenotypes (3, 11-13). Extensive
studies suggest that these residues are involved in the formation of the binding pocket for
the drug (14-18). Amantadine-resistant phenotypes are prevalent in the currently
circulating influenza A virus H3N2 and H1N1 2009 strains. Although the S31N mutation
was observed in more then 90% of influenza A cases in certain years (19, 20), other
amantadine insensitive phenotypes like L26F and V27A were isolated from influenza A
patients with the emerging frequencies of 8-67% (19, 20). Other amantadine-resistant
mutations have been found much less frequently (11, 20). Being resistant to amantadine,
these naturally occurring mutants are also insensitive to all other known organic A/M2
channel inhibitors, including BL-1743 and spiro piperidine 20 (9, 10). Thus there is a
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great need for novel anti-influenza drugs that target the most common amantadine
resistant phenotypes, S31N , V27A and L26F (19, 20).

Figure 1: Chemical structures of A/M2 channel inhibitors.
In the current study we synthesized a family of spiro-[5,5]-undecane compounds based
on the structure of the previously investigated A/M2 channel inhibitor BL-1743. We
found a simple amino derivative of BL-1743, spiro[5.5]undecan-3-amine (spiran amine 8,
Table 1) to be effective not only for inhibition of the wt A/M2 channel, but also for
inhibition of two widely occurring amantadine resistant mutants, L26F and V27A. The
efficiency of this compound was investigated on A/M2 channels heterologously
expressed in Xenopus oocytes and confirmed by the in-vivo plaque reduction assay of
recombinant influenza A virus.

The pharmacologically relevant binding site for amantadine has been found to lie either
inside (15), or outside (21, 22) the pore, although the physiological relevance of the latter
finding has not been confirmed with either electrophysiology in oocytes or plaque
reduction assays with recombinant virus (23). However, BL-1743 was shown to inhibit
channel activity by binding inside the channel pore (24). Previous findings have shown
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that the kinetics of A/M2 channel inhibition by BL-1743 are more rapid than those
reported for amantadine (9, 25), making it possible to test for competition between these
drugs to determine whether they compete for the same binding site inside the channel
pore. Our results support the previously published structural and functional studies that
showed that amantadine inhibits the A/M2 channel by coordinating with pore lining
residues (12, 15, 16). We found that inhibition by amantadine, BL-1743, spiro piperidine
20 and spiran amine 8, all of which are positively charged at physiological pH, is
independent of membrane voltage, consistent with binding in the N-terminal portion of
the pore.

The current study shows that a novel compound, spiran amine 8, is a potent inhibitor of
the L26F and V27A amantadine resistant mutants of the A/M2 protein. Additional
evidence supports the conclusion that amantadine binds inside the N-terminal half of the
channel pore. These findings show that novel anti-influenza drugs, capable of targeting
wt and amantadine resistant virus phenotypes, can be identified and that the N-ternial part
of the pore is a good target for such drugs.

6.3 MATERIALS AND METHODS
Spiran AM2 inhibitor library synthesis - The syntheses of the primary amine analog (8)
of spiropiperidine-azaspiro[5,5]undecane and the methyl substituted secondary amine 9
are shown in Scheme 1. Intermediate spiro[5.5]undec-1-en-3-one 1 was prepared from
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both acid catalyzed one-pot Robinson annulation reaction and

through Diels-Alder

adduct followed by acid hydrolysis and aldol ring formation. The acid-catalyzed
annulation often led to low yields (62% or lower) due to acid catalyzed polymerization of
methyl vinyl ketone as evidenced by black oily substance formed in the reaction flask
(26). While catalysis with proline derivatives might allow circumvention of these
problems , we found the alternative Diels-Alder route provided better overall yields
(75%) (27). Hydrogenesis of enone 1 with Pd/C with an H2 balloon gave
spiro[5.5]undecan-3-one 2. Conversion of ketone 2 to amine 8 was achieved by treatment
with hydroxylamine followed by LiAlH4 reduction. Methylamine 9 was prepared by
reductive amination of 8 with formaldehyde as reported.

Scheme 1. Synthesis of spiran amine 8, 9 and guanidine 10.
Syntheses of spiran triazole 11 and spiran amine 12-14 with extended linkers in scheme 2
were accomplished by reductive amination as described before.
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Scheme 2. Synthesis of spiran triazole 11 and spiran amine 12, 13 and 14 with extended
linkers.

Compound 15, with an imidazole head group, was synthesized by nucleophilic attack of
imidazol-4-yl anion (generated by treatment of N-trityl 4-iodoimidazole) onto ketone 2
(28), followed by deprotection in TFA/DCM as in scheme 3. The hydroxyl group in 15
was either reduced by Et3SiH/BF3*OEt2 to give 16 or fluorinated by DAST to give 17
after deprotection. Ketone 2 was converted to aldehyde 6 by the Wittig reaction, followed
by acid hydrolysis. Comopunds 18 and 19 were then synthesized from compound 6 in
the same manner as described for 15 and 17.
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Scheme 3. Synthesis of spiran with imidazole head group 15, 16, 17.

Scheme 4. Synthesis of spiran 18, 19.
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Molecular Biology, in vitro cRNA transcription - The cDNA encoding to the Influenza
virus A/Udorn/72 A/M2 protein and to the A/M2 amantadine insensitive mutants were
inserted into pGEMHJ (a gift from N. Dascal Tel-Aviv University, Israel) for the
expression on Xenopus oocytes. cRNA was prepared as previously described (29).

Heterologous Expression and Electrophysiological Recordings - Stage V-VI Xenopus
laevis oocytes were prepared as described previously (30). Oocytes injection and TEVC
electrophysiological measurements were done as previously described (29). Amantadine
(Sigma, St. Louis, MO) was applied to inhibit A/M2 induced currents. Data were
analyzed using ORIGIN 8.0 software (OriginLab, Northampton, MA).

Cells, viruses and plasmids - 293-T and Madin–Darby canine kidney (MDCK) cells were
maintained in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, Carlsbad, CA,
Valencia, CA) supplemented with 10% FBS. Influenza A/Udorn/72 virus (wt) and mutant
viruses were propagated in MDCK cells overlaid with serum-free DMEM containing 3.0
µg/ml N-acetyl trypsin (NAT; Sigma-Aldrich, St. Louis, MO) at 37°C. WT and mutant
virus (V27A/L38F) were generated by using reverse genetics from cDNAs essentially as
described previously (31). The eight genome- sense (pHH21) plasmids and four proteinexpressing (pcDNA3.1) plasmids used to generate influenza virus by reverse genetics
have been described previously (31). Mutation into the M2 gene in pHH21 vector was
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generated using Quick Change mutagenesis (Stratagene, La Jolla, CA). 293T cells were
transfected using TransIT-LT1 (Mirus, Madison, WI) according to the manufacturer’s
protocols. Virus stocks were propagated in MDCK cells, and the virus titers were
determined by plaque assay on MDCK cells. For determination of viral genome
sequences viral RNA was extracted by using the QIAamp viral RNA kit (Qiagen,
Valencia, CA), followed by Super Reverse Transcriptase (Molecular Genetic Resources,
Tampa, FL.) and using genome-specific primers, and amplified with AmpliTaq DNA
polymerase (Applied Biosystems, Foster City, CA). The complete nucleotide sequences
of the M genes were determined using a 3100-Avant genetic analyzer (Applied
Biosystems).

Plaque reduction assays - Confluent monolayers of MDCK cells were incubated with the
wt Udorn virus (100 plaque forming units (p.f.u.) per well) and V27A/L38F mutant virus
(1000 and 100 p.f.u. per well) in DMEM-1% bovine serum albumin for 1 h at 37oC. The
inoculums were removed, and the cells were washed with phosphate-buffered saline
(PBS). The cells were then overlaid with DMEM-containing 0.6% Avicel
microcrystalline cellulose (FMC BioPolymer, Philadelphia, PA) and NAT (2.0 μg/ml).
To examine the effect of drugs (BL-1743, spiran amines and amantadine) on plaque
formation, monolayers were preincubated with DMEM supplemented with indicated
concentrations of the drugs at 37°C for 30 min, and virus samples were preincubated with
DMEM-1% BSA with indicated concentrations of the drugs at 4°C for 30 min before
192

infection. At 2 to 3 days after infection, the monolayers were fixed and stained with
naphthalene black dye solution (0.1% naphthalene black, 6% glacial acetic acid, 1.36%
anhydrous sodium acetate).

6.4 RESULTS
6.4.1 Structure-activity relationship (SAR) of 3-substituted spiro-[5,5]-undecanes.
Our previous SAR study of 2-[3-azaspiro(5,5)undecanol]-2-imidazoline (BL-1743)
revealed a very potent spiro-piperidine compound 20 with IC50 of 0.9 μM (10). However,
compounds in this series failed to inhibit amantadine-resistant variants of A/M2, which
prompted us to test alternative structures. In particular, a consideration of the overlay of
the parent compound on derivatives of amantadine suggested that conversion of the
piperidine in spiro piperidine 20 to a 3-amino-cyclohexyl amine while maintaining the
second spiro-6-member ring would produce a more effective inhibitor. We therefore
synthesized a family of spiro-[5,5]-undecanes, in which the 3-position was substituted
with amines or other basic substituents (Table 1).
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Table 1. Inhibition efficiency of the synthesized compounds on A/M2 channels. aKd was
obtained by global fitting of Circular Dichroism (CD) data of ligand titration to A/M2TM
(22-46) using Igor Pro (wavemetrics). The variation of Kd values is ±25% based on
different fitting values obtained from three repeats of amantadine titration and two
repeats of compound 20 titration. See supplementary information for details.
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The compounds were tested on A/M2 channels expressed in Xenopus oocytes using
TEVC technique. The inhibitory effect of the compounds was confirmed by in-vivo
plaque reduction assays of influenza A virus (A/Udorn/72).

The simple amino-

derivative, 8, showed an activity on par with that of amantadine. However, further
substitutions to the amine tended to cause a loss in activity. N-methylation (compound 9)
led to a slightly less potent compound, while the guanidine derivative, 10, had similar
potency as methylamine 9. Modifying the amine by addition of polar substituents and
extended linkers (compounds 11 – 14) led to a marked decrease in activity. On the other
hand, replacing the amine with an imidazole group caused a slight decrease in activity
(compound 16). We also examined additional substitutions at the 3-methylene of 16,
through the introduction of a hydroxyl and fluoro-substituent in 15 and 17, respectively.
These substitutions gave rise to compounds with lower potency. Furthermore, the
similarly substituted compounds 18 and 19 had decreased activity compared to the
primary amine 8.

In summary, these data show that the primary amino group is likely to be a nearly
optimal substituent for the spiro-[5.5]-undecane scaffold.

We therefore turned our

attention to determining how the piperidine for cyclohexylamine substitution in 20 vs. 8
affected the ability of these compounds to inhibit amantadine-resistant forms of A/M2.

6.4.2 Inhibition effect of spiran amine compound 8 on wt and amantadine insensitive
A/M2 channels.
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Amantadine resistant mutants carry naturally occurring point mutations of the pore lining
residues of the A/M2 channel (3, 11, 12). Extensive structural, electrophysiological and
in-silico investigations suggest that these residues form the binding pocket for the drug
(14-18). We have tested the effect of spiran amine 8 on wt A/M2 channels and A/M2
channels with altered amantadine sensitivity and compared the inhibition by compound 8
to that of amantadine and BL-1743. We found that spiran amine 8 efficiently inhibits the
activity of A/M2 wt channels and of A/M2-V27A mutants, with IC50 values of 12.6 μM
and 84.9 µM respectively (Figure 2; Table 2). The inhibition of V27A mutants is
particularly interesting, given that amantadine, BL-1743, and spiro piperidine 20 gave
less than 10% inhibition of the mutant, when applied at 100 µM concentration. It is also
interesting to note that the mutant V27G, which is also naturally occurring (32) is highly
resistant to all compounds tested (Table 2).
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Figure 2. Inhibition efficiency of amantadine, BL-1743 and spiran amine 8 on wt A/M2
channels and A/M2 L26F, V27A and S31N mutants. Channel activity was assayed by
TEVC for A/M2 channels expressed in Xenopus oocytes. Responses in the presence of
various concentrations of an inhibitor (I) were normalized to the current evoked by
application of the activating (pH 5.5) solution without inhibitor (I0). The experimental
data are the average of three independent experiments. Each point is the mean (±SD) of
5-8 oocytes. IC50 values in μM: A/M2 with amantadine IC50=15.76±1.24; with BL-1743
IC50=46.25±3.56; with spiran amine 8 IC50=12.59±1.11. A/M2-L26F with amantadine
IC50=164.46±14.40; with BL-1743 IC50>10 mM; with spiran amine 8 IC50=30.62±8.13.
A/M2-V27A with amantadine IC50=1840; with BL-1743 IC50>10 mM; with spiran amine
8 IC50=84.92±13.61. A/M2-S31N with amantadine IC50=237.01±22.14; with BL-1743
IC50>10 mM; with spiran amine 8 IC50>10 mM.

Table 2: Inhibition effect of amantadine, BL-1743, spiran amine 8 and spiran amine 9 on
A/M2 wt and amantadine insensitive mutant channels. Data presented as a percent of
remaining A/M2 activity after application of an inhibitor (100 μM) for 2 min. The
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experimental data are the average of three independent experiments. Each point is a mean
(±SD) of 5-7 oocytes.
BL-1743

SPIRAN AMINE
8

SPIRAN AMINE
9

AMANTADINE

% remaining activity after application of 100 μM compound
A/M2

25.3±1.3

10.6±0.7

8.4±1.1

6.1±1.0

A/M2-L26F

89.2±4.8

32.4±3.3

72.6±8.4

51.8±3.5

A/M2-V27A

97.4±1.8

46.6±6.6

70.2±1.55

93.07±1.9

A/M2-V27G

82.9±9.3

87.9±6.1

89.6±4.1

95±4.9

A/M2-A30T

102±2.3

98.1±7.0

101. ±3.2

104.6±4.3

A/M2-S31N

100±0.67

99.1±0.9

100±4.1

65.3±2.7

A/M2-G34E

89.8±6.9

96. ±5.

101.7±2.8

100.4±6.7

We next examined the ability of compound 8 to inhibit other pore-lining mutants. S31N
is a highly frequent mutation, which gives rise to decreased sensitivity to amantadine
(IC50 = 237.0 µM versus 15.8 µM for the wt A/M2 channel, Figure 2), and complete
resistance to rimantadine (IC50 > 10mM).

Similarly, compound 8 showed little

inhibition of this mutant. Other mutations deeper inside the pore than V27 (A30T and
G34E) completely eliminate the ability of all drugs tested to inhibit the channel (Table 2).

By contrast to the other mutations considered here, L26F does not involve a pore-lining
residue, and instead involves a partially largely lipid-exposed residue that packs at the
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interface between the helices adjacent to the V27. Thus, this residue is expected to play a
more subtle and less direct role in defining the steric properties of the drug-binding site.
Indeed, amantadine inhibits this mutant with reduced affinity (IC50=164.5 µM), versus
the much larger decreases seen for other variants. Compound 8 is an even more potent
inhibitor of A/M2 L26F (IC50 = 30.6 µM, Figure 2).

The inhibitory effect of compounds 8 and 9 on the recombinantly expressed A/M2 wt and
mutant channels was confirmed by in-vivo plaque reduction assays of influenza A viruses.
Plaque formation of wt influenza virus (A/Udorn/72) was inhibited by amantadine, 8 and
9 at concentrations ranging from 0.5 to 5 μM (Figure 3A), with compound 8 showing
slightly more potent activity than compound 9. BL-1743 inhibited wt virus plaque
formation only at high concentrations (50-100 μM) (Figure 3B). On the other hand,
plaque count and size resulting from infection by an influenza virus A/M2-V27A/L38F,
that contains the M2-V27A mutation was reduced by 50 μM spiran amine 8 (Figure 3C).
These findings are consistent with the electrophysiological data (Figure 1). In comparison,
amantadine and BL-1743 at the same concentration range failed to inhibit plaque
formation of A/M2-V27A/L38F viruses (Figure 3C). The L38F mutation is naturally
found in the Weybridge strain of the virus. This mutation is pharmacologically silent to
the drugs used and does not affect M2 channel function in electrophysiological
recordings (25, 33, 34). The activity of the double mutant A/M2-V27A/L38F was tested
by TEVC and compared to that of a single mutant A/M2-V27A. We found that sensitivity
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of the double mutant channel to the tested compound was comparable to that of the single
A/M2-V27A mutant. The A/M2-V27A/L38F mutant channels were not sensitive to either
amantadine, or BL1743, while being efficiently inhibited by compound 8 (A/M2V27A/L38F IC50=78.21±15.06; A/M2-V27A IC50= 84.92±13.61). Based on these
findings we decided that the results of the plaque formation assay performed on the
double mutant A/M2-V27A/L38F adequately represent the behavior of the single A/M2V27A mutant.
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Figure 3. In vivo plaque reduction assay. Wt influenza virus (A/Udorn/72) and influenza
virus containing mutations in the M2 TM domain (V27A/L38F) were recovered from
cloned DNA and assayed for plaque formation on MDCK cells in the presence or absence
of drugs as described in Materials and Methods. A. Effects of amandadine, BL-1743 and
compounds 8 and 9 (0.5 and 5 μM) on Udorn plaque formation. B. Effect of BL-1743 (50
and 100 μM) on influenza virus plaque formation. C. Effects of amantadine, BL-1743
and spiran amine 8 (50 μM ) on influenza mutant virus V27A/L38F plaque formation. C,
upper panel: ~1000 p.f.u. / well of mutant virus were used. C, bottom panel: ~100 p.f.u. /
well of mutant virus were used. Plaque count: no drug – 99 plaques / well; amantadine
50μM – 82 plaques / well; BL-1743 50 μM – 86 plaques / well; spiran amine 8 50 μM –
37 plaques / well.

Thus, spiran amine 8 is capable of efficiently inhibiting not only wt A/M2 channels and
A/M2-L26F and A/M2-V27A mutant channels expressed in oocytes, but it also prevents
replication of wt virus and these mutant recombinant viruses. As discussed below, we
attribute to the greater potency of compound 8 in the plaque versus the
electrophysiological studies to kinetic effects arising from the slow kinetics of binding of
this class of inhibitors. Compounds are incubated with oocytes for brief periods in the
electrophysiological experiments, but much longer periods in the plaque-binding studies.

We also measured the binding of selected drugs to the transmembrane domain of wt
A/M2 protein (M2TM, residues 22-46), using a spectroscopic assay that relies upon
changes in the CD spectrum of M2 induced by binding of drugs (Table 1 and described in
supplementary materials). All drugs bound in a stoichiometry of approximately one
drug/tetramer. At pH 7.4, potent compounds were found to bind to the transmembrane
tetrameric form of M2TM with low µM binding constants. Compounds 8 and 10 were
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found to be approximately equipotent with amantadine, displaying dissociation constants
in the range of 7 – 8 µM (Table 1). In agreement with the plaque assay, compound 9 was
approximately four-fold less potent than amantadine or compound 8. These data support
the expectation that the drugs inhibit the channel activity by binding directly to the A/M2
proton channel.

6.4.3 Competition among inhibitors.
In 1999 Gandhi and co-workers concluded from competition experiments with Cu(II) that
BL-1743 inhibits A/M2 channel activity by binding inside the channel pore (24).
However, conflicting structural studies have shown that adamantane derivatives bind
either inside (15), or outside (21) the channel pore, although the pharmacological
relevance of the latter finding has not been confirmed (23). Furthermore, solid-state NMR
experiments have shown that a member of the spiran series of compounds binds A/M2 in
a manner similar to that of amantadine (10). Given that BL-1743 appears to bind within
the pore, we were interested to determine whether amantadine binds competitively with
respect to this compound, or whether it binds to an independent site.

The second-order rate constant (κon) for the association and inhibition of the wt A/M2
channel with BL-1743 was calculated to be 720 M-1 s-1 (9), which is comparable with the
κon of amantadine (600 to 900 M-1 s-1) (25). However, the dissociation rate constant (κoff)
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for BL-1743 is approximately an order of magnitude faster than that calculated for
amantadine (10-3 s-1 and 10-4 s-1 respectively) (9, 25). We exploited this difference in κoff
of BL-1743 and amantadine to investigate the mechanism of A/M2 channel inhibition by
amantadine by testing whether this drug competes with BL-1743 for the inhibition of
A/M2 channel activity.

For these experiments A/M2 channels were expressed in

Xenopus oocytes, and the channel activity was assayed by TEVC. A/M2 channel activity
was evoked by application of the low pH activating solution (pH 5.5). In the control
experiments the channel activity was inhibited by saturating concentrations of either BL1743 (1000 μM) or amantadine (100 μM) alone (Figure 4A and B). As seen from Figure
4A and 4B, the inhibition of A/M2 was essentially fully reversible in the time frame of 5
min for BL-1743, but only about 10% complete for amantadine.

This finding is

consistent with the slower off-rate for amantadine than for BL-1743. Compound 8 also
showed an off-rate similar to that of amantadine, as expected from their similar IC 50
values (Figure 2, Figure 4C).

203

Figure 4: Inhibition of A/M2 channel activity by saturating concentrations of BL-1743,
amantadine and spiran amine 8. A-C; Representative traces of A/M2 channel activity
inhibited by either BL-1743 (1000 μM, A), amantadine (100 μM, B), or spiran amine 8
(100 μM, C). A/M2 channel activity was induced by application of the activating solution
(pH 5.5, red horizontal bar above the trace). The currents were inhibited by the
application of the activating solution containing either BL-1743 (green horizontal bar, A),
amantadine (yellow horizontal bar, B), or spiran amine 8 (orange horizontal bar, C) for
60-90 sec. After the maximal inhibition was achieved, oocytes were superfused with the
non-activating solution (pH 8.5, second blue horizontal bar) for 5 min to allow current
recovery and the channel activity was assayed again by the application of the activating
solution (second red horizontal bar). Note that recovery was complete only for BL-1743.

We next examined the competition between BL-1743 and amantadine, chosen as a
representative example of the slow-dissociating class of inhibitors. We subjected the
oocytes to sequential treatment with drugs and drug-free recording solutions in a manner
designed to probe both the kinetic and thermodynamic aspects of inhibition. A resting
oocyte, incubated in the non-activating solution (pH 8.5), was treated as follows. 1) The
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oocyte was acidified by the application of the activating solution (pH 5.5) (red bar in
Figure 5); 2) The oocyte was pulsed with the activation solution containing rapidly
reversible BL-1743 at various concentrations ranging from 3 to 1000 μM for 60 sec
(green bar);

3) BL-1743 in the activating solution was replaced with the slowly

reversible inhibitor amantadine (100 μM) for an additional 90 sec (yellow bar); 4) The
pH was shifted to 8.5 to allow the system to re-equilibrate for 5 min (second blue bar); 5)
The oocyte was re-acidified (second red bar) and the degree of recovered channel activity
determined.

Figure 5. Inhibition of A/M2 channel activity by consecutive application of BL-1743 and
amantadine. A-D; Representative traces of the A/M2 channel activity modulated by
consecutive application of BL- 1743 and amantadine. A/M2 channel activity was induced
by the application of the activating solution (pH 5.5, red horizontal bar above the trace).
The currents were first inhibited by the application of the activating solution (pH 5.5)
containing various concentrations of BL-1743 (3-1000 μM, green horizontal bar) for 60
sec. After maximal inhibition of the channel activity was achieved, amantadine (100 μM)
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was substituted for BL-1743 (3-1000 μM) in the activating solution for 90 sec (yellow
horizontal bar). The inhibitors were washed out for 5 min by the non-activating solution
(pH 8.5, second blue horizontal bar) and the pH-induced activity of A/M2 channels was
measured again (second red horizontal bar). Note the biphasic current upon application of
amantadine during washout of a saturating concentration of BL-1743 (during yellow bar
in D).

As expected from a reversible second-order binding event, the rate and extent of
inhibition observed during the BL-1743 incubation period increased in a concentrationdependent manner (Figure 5). The ensuing traces observed during the amantadine-chase
period reflect several processes, including (a) the binding of amantadine to the fraction of
channels that were not inhibited in the initial BL-1743 pulse, (b) dissociation of BL-1743
to generate uninhibited channel, and (c) binding of amantadine to newly uninhibited
A/M2 channels following dissociation of BL-1743. With low concentrations of BL-1743,
little inhibition was achieved; thus, upon addition of 100 µM amantadine the kinetics
were dominated by this process, and the trace approached a simple exponential decay
(Figure 5A and B). On the other hand, with a 1000 µM BL743 pulse, inhibition was
complete and the resulting traces reflected a competition between dissociation of BL1743 and the on-rate for amantadine-binding, both of which occur with relaxation times
in the sec to min time scale under these conditions (Figure 5D). Thus, biphasic kinetics
were observed, with the rising phase reflecting the fact that as the BL-1743 dissociates
from the channel, amantadine does not bind instantly, leading to a partial recovery
followed by inhibition by amantadine at longer times.

As expected, intermediate

behavior was observed with an initial pulse of 100 µM BL-1743 (Figure 5C).
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In the complementary experiments A/M2 channels were first inhibited by various
concentrations of amantadine (1-100 μM) for 60 sec; then, BL-1743 (100 μM) was
substituted for amantadine in the activating solution for 90 sec (Figure 6). The lower
were the amantadine concentrations the higher was the effect of BL-1743 inhibition as
evidenced by more current recovered after the 5 min long washout (Figure 6A and B).
When amantadine was applied at a saturating concentration (100 μM), substitution with
BL-1743 did not add to the existing inhibition by amantadine (Figure 6D).

Figure 6. Inhibition of A/M2 channel activity by consecutive application of amantadine
and BL-1743. A-D, Representative traces of the A/M2 channel activity modulated by
consecutive application of amantadine and BL-1743. A/M2 channel activity was induced
by the application of the activating solution (pH 5.5, red horizontal bars above the traces).
The currents were first inhibited by the application of the activating solution (pH 5.5)
containing various concentrations of amantadine (1-100 μM, yellow horizontal bar) for
60 sec. After the maximal inhibition of the channel activity was achieved, BL-1743 (100
μM) was substituted for amantadine (1-100 μM) in the activating for 90 sec (green
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horizontal bar). The inhibitors were washed out for 5min by the non-activating solution
(pH 8.5, second blue horizontal bar) and the pH-induced activity of A/M2 channels was
measured again (second red horizontal bar). Note that in no instance was a biphasic
current observed during application of BL-1743 as amantadine was washed-out (yellow
bars).

Taken together, these results suggest competition between BL-1743 and amantadine for
inhibition of the A/M2 channel and support the conclusion that amantadine inhibits A/M2
channel activity by binding inside the channel pore. The results of this competition study
also are in a good agreement with the amantadine inhibition kinetic rates reported by
Wang et. al. (25)

The reaction rate constants for the spiran amine compounds were not precisely
determined; however, as shown in Figure 4C, the washout rate for the spiran amine 8 was
not significantly different from that of amantadine, suggesting it should behave similarly
to amantadine.

6.4.4 Voltage dependence of inhibition of A/M2 channel activity by amantadine, BL 1743
and spiran amine.
Since spiran amine 8 is a positively charged molecule in aqueous solution over the pH
range used in this study, its inhibitory effect on A/M2 channels may depend on
membrane voltage. To address this possibility, we tested the voltage dependence of A/M2
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channel inhibition by spiran amine 8 and compared it to that of BL-1743, spiro piperidine
20 and amantadine. Previous studies have shown that the inhibition of A/M2 channel
activity by BL-1743 does not depend on voltage (9), while voltage dependence of
amantadine inhibition has not been addressed directly. We observed that inward and
outward A/M2 channel currents measured in the presence of each of the tested
compounds were equally inhibited in the voltage range from -40 to +40 mV (Figure 7).
These findings indicate that inhibition by none of the tested compounds is voltage
dependent.

Figure 7. Voltage dependence of A/M2 inhibition by amantadine, BL-1743, spiran amine
8 and spiro piperidine 20. Inhibition of A/M2 channel activity by amantadine, BL-1743,
spiran amine 8 and spiro piperidine 20 was assayed at various holding voltages (from 40mV to +40mV). The mean (±SD) channel activity remaining after the maximal
inhibition by each of the inhibitors (100 μM) was achieved was plotted as a function of
the holding voltage. The experimental data are the average of three independent
experiments. Each point is a mean (±SD) of 6-10 oocytes.

6.5 DISCUSSION
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As amantadine resistant influenza A strains become prevalent, the need for novel small
molecule inhibitors grows. Our previous SAR of the BL-1743 series of compounds
revealed one tight binding inhibitor - spiro piperidine 20 with IC50 of 0.9 μM, which has
been shown to perturb a larger region in the pore-lining area of wt A/M2 than amantadine
(10). In the current study an additional set of compounds was made by converting the
spiro-piperidine scaffold to spiran amine, which still retains the conformation of
spirocycles for tight binding, but has a slightly more extended structure. Compound 8
from this series shows promising inhibitory activity against two of the naturally occurring
A/M2 point mutants: A/M2-L26F and A/M2-V27A (Figure 2). L26 and V27 are the
residues closest to the channel exterior (Figure 8) to have been associated with
amantadine-resistance in naturally occuring mutants of A/M2 (12, 16, 34). It is
interesting to note that, although these L26F and V27A were inhibited by 8, none of the
amantadine insensitive mutants located deeper in the pore was sensitive to spirane amine
8 (Table 2). However, of these, only S31N poses a significant clinical threat.
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Figure 8. Structure of amantadine complexes with the transmembrane domain of A/M2
protein. Panel A and B illustrates the crystal structure of the channel (pdb code 3K9J);
viewed from the outside of the virus (A) and in a side-on view with on helix removed for
clarity (B). Panel C shows a lower resolution model (2KAD) obtained from an analysis
solid-state NMR angular and distance restraints. The identities of critical residues are
shown below, showing the C-alpha and sidechain atoms.

Figure 8A and 8B illustrates the position of L26 and V27 in the crystal structure of the
transmembrane domain of A/M2 complexed with amantadine at low pH, while Figure 8C
shows a model of the complex at high pH in phospholipid bilayers obtained by solid state
NMR (12). Although there are significant differences between the details of these and
other experimental models (35, 36), V27 projects directly towards the pore, while L26 is
critical for packing at the helix-helix interface. Thus, changes to residues at these
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positions are likely to cause changes to the N-terminal region of the channel lumen,
precisely at a location where amantadine has been found to bind. We are currently
conducting crystallographic and molecular dynamics analyses of these mutants to
determine their affect on the channel structure, and also to define the mechanism by
which compound 8 is able to inhibit these otherwise drug-resistant variants. However, it
is inviting to speculate that the decrease in hydrophobicity and steric bulk associated with
the V27A mutation might increase the polarity and pore radius near the N-terminal region
of the binding site. In this scenario, the extended length of compound 8 would provide
increased steric and physicochemical complementarity to the variants, particularly its
amine group projected outward toward the exterior of the virus.

It was previously shown that BL-1743 inhibits A/M2 channel activity by binding inside
the channel pore with the κon kinetic similar to that of amantadine, but with nearly 10-fold
faster koff kinetic (9, 25). By employing the differences in the kinetic properties of
amantadine and BL-1743 inhibition, we tested whether these two compounds compete for
the same binding site. Figure 5D shows that when A/M2 channels are occupied with BL1743, after amantadine substitution for BL-1743 in the recording solution, no additional
inhibition by amantadine occurs, and slow re-initiation of amantadine binding starts only
as the unbinding of rapidly reversible BL-1743 occurs. These findings are consistent
with bound BL-1743 molecules preventing the channel from binding amantadine. Since
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BL-1743 binds in the pore, this result indicates that amantadine also inhibits A/M2
channel activity by binding in the channel pore.

As amantadine, BL-1743 and spirane amine 8 are all easily protonated in the pH range
used in this study, and it is often observed that the efficacy of a positively charged
channel inhibitor increases as membrane voltage is made more negative, we tested the
voltage dependence of these compounds and of spiro piperidine 20 in the range of -40 to
+40 mV. Earlier electrophysiological characterizations of AM2 inhibition by BL-1743
revealed that the inhibition was not voltage dependent (9). The present study confirms the
voltage-independence of BL-1743, amantadine, spiro piperidine 20, and spirane amine 8
(Figure 7). This finding is consistent with the location of the binding site occurring on the
N-terminal half of the pore in a location exterior (N-terminal in peptide sequence) to the
Trp/His gate, over which the transmembrane voltage drop is expected to occur. This
binding mode is also consistent with the site inferred from solid state NMR
measurements of the perturbation to channel resonances associated with binding of spiro
piperidine 20 (10). Furthermore, the existence of mutants conferring BL-1743 resistance
(9, 24) suggest that the drug binding site is located on the extracellular-facing portion of
the pore, N-terminal of H37. The lack of voltage dependence of amantadine inhibition
and failure for intracellularly injected amantadine to inhibit (37) are also consistent with
this binding location, and argue against a proposed mechanism of amantadine binding to
the outer intracellular-facing side of pore of the protein (21, 22).
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Together, these data argue for the previously proposed mode of binding to the pore of the
channel (14-17). However, assuming the voltage drop occurs at the His/Trp gate, these
data do not differentiate models in which the positively charged ammonium (or
guanidinium group of BL-1743) of the drugs are directed toward the viral exterior or
downward toward the H37 residues. It also should be born in mind that the lack of a
voltage-dependence might occur if the binding of the positively charged inhibitor occurs
in an exchange in which one proton is released to the outside of the cell when one
inhibitor molecule enters the pore without changing the total charge inside the pore.
While this is a formal possibility that is consistent with the fact that the binding of drug
occurs with concomitant loss of one or more protons from the H37 residues (38), it seems
unlikely that the proton release would obligatorily occur to the exterior, rather than the
interior, which is the natural direction of proton flow.

In summary, these results demonstrate the feasibility of designing anti-viral drugs
effective against amantadine-resistant escape mutants of influenza A virus. Relatively
modest modifications to BL-1743 have now resulted in a potent inhibitor of two naturally
occurring A/M2 amantadine insensitive mutants: A/M2-L26F and A/M2-V27A.
Moreover, the electrophysiological experiments lend support for the existence of the
binding site in the outer portion of the channel pore (12, 15, 16, 23, 34). Thus, threedimensional models in which the drug is bound in the N-terminal regions of the pore
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should provide useful starting points for the design of even more tight-binding and broadspectrum agents.
Supporting Information Available.
Supporting information which describes the chemical synthesis of the compounds and the
CD titration assay is available free of charge online at http://pubs.acs.org .
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6.7 SUPPORTING INFORMATION

Design and Pharmacological Characterization of Inhibitors of
Amantadine-Resistant Mutants of the M2 Ion Channel of Influenza A
Virus

Victoria Balannik, Jun Wang, Xianghong Jing, Emma Magavern, Robert A Lamb,
William F DeGrado, Lawrence H Pinto

Chemical Synthesis. All chemicals were purchased from commercial vendors and used
without further purification unless otherwise noted. 1H and 13C NMR spectra were
recorded on a DMX-360 NMR spectrometer. Chemical shifts are reported in parts per
million referenced with respect to residual solvent (CHCl3) 7.26 ppm and (DMSO-d6)
2.50 ppm or from internal standard tetramethylsilane (TMS) 0.00 ppm. The following
abbreviations were used in reporting spectra: s ) singlet, d ) doublet, t ) triplet, q ) quartet,
m ) multiplet, dd ) doublet of doublets. All reactions were carried out under a N2
atmosphere, unless otherwise stated. HPLC grade solvents were used for all the reactions.
Column chromatography was performed using silica gel (230-400 mesh). Low-resolution
mass spectra were obtained using an ESI technique on 3200 Q Trap LC/MS/MS system
(applied biosystem).

Spiro[5.5]undec-1-en-3-one (1)
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Acid catalyzed reaction:(1) Cyclohexanecarbaldehyde (1.12g, 10mmol), but-3-en-2-one
(0.70g, 10mmol) was refluxed in tolune (10ml) with catalytic amount H2SO4 (0.05ml) in
a round bottom flask equipped with Dean-Stark trap until no more H2O condensed from
the reaction mixture. After 5 hrs, 50ml 1M NaHCO3 was added, and the organic phase
was separated. The aqueous phase was extracted with tolune, the combined organic phase
was washed with brine and dried over MgSO4, the solid was filtered, and concentrated in
vacuoto give crude yellow oil which was separated by flash column to give 1 as yellow
oil in 62% yield. (CHCl3/hexane =30%, 50% to 100%).

Diels-Alder reaction:(2) To a three-necked flask equipped with Dean-stark trap was
added cyclohexanecarbaldehyde (11.2g, 100mmol) under N2 protection. Pyrrolidine (7.2g,
100mmol) was added dropwise to the flask with stirring over 10 mins via syringe. The
mixture was heated to reflux for 3.5hrs until no more H2O condensed in the Dean-Strak
trap. The enamine intermediate was used in the next step without purification. When the
flask was cooled down to room temperature, it was immersed in ice water bath, and
methyl vinyl ketone (5.6g, 80mmol) was added dropwise with stirring. Cooling was
continued for 10mins after addition, and then the mixture was stirred at ambient
temperature for 4hrs. The final step acid hydrolysis and aldol cylization was
accomplished with slow addition of 8 M HCl (40ml) to the reaction at 0oC, followed by
stirring overnight at r.t. The resulting brown mixture was extracted twice with ether, and
the aqueous phase was cautiously neutralized with slow addition of sodium bicarbonate
and extracted with ether. The ether layer was combined and dried over MgSO 4,
concentrated in vacuo and purified by flash column. (CHCl3/hexane =30%, 50% to 100%,
v/v). 1H NMR (360 MHz, CDCl3) δ 6.84 (d, J = 10.23 Hz, 1H), 5.88 (d, J = 10.23 Hz,
1H), 2.43 (t, J = 6.61 Hz, 2H), 1.91 (t, J = 6.61 Hz, 2H), 1.55-1.48 (m, 10H); 13C NMR
(90 MHz, CDCl3) δ 200.24, 159.22, 127.56, 36.18, 35.73, 33.99, 33.05, 26.15, 21.87;
ESI-MS: Calculated for C11H16O (M + H)+ 165.2, Found: 165.4.
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Spiro[5.5]undecan-3-one (2)
To spiro[5.5]undec-1-en-3-one (1.64g, 10mmol) in anhydrous THF was added Pd/C
(0.2g), the flask was subsequently charged with an H2 balloon. The mixture was stirred at
r.t overnight and Pd/C was filtered, washed with THF. The filtrate was concentrated and
used without purification. 95% yield. 1H NMR (360 MHz, CDCl3) δ 2.27 (t, J = 6.94 Hz,
4H), 1.66 (d, J = 6.94 Hz, 4H), 1.43-1.42 (m, 10H); 13C NMR (90 MHz, CDCl3) δ 213.14,
37.40, 36.36, 36.04, 32.24, 26.88, 22.17; ESI-MS: Calculated for C11H18O (M + H)+
167.3, Found: 167.3

Spiro[5.5]undecan-3-aminium chloride (8)
To a solution of spiro[5.5]undecan-3-one (1.66g, 10mmol) in pyridine (10ml) was added
HONH2*HCl (0.70g, 10mmol). After stirring at ambient temperature for 2hrs, pyridine
was removed by azeotropic evaporation in vacuo with toluene for several times. The
resulting oxime was dissolved in anhydrous THF and cooled down to 0oC. LiAlH4 (1.50g,
40mmol) was added portionwise to the solution and the mixture was heated to reflux
overnight. After cooling down to 0oC, the solution was quenched with H2O (1.5 mL), 15%
NaOH (1.5 mL), and H2O (4.5 mL) sequentially. The resulting slurry was filtered. The
filtrate was concentrated in vacuo, and purified by flash chromatography to give
spiro[5,5]undecan-3-amine as a colorless oil in 72% yield. The hydrochloride salt was
prepared by purging HCl gas into the ether solution of spiro[5,5]undecan-3-amine at 0 °C,
followed by centrifugation and decanting of the ether supernatant. 1H-NMR (360 MHz,
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CDCl3) δ 8.30 (br s, 3H), 3.13-3.12 (m, 1H), 1.96-1.91 (m, 2H), 1.76-1.66 (m, 4H), 1.421.38 (m, 8H), 1.22-1.21 (m, 2H), 1.34-1.06 (m, 2H); 13C-NMR (90 MHz, CDCl3) δ 51.59,
40.37, 34.33, 32.63, 31.79, 26.97, 26.33, 21.97, 21.77; ESI-MS: Calculated for C11H21N
(M + H)+ 168.3, Found: 168.5.

N-methylspiro[5.5]undecan-3-aminium chloride (9)
To a solution of spiro[5,5]undecan-3-amine (1.67 g, 10 mmol), formaldehyde (0.82 ml,
10 mmol, 37% wt in H2O), and NaBH(OAc)3 (3.18 g, 15 mmol) in dichloroethane (20
mL) was added AcOH (0.12 mL, 2 mmol), and the resulting suspension was stirred
overnight, quenched with NaHCO3, and extracted with CH2Cl2 twice. The combined
organic layer was washed with brine and dried over MgSO4. The solution was filtered,
concentrated in vacuo, and purified by flash chromatography. The compound was
converted to the hydrochloride by purging HCl gas into the ether solution of Nmethylspiro[5.5]undecan-3-amine at 0°C, followed by centrifugation and subsequent
decanting of the ether supernatant. The resulting white solid (0.39 g, 80% yield) was
dried in vacuo. 1H-NMR (360 MHz, CDCl3) δ 9.45 (br s, 2H), 3.74-3.71 (m, 1H), 2.64 (t,
J = 5.67 Hz, 3H), 2.00-1.97 (m, 2H), 1.97-1.80 (m, 4H), 1.63-1.43 (m, 8H), 1.23-1.20 (m,
2H), 1.11-1.06 (m, 2H); 13C-NMR (90 MHz, CDCl3) δ 59.26, 40.73, 34.58, 32.16, 32.02,
30.06, 26.94, 24.30, 21.98, 21.18; ESI-MS: Calculated for C11H23N (M + H)+ 182.3,
Found: 182.5.
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1-(spiro[5.5]undecan-3-yl)guanidine (10)
Spiro[5.5]undecan-3-amine (0.34 g, 2 mmol), HgCl2 (0.54 g, 2 mmol), and 1,3- bis(tertbutoxycarbonyl)-2-methyl-2-thiopseudourea (0.58 g, 2 mmol) were stirred in DMF (10
mL) under a N2 atmosphere for 24 h. H2O was added to the reaction mixture, and the
white precipitate was removed by filtration. The precipitate was washed with CH2Cl2
twice, and the combined filtrate was extracted with CH2Cl2, washed with brine and dried
over MgSO4, concentrated in vacuo, and purified by flash chromatography. The Boc
protecting group was removed by 50% TFA/CH2Cl2 for 2 h at RT. Excess TFA was
removed by passing N2 through the solution to give a yellow solid which was
subsequently purified by flash chromatography (0.31 g, 74% over two steps). 1H-NMR
(360 MHz, CD3OD) δ 3.70-3.64 (m, 1H), 1.91-1.83 (m, 4H), 1.60-1.53 (m, 10H), 1.341.24 (m, 4H); 13C-NMR (90 MHz, CD3OD) δ 159.35, 50.23, 41.03, 31.79, 27.60, 26.98,
22.43, 22.08; ESI-MS: Calculated for C11H23N3 (M + H)+ 210.3, Found: 210.2.

N-(spiro[5.5]undecan-3-yl)-1H-1,2,4-triazol-3-amine (11)
Synthesis of 11 was accomplished following the same procedure described for 9. 72%
yield. 1H-NMR (360 MHz, CD3OD) δ 7.56 (s, 1H), 3.52-3.48 (m, 1H), 1.79-1.71 (m, 4H),
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1.45-1.40 (m, 10H), 1.25-1.20 (m, 4H); 13C-NMR (90 MHz, CD3OD) δ 147.41, 53.25,
41.80, 36.34, 34.05, 33.06, 31.18, 29.26, 28.19, 23.19, 23.12, 22.83; ESI-MS: Calculated
for C13H22N4 (M + H)+ 235.3, Found: 235.3.

N1-(spiro[5.5]undecan-3-yl)ethane-1,2-diaminium chloride (12)
Synthesis of 12 was accomplished following the same procedure described for 9,
followed by TFA deprotection. 78% yield. 1H-NMR (360 MHz, CD3OD) δ 3.31-3.26 (m,
4H), 3.13-3.05 (m, 1H), 1.92-1.88 (m, 2H), 1.81-1.77 (m, 2H), 1.65-1.58 (m, 2H), 1.441.40 (m, 8H), 1.24-1.10 (m, 4H); 13C-NMR (90 MHz, CD3OD) δ 59.65, 42.83, 41.90,
40.66, 37.26, 35.48, 32.96, 32.93, 27.97, 25.29, 22.95, 22.70; ESI-MS: Calculated for
C13H26N2 (M + H)+ 211.4, Found: 211.5.

N1-(spiro[5.5]undecan-3-yl)propane-1,3-diaminium chloride (13)
Synthesis of 13 was accomplished following the same procedure described for 9,
followed by TFA deprotection. 74% yield. 1H-NMR (360 MHz, CDCl3) δ 9.05 ( br s, 2H),
8.15 (br s, 3H), 3.32-3.18 (m, 4H), 3.03-3.01 (m, 1H), 2.46-2.42 (m, 2H), 2.09-2.01 (m,
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2H), 1.78-1.74 (m, 4H), 1.41-1.40(m, 8H), 1.21-1.07 (m, 4H); 13C-NMR (90 MHz,
CDCl3) δ 58.80, 42.64, 41.08, 37.91, 34.84, 32.02, 27.00, 24.79, 24.34, 22.01; ESI-MS:
Calculated for C14H28N2 (M + H)+ 225.4, Found: 225.7.

N1-((1H-imidazol-5-yl)methyl)-N2-(spiro[5.5]undecan-3-yl)ethane-1,2-diaminium
chloride (14)
Synthesis of 14 was accomplished following the same procedure described for 9. 71%
yield. 1H-NMR (360 MHz, CDCl3) δ 8.85 (s, 1H), 7.54 (s, 1H), 3.85 (s, 2H), 3.40-3.38
(m, 2H), 3.31-3.30 (m, 1H), 3.22-3.18 (m, 1H), 2.85-2.83 (m, 1H), 1.88-1.82 (m, 4H),
1.61-1.57 (m, 2H), 1.46-1.43 (m, 8H), 1.38-1.35 (m, 2H), 1.30-1.27 (m, 2H); 13C-NMR
(90 MHz, CDCl3) δ 136.03, 132.15, 119.55, 59.63, 59.48, 41.97, 40.64, 35.70, 32.95,
27.97, 25.29, 22.96, 22.67; ESI-MS: Calculated for C17H30N4 (M + H)+ 291.4, Found:
291.7.

3-(1-trityl-1H-imidazol-4-yl)spiro[5.5]undecan-3-ol (5)(3)
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4-Iodo-1-trityl-1H-imidazole (0.44g, 1mmol) in THF was protected with N2 in a three
neck flask, EtMgBr in THF (1mmol) was added dropwise and the mixture was stirred for
30mins at r.t. Spiro[5.5]undecan-3-one (0.18g, 1.1mmol) in THF was added dropwise
and the mixture was stirred overnight. The reaction was quenched with saturated NH4Cl
and extracted with CH2Cl2. The combined CH2Cl2 was dried with MgSO4 and
concentrated in vacuo. Flash column purification (CHCl3 to 5% CH3OH/CH3Cl, v/v)
gave 0.34g spiro[5.5]undecan-3-yl(1-trityl-1H-imidazol-4-yl)methanol as white solid
(Yield: 70%). 1H-NMR (360 MHz, CDCl3) δ 7.34 (d, J =1.35 Hz, 1H), 7.32-7.30 (m, 9H),
7.13-7.05 (m, 6H), 6.67 (d, J =1.35 Hz, 1H), 1.93-1.87 (m, 2H), 1.54-1.29 (m, 16H); 13CNMR (90 MHz, CDCl3) δ 142.73, 138.53, 130.01, 128.58, 128.24, 116.57, 70.74, 33.38,
32.65, 31.99, 27.22, 22.08, 21.95; ESI-MS: Calculated for C33H36N2O (M + H)+ 477.7,
Found: 477.7.

3-(1H-imidazol-4-yl)spiro[5.5]undecan-3-ol (15)
3-(1-trityl-1H-imidazol-4-yl)spiro[5.5]undecan-3-ol (0.48g, 1mmol) was dissolved in 3ml
20% TFA/CH2Cl2, the mixture was stirred 2hrs at room temperature. Excess TFA and
CH2Cl2 were removed by purging N2, the final product was subsequently purified by
flash column (5% CH3OH/CH2Cl2 to 10% CH3OH/CH2Cl2, v/v) to gave white solid
(0.19g, Yield: 82%). 1H-NMR (360 MHz, CDCl3) δ 8.82 (d, J = 1.08 Hz, 1H), 7.45 (d, J
= 1.08 Hz, 1H), 2.70 (s, 1H), 1.99-1.98 (m, 2H), 1.96-1.95 (m, 2H), 1.85-1.81 (m, 2H),
1.71-1.64 (m, 10H), 1.33-1.29 (m, 2H); 13C-NMR (90 MHz, CDCl3) δ 138.62, 136.42,
117.34, 73.21, 35.24, 33.13, 32.86, 28.14, 22.96, 22.89; ESI-MS: Calculated for
C14H22N2O (M + H)+ 235.2, Found: 235.7.
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5-(spiro[5.5]undecan-3-yl)-1H-imidazole (16)
To a stirred solution of 3-(1-trityl-1H-imidazol-4-yl)spiro[5.5]undecan-3-ol (0.48g,
1mmol) in CH2Cl2 at 0oC was added Et3SiH (0.383ml, 2.4mmol), followed by BF3*OEt2
(0.377ml, 3mmol). The solution was allowed to warm to r.t and stirred for 2hrs. The
reaction was quenched with saturated NH4Cl and extracted with CH2Cl2. The combined
CH2Cl2 was dried with MgSO4 and concentrated in vacuo. Flash column purification
(CHCl3 to 2% CH3OH/CH3Cl) yielded 0.37g 4-(spiro[5.5]undecan-3-yl)-1-trityl-1Himidazole as white solid (Yield: 80%). The trityl protection group was subsequently
removed by treatment with 20%TFA/CH2Cl2 as described for 15. (Yield: 78%). 1H-NMR
(360 MHz, CDCl3) δ 8.81 (s, 1H), 7.43 (s, 1H), 6.30 (s, 1H), 2.35-2.34 (m, 2H), 2.122.10 (m, 2H), 1.84-1.70 (m, 1H), 1.66-1.63 (m, 2H), 1.48-1.46 (m, 8H), 1.38-1.35 (m,
4H); 13C-NMR (90 MHz, CDCl3) δ 136.35, 127.63, 115.40, 42.63, 38.09, 37.55, 36.24,
33.47, 32.19, 28.24, 27.91, 23.82, 22.93, 22.87; ESI-MS: Calculated for C14H22N2 (M +
H)+ 219.4, Found: 219.4.

4-(3-fluorospiro[5.5]undecan-3-yl)-1H-imidazole (17)
DAST (0.146ml, 1mmol) was added to anhydrous CH2Cl2 under a N2 atmosphere. The
solution was cooled to -78oC with dry ice/acetone mixture, 3-(1-trityl-1H-imidazol-4yl)spiro[5.5]undecan-3-ol (0.49g, 1mmol) in CH2Cl2 was added dropwise. After addition,
the solution was allowed to warm to room temperature and stirred for another 2 hrs. H2O
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was added and CH2Cl2 layer was separated. The organic layer was washed with brine,
dried over MgSO4, concentrated in vacuo and purified by flash column
(2%CH3OH/CH2Cl2 to 5% CH3OH/CH2Cl2, v/v) to yield 0.37g yellow solid. (Yield:
75%). The trityl protection group was subsequently removed by treatment with
20%TFA/CH2Cl2 as described for 15. (Yield: 81%). 1H-NMR (360 MHz, CD3OD) δ
8.82 (d, t = 1.4 Hz, 1H), 7.44 (d, t = 1.4 Hz, 1H), 1.98-1.93 (m, 2H), 1.84-1.80 (m, 2H),
1.66-1.63 (m, 2H), 1.53-1.49 (m, 10H), 1.39-1.36 (m, 2H); 13C-NMR (90 MHz, CD3OD)
δ 134.91, 115.54, 69.65, 43.34, 33.88, 32.85, 28.14, 22.96, 22.89; ESI-MS: Calculated for
C14H21FN2 (M + H)+ 237.3, Found: 237.4.

Spiro[5.5]undecane-3-carbaldehyde (6)
To a three neck N2 protected RBF was added (Methoxymethyl)triphenylphosphonium
chloride (0.348g, 1mmol) and THF (10ml). The solution was cooled down to -78oC and
LDA (1.2mmol) was added dropwise via syringe, after addition the solution was slowly
warmed to room temperature (15mins) and kept stirring for 1hr. The solution was again
cooled down to -78oC and spiro[5.5]undecan-3-one (0.166g, 1mmol) in THF was added
dropwise via syringe. The reaction was left stirring overnight, and quenched cautiously
with H2O, CH2Cl2 was added and the solutin was extracted with saturated NH4Cl, brine,
and dried over anhydrous MgSO4. The solution was filtrated and dried in vacuum to give
brown solid. The brown solid was washed with ether several times (3×5ml), the ether
solution was combined and dried in vacuum again until no more brown solid formed. To
this brown oil was added THF (2ml) and 5M HCl, the solution was heated to reflux for
2hrs, cooled down to r.t and neutralized with 1M NaHCO3, extracted with CH2Cl2, and
dried with anhydrous MgSO4. The final product was purified by flash column (50%
CH2Cl2/Hexane to 100% CH2Cl2) to give 0.116g spiro[5.5]undecane-3-carbaldehyde as
brown oil. (Yield: 70% for two steps). 1H-NMR (360 MHz, CDCl3) δ 9.63 (s, 1H), 2.222.18 (m, 1H), 1.82-1.21 (m, 18H); 13C-NMR (90 MHz, CDCl3) δ 205.30, 50.51, 45.12,
40.10, 35.35, 33.54, 32.31, 32.87, 29.92, 27.07, 21.84, 21.69, 21.15. ESI-MS: Calculated
for C12H20O (M + H)+ 181.3, Found: 181.5.
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(1H-imidazol-5-yl)(spiro[5.5]undecan-3-yl)methanol (18)
Synthesis of 18 was accomplished following the same procedure as described for 15. 74%
yield. 1H-NMR (360 MHz, CDCl3) δ 8.78 (s, 1H), 7.36 (s, 1H), 4.56 (d, J= 6.25 Hz, 2H),
1.70-1.61 (m, 4H), 1.42-1.36 (m, 8H), 1.29-1.19 (m, 5H), 1.04-1.03 (m, 2H); 13C-NMR
(90 MHz, CDCl3) δ 138.24, 134.87, 116.80, 70.59, 45.65, 42.94, 37.42, 33.41, 33.18,
28.20, 25.05, 24.10, 22.96, 22.76; ESI-MS: Calculated for C15H24N2O (M + H)+ 249.4,
Found: 249.7.

5-(fluoro(spiro[5.5]undecan-3-yl)methyl)-1H-imidazole (19)
Synthesis of 19 was accomplished following the same procedure as described for 17. 1HNMR (360 MHz, CDCl3) δ 8.74 (s, 1H), 7.35 (s, 1H), 4.46 (m, 1H), 1.93-1.68 (m, 4H),
1.42-1.36 (m, 9H), 1.28-1.22 (m, 4H), 1.12-1.07 (m, 2H); 13C-NMR (90 MHz, CDCl3) δ
138.24, 134.83, 116.80, 98.4, 45.55, 42.96, 37.52, 33.44, 33.19, 28.21, 25.05, 24.10,
22.97, 22.76; ESI-MS: Calculated for C15H23FN2 (M + H)+ 251.4, Found: 251.4.

CD titrations: CD titrations were conducted using materials and procedures described in
a previous study.(4) Synthetic M2TM 22-46 (41 µM) was dissolved in DPC micelles
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(detergent concentration, 2.5 mM) potassium phosphate buffer (10mM), pH 7.4. For
titrations, the drug was added from concentrated solutions in the same buffer. Spectra
were recorded in a 1 mm path length cuvette using a Jasco J-810 spectropolarimeter
(Jasco, Easton, MD) at 25°C with 1 nm step scans (4 sec acquisitions; 6 accumulations).
To compute the ellipticity ratio (θ223/θ209) the ellipticity at 223±2 nm and at 209±2 nm
were averaged to improve signal-to-noise.

The ratio of the mean residue ellipticity (θ223/θ209) is shown vs. the concentration of
various compounds below. Also included in each panel for reference is a curve for
rimantadine, which is a tight-binding inhibitor. To obtain dissociation constants for
binding of the drugs to the tetramer it is necessary to consider the monomer/tetramer
equilibrium of the peptide, which is not 100% tetrameric under the conditions of the
assay. The equilibrium is shown below (eq. S1, in which Mon is the monomer, Tet the
tetramer, Drug is amantadine or another ligand, and n the number of independent binding
sites per tetramer). Thus, the experimentally observed curves depend on the
peptide/detergent ratio, which defines the fraction of monomer vs. tetramer.(4, 5) As the
fraction of tetramer is decreased, larger concentrations of drug are needed to drive the
equilibrium towards the tetrameric form. However, if the dissociation constant for
tetrameric formation is known from independent experiments (Ktet).(4) the desired
ligand-dissociation constant (Kd) can be determined.
Kd
TnDrug

Ktet
nDrug + Tet

4Mon

eq. S1

The change in the ellipticity ratio versus ligand concentration is analyzed using IGOR
Pro (Wavemetrics) and functions derived from the above equilibrium scheme. The
experimental observable is the ellipticity ratio at a given concentration of peptide,
detergent, and ligand. The mass balance equations are:
Pep total  [Mon]+4[Tet]+4[Tet  nDrug]
Pep total  [Mon]+

[Mon]4 [Drug F ]n
4[Mon]4
+4
K tet
K tet K d

eq.S2
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Drug total =[Drug F ]+

n[Mon]4 [Drug F ]n
K tet K d

eq.S3

in which the subscript denotes total and free, respectively. Equation S2 and S3 are solved
numerically for [DrugF] as a function of [Peptotal], Ktet, and Kd using the root-finding
algorithm in IGOR Pro.
Ktet is known independently from analytical
ultracentrifugation(4) , leaving n and Kd as fitting variables.

The experimental curves are analyzed according to the final fitting equation S4 in which
Robs is the ellipticity ratio observed at a given ligand concentration, and Rmon, RTet and
RTetDrug are the ellipticity ratios associated with the monomeric, tetrameric, and
amantadine-bound tetrameric species.

Robs=(Rmon[Mon]+ 4RTet[Tet] + 4RTetDrug[Tet·nDrug])/Peptotal

eq. S4

The variable Rmon is treated as a constant, and determined independently from data at low
peptide/detergent ratios.(5) We find that the most accurate values of the parameters can
be obtained by global fitting, in which Rtet n, and RTetDrug are global parameters, and the
values of Kd is allowed to vary for each compound. Because rimantadine binds very
tightly, inclusion of curves for this molecule in the global fits, helps to constrain the
values of RTetDrug. Kbind for rimantadine was obtained using a more extensive number of
experiments and points, and this value was held constant in the global fitting of the
remaining compounds. Using this procedure, we find the value of n is 1.04 ± 0.4, very
close to the theoretical value of 1.0 molecule ligand bound per tetramer. The values
quoted in Table 1 of the main manuscript are from duplicate runs.
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7.1 Abstract
Influenza A virus M2 (A/M2) forms a homotetrameric proton selective channel in viral
membrane. It is the target of amantadine and rimantadine class of antiviral drugs. Most of
current circulating influenza A virus carry drug resistant mutations mapped alongside the
drug binding site, namely S31N, V27A and L26F etc, each of which might be dominant
in a given flu season. Among those mutations, V27A mutation was shown to be evolved
from drug selection pressure, and has not shown to be druggable despite years of
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extensive medicinal chemistry research efforts and library screening. As it is impractical
to predict which mutation would dominate in the next influenza A viruses outbreak, there
is an urgent need to develop novel antivirals targeting all strains of flu viruses, especially
V27A. Herein, based on X-ray structure of amantadine complexed A/M2 and dynamic
influence of A/M2 upon drug binding from earlier solid state NMR studies, we designed
a series of potent spiran amine inhibitors targeting not only wt, but more importantly both
A/M2-27A and L26F mutants with low micromolar IC50s. The potencies of these
inhibitors were further verified in in vivo plaque reduction assay. ssNMR study indicated
the binding of the drug inside the channel. Molecular dynamics (MD) simulations of the
potent inhibitors M2WJ180 and M2WJ206 on A/M2-V27A inhibition is consistent with
our design assumption that the drug indeed occupies a larger portion of the channel and is
able to fill in the extra space created by the V27A and L26F mutations. Our study for the
first time demonstrated the druggability of A/M2 mutants and resulted in a potent lead
compound that will be further pursed in animal study.

7.2 Introduction
The outbreak of highly pathogenic swine flu H1N1 caused global health crisis back in the
early of 20091. While vaccine offers first line protection against influenza A virus
infection, its effectiveness is diminished due to the gap between vaccine development and
massive production, immunization2, during which time the influenza A virus might
undergo antigenic drift or antigenic shift that results in new types of viruses capable of
escaping from previous vaccine3. This is what happened for the vaccine recall from
Sanofi Pasteur because of the effectiveness dropped below its pre-specific limit over
time4. Another option of preventing and treating influenza A viruses infection is
chemotherapy with small molecule inhibiting either neuraminidase (zanamivir and
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oseltamivir) or M2 channel (amantadine and rimantadine)5. Increasing number of
influenza A strains become resistant to oseltamivir (Tamiflu) in the past years, and the
use of zanamivir is limited by poor bioavailability and non-conventional administration
by inhalation. The use of amantadine and rimantadine to treat influenza A virus infection
was suspended by CDC in U.S until further notice due to the rapid development of
resistance and central neuron system (CNS) side effects6. Thus there is an urgent need to
develop novel antivirals capable of targeting all strains of influenza A viruses.
Comparing with neuraminidase, A/M2 is more conserved in the transmembrane drug
binding site with only three major drug resistant mutations S31N, V27A and L26F. Thus
from the drug development point of view, inhibitors targeting those mutants would be
more advantageous to be used as antiviral drugs.

A/M2 forms a homotetrameric channel in viral membrane which selectively conducts
proton7,8. Once viruses enter the infected cell by sialic acid receptor mediated endocytosis,
the low pH in the endosome activates A/M2 and facilitates proton influx which results in
the fusion of viral membrane and the endosome membrane, and subsequently releasing
the viruses’ RNA into the cytoplasm9. Another function of A/M2 is to equilibrate the pH
across Golgi in order to prevent the premature conformation change of hemaglutalin10-12.

The predominant A/M2 mutations conferring amantadine resistance are S31N, V27A and
L26F etc, all of which are mapped alongside the drug binding site13. Although S31N is
the predominant mutation in certain years, recent studies showed that S31N mutation is
not the result of drug selection pressure due to the fact that (1) S31N was identified even
before amantadine was used to treat influenza A virus infection, (2) In certain areas
where amantadine was never used14,15. Instead V27A was identified to be the major
239

mutation emerging from drug selection pressure, and V27A is indeed the dominant
mutation in certain flu seasons16,17. Thus it would be of higher priority to design V27A
inhibitors because this mutation will become dominant when any A/M2 inhibitors
become in use. However, despite years of medicinal chemistry research efforts focusing
on develop novel antivirals targeting drug-resistant influenza A/M2 by either compound
synthesis or library screening, it has not been shown that small molecule inhibitors are
able to target amantadine resistant A/M2 channel. Part of the failure might due to the lack
of structural information of A/M2 mutants, as well as the difficulties associated with
membrane protein study such as protein production, assay and structural characterization
of drug binding. What makes it even more challenge for A/M2 drug design is due to the
fact that unlike enzymes’ active sites, there is no polar residues, except S31 which
hydrogen bonds to V27 backbone carbonyl, in the A/M2 drug binding site that inhibitor
can directly interact, except hydrophobic interaction, this is seen from X-ray structure of
amantadine complexed A/M2 - there is no specific interaction formed between drug and
the protein13.

From both X-ray13 and solution NMR18 structures of A/M2, V27 forms a selection gate at
the N-terminal lumen which filter hydronium versus other cations like K+ and Na+. Very
recent high resolution (1.65Å) structure of A/M2 TM showed V27 forms the narrowest
valve of the central cavity (2 Å)19, which only allows the passage of hydrated proton.
Our hypothesis of V27A resistance to amantadine might be due to the fact that valine to
alanine mutation creates a larger cavity in the N-terminal luminal which results in a shape
mismatch between the central channel cavity and amantadine.
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We rationalize that by expanding the size of the inhibitor to complement that of the drug
binding site, we might be able to target V27A mutant. Here we report our inhibitor design
principle in targeting A/M2-V27A mutant, synthesis strategy, influenza A virus inhibition
results, ssNMR characterization of drug binding and mechanism of inhibition by
molecular dynamics (MD) simulation.

7.3 Results
7.3.1 Homology modeling of V27A mutant indicates V27A mutation creates a larger
cavity at N-terminal luminal site
V27 forms a lid at the N-terminal luminal site of A/M2 with side chain pointing towards
the channel. Our design hypothesis of V27A inhibitor is that V27A mutation expanded
the drug binding site at the N-terminal of A/M2, thus causes a shape mismatch between
amantadine and the mutant channel which result in escape from inhibition.

To

investigate how V27A and L26F mutations affect the size and the shape of the binding
site, we built theoretical models of the structures these mutants in the apo form using the
recently solved high resolution structure of A/M219 as initial configuration.

Initial

models were obtained by replacing the sidechains of Val27 and Leu26 with alanine and
phenalanine, respectively, and refined by performing classical MD simulations in a
bilayer of DMPC lipids hydrated by explicit solvent molecules. After a relaxation phase
of several ns with the protein gradually released, the structures of the mutants were
observed to be stable over a timespan of few tens of ns (backbone RMSD of the order of
1 Å). As expected, the mutation of the valines into alanines at position does not perturb
significantly the overall structure of the bundle. Therefore the effect of the mutation can
be easily rationalized by observing that replacing the bulky Val sidechain with a small
methyl moiety results into an expansion of the pore radius in the region lining the
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amantadine binding site (Figure 1.). Particularly noteworthy, however, is the fact that a
similar net effect is observed upon mutation of Leu26, which is not pore-lining, into
phenylalanine. In this case the introduction of the phenyl groups results in a less tight
helix-packing, and, as a result, the entry region of the pore is more disordered and
features, on average, a larger radius.

Figure 1 | Shape modulation of the drug-binding pocket in the pore of A/M2 channel. A
cartoon representation of the A/M2-TM helix bundle is shown for wt (a), V27A (b), and
L26F (c). The molecular surface of the channel pore is highlighted and pore-lining
residues Leu/Phe26 (brown), Val-Ala27 (blue), His37 (orange), and Trp41 (violet) are
shown as sticks. Pore waters and amantadine are shown for wt as red spheres and sticks,
respectively. The positions of water oxygens and amantadine are obtained from the
crystal structure of the G34A mutant19, and the ssNMR structure of the A/M2-amantadine
complex20, respectively. Foe each structure, the radius of the pore (computed using
Hole21) is plotted as a function of the displacement along the channel axis in the region
between His37 and Val-Ala27; the range of values corresponding to the entry region of
the channel pore is highlighted in pink.

7.3.2 Design and synthesis of inhibitors targeting V27A mutant based on shape
complementary principle
A common feature of most known A/M2 inhibitors contains a polar head group
(positively charged amine) and a hydrophobic aliphatic scaffold. Among the every few
scaffolds other than adamantane that have been explored for A/M2 inhibition, our
previous structural and activity relationship (SAR) study of BL-1743 revealed one of the
most potent inhibitor spiro-piperidine M2WJ10 against A/M2 (IC50 = 0.92 µM), being
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16 fold more potent than amantadine22. More importantly, solid state NMR (ssNMR)
characterization of M2WJ10 binding to A/M2 in DMPC bilayers showed that spiropiperidine influences the dynamics and magnetic environment of more residues within
the transmembrane helices than amantadine. This result sheds light on V27A inhibitor
design and suggests spiro scaffold is more advantageous for V27A inhibition over
amantadine, because its extended conformation is able to fill in the extra space created by
bulkier valine to smaller alanine mutation. Indeed, one carbon extension from spiropiperidine M2WJ10 gave spiran amine M2WJ34 that shown moderate inhibition against
V27A (IC50 = 84.9 µM)23. To the best of our knowledge, this is the first example of small
molecule reported to be active against V27A mutant. Docking of M2WJ34 with A/M2V27A indicates extra space in the channel. Thus to further improve the potency, two
focused libraries of spiran amines were designed based on spiran amine M2WJ34
scaffold; one with expanded ring size (M2WJ164, M2WJ152, M2WJ180), another with
extended head group (M2WJ151, M2WJ198). As negative control, M2WJ189 with
reduced ring size was also included for comparison.

243

Figure 2 | Inhibitor design to target A/M2 V27A mutant. (a) Known examples of wt
A/M2 inhibitors (b) Two libraries of spiran amines were designed to either expand the
ring size or extend the polar head group region.
The synthesis of ring expanded spiran amines started with one pot robinson annelation
reaction using H2SO4 as catalyst24. Spiro enones were prepared from aldehydes in 50-70%
yield with an optimized procedure. Reduction of the enones with Et3SiH/PdCl2 gave the
spiro ketones in quantitative yield25. Subsequently the spiro ketones were converted to
amines (M2WJ189, M2WJ34, M2WJ164) using a two step amination reaction in 72-80%
yield. For ring expansion of the cyclohexanone, it was converted to lactam using
hydroxylamine-O-sulfonic acid/formic acid mediated rearrangement26 followed by
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LiAlH4 reduction to give M2WJ196 in 70% yield. One carbon homologation of the
spiro cyclohexanone was achieved via the corresponding diazo-hydroxy ester which was
converted into the beta-keto ester, using ethyl diazoacetate/LDA, then a catalytic amount
of rhodium(II) acetate27. Finally the keto ester was hydrolyzed under acidic condition to
afford the ketone intermediates, which were subsequently transformed to amines. For
expansion in the amino head group, reductive cyanation of spiro[5,5]undecan-3-one with
tosyl-methylisocyanide (TOSMIC) gave the nitrile28. The nitrile was either reduced to
amine M2WJ151 by LiAlH4 or hydrolyzed to the corresponding acid, which was
converted to methyl ketone using 2.2eq CH3Li. Ethyl amine M2WJ198 was synthesized
by treatment of methyl ketone with hydroxylamine, followed by LiAlH4 reduction. All
amines were finally prepared as their hydrochloride salts before testing.
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Figure 3 | Synthesis scheme of designed A/M2-V27A inhibitors. Details about
experiment procedure can be found in supplement.

7.3.3 Spiran amines are active aganist A/M2-V27A mutant in recombinant Oocyte
electrophysiology assay
The inhibitors were tested in Oocyte cells expressing either wt or V27A mutant A/M2
using two electrode patch clamp (TEV) electrophysiology method. The potency of
inhibitors was expressed as percent inhibition of A/M2 proton conductance with 100 μM
inhibitor applied. The initial hit [5,5]spiran amine M2WJ34 only has moderate activity
against V27A mutant with IC50 of 84.9 μM, however, by expanding either cyclohexane
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rings of M2WJ34 to cycloheptane, a dramatic increase in potency was seen for both
M2WJ152 and M2WJ164 against V27A with IC50s of 68.1 and 28.1 μM, respectively.
In contrast, wt M2 was insensitive to this structural transformation as all three inhibitors
have similar IC50s. Next we rationalized that by adding the beneficial effects of ring
expansion, we would be able to further increase the potency. Indeed, the activity of
[6,6]spiran amine M2WJ180 was increased 8 fold against V27A mutant comparing with
the initial hit [5,5]spiran amine M2WJ34. M2WJ180 was also more active than
M2WJ34 in inhibiting wt M2 with IC50 of 8.7 μM. As a control to test our hypothesis
that V27A mutant favors binding of bulkier molecule due to the expanded A/M2 central
cavity, M2WJ189 with cyclopentyl ring was synthesized and found to be 4 fold less
active than M2WJ34 on V27A inhibition, but it was 4 fold more active on wt A/M2.
Consistent with the previous result that a primary amine is more active than a secondary
amine in targeting V27A mutant, 3-azaspiro[6.6]tridecane M2WJ196 was found 20 fold
less active than M2WJ180. For the second library with extended head group, one carbon
insertion of M2WJ34 yielded M2WJ151, which was 2.5 fold more potent than M2WJ34.
1-spirosubstituted ethylamine M2WJ198, analog of rimantadine, was 3.4 fold more
potent than M2WJ34 on V27A inhibition with enantiomeric mixture tested. Overall, a
positive correlation has seen between increased inhibitor size (hydrophobicity) and
potency on A/M2-V27A inhibition.
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Table 1 | Electrophysiology measurement of inhibitors potencies in two electrode voltage
clamp assay.
Inhibitor ID

Amantadine

M2WJ10

M2WJ34

M2WJ152

M2WJ164

90.8%
16.0 μM
6.9%
N.D
M2WJ180

95.0%
0.92 μM
11.04%
N. D
M2WJ189

89.0%
12.6 μM
53.4%/84.9
mM
M2WJ196

94.4%
13.2 μM
54.8%/68.1
mM
M2WJ151

95.0%
13.0 μM
70.2%/28.1
mM
M2WJ198

90.4%
8.7 μM
82.7%
11.3 μM

95.9%
3.3 μM
25.2%
318.6 μM

86.0%
13.8 μM
26.0%
220.4 μM

90.5%
8.9 μM
67.7%
31.1 μM

85.8%
16.0 μM
75.6%
25.2 μM

Structures

A/M2-wt %
inhibition/IC50
A/M2-V27A %
inhibition/ IC50
Inhibitor ID

Structures

A/M2-wt
%inhibition/IC50
A/M2-V27A %
inhibition/IC50

7.3.4 Further optimization yielded Spiroadamantane as one of the most potent V27A
inhibitor
The drug binding site of A/M2-V27A has a shape of truncated cone, which suggests a
polycyclic scaffold would better fit inside the channel. Aside from increasing the ring
size in order to fill the extra space inside the A/M2 channel, another strategy would be to
convert the bottom cyclohexane ring of M2WJ34 to bicyclo[3.3.1]nonane (Intermediate I,
Figure 4a), which can be further constrained by a methylene linkage to give
spiroadamantane M2WJ206. This inhibitor was synthesized using robinson annelation
reaction starting from 2-adamantanecarboaldehyde as described above (Supporting
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information). This structure transformation resulted in the most potent A/M2-V27A
inhibitor-spiroadamantane M2WJ206 that is 265 fold more potent than M2WJ34. More
encouraging, this inhibitor was also highly active against another amantadine resistant
mutant L26F, consistent with homology modeling result that L26F and V27A have
similar expanded central cavities.
a

b

Figure 4 | Spiroadamantane inhibitor design and its does response curve on wt, V27A,
L26F and S31N inhibition.

7.3.5 Spiran amines were shown to be active in plaque reduction assay
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The inhibitory effect of four of the most potent inhibitors on V27A mutant was confirmed
by in vivo plaque reduction assay of influenza A virus. Both the size and number of
plaque formation were significantly reduced by all four inhibitors at 10 μM concentration.
Consistent with the electrophysiology result, M2WJ206 was most potent and inhibited
plaque formation dramatically at as low as 1 µM concentration. As negative control,
amantadine showed no inhibition of A/M2-V27A viruses replication even at 50 µM
concentration. Thus, spiran amines are not only capable of effectively inhibiting wt A/M2
channels and amantadine resistant A/M2-V27A mutant channels in electrophysiology
assay; they are also active in in vivo plaque reduction assays of influenza A viruses.

Figure 5 | Plaque reduction assay of spiran amines on A/M2-V27A mutant virus. Effects
of compounds on influenza A virus (A/Udorn/72) V27A mutant were evaluated by
plaque formation on MDCK cells in the presence or absence of the compounds (10 μM or
dose dependent) as described previously (XX). M2WJ206 is able to significantly reduce
A/M2-V27A replication in as low as 5 µM conc. As control, amantadine has no effect on
virus replication at up to 50 µM.

7.3.6 Solid state NMR (ssNMR) indicated binding of spiran amine in the central
cavity of V27A
Solid state NMR (ssNMR) spectroscopy is advantageous in characterizing membrane
protein structural change as the protein can be reconstituted in a more native bilayer
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environment, thus better mimic its native conformation. We used ssNMR to study how
spiran amine M2WJ180 binds to A/M2-V27A mutant channels, as it will offer insightful
clue for next generation of drug design. A/M2-V27A transmembrane (TM) peptide (2246) was synthesized with three residues A27, V28 and G34 uniformly 15N and 13C
double labeled (Supporting Information). When reconstituted in DMPC bilayers, the V28
15N chemical shift was cleared changed by 2ppm upon titrating 4 drugs/channel. In
addition, G34 chemical shift change was previously shown to be characteristic of drug
binding in wt A/M2 as it forms a kink in the drug bound form. Binding of M2WJ180 to
A/M2-V27A split the G34 15N peak, indicating the drug binding site locates close to
G34.

Figure 6 | ssNMR characterization of spiran amine M2WJ180 binding to A/M2-V27A
mutant in DMPC bilayers.

7.3.7 Molecular Dynamics (MD) simulation of drug binding
To gain insight into the relationship between potency and size of the aliphatic scaffold,
we performed classical MD simulations on A/M2 mutants V27A and L26F in complex
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with M2WJ180 and M2WJ206; focusing on the binding site, we analyzed the
conformational distribution of the drug molecules and of the H-bonded water molecules.
Using the case of amantadine bound to wt as a reference, we first compared the binding
mode of M2WJ180 to wt and V27A.

The binding mode of M2WJ180 to wt is significantly different from that of amantadine:
the more extended aliphatic scaffold of M2WJ180 is constrained in one direction by the
steric hindrances provided by the bulky Val27 sidechains, therefore a net shift of 2/3 Å
toward the histidine tetrad is observed in the position of the amine group (Fig. 7). As a
result some of the highly structured water molecules solvating the amine group of
amantadine are not present in the wt:M2WJ180 (Fig. 7).

Figure 7 | Heavy atoms density maps in different M2TM:drug complexes, as computed
from 20 ns MD runs; the density is plotted with respect to the coordinate along the pore
axis (indicated as z) and to the distance from it (r). Protein atoms are shown in green
(with labels indicating important pore-lining residues), water oxygens in red, the drug's
nitrogen atoms in blue and carbon atoms in black. Shown are the following mutant:drug
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complexes: (a) WT:amantadine, (b) WT:M2WJ180, (c) V27A:M2WJ180, (d)
WT:M2WJ206, (e) V27A:M2WJ206, and (f) L26F:M2WJ206.
Interestingly, the arrangement of M2WJ180 into the pore of V27A highly resembles that
of the wt:amantadine structure. Although the drug molecule is less tightly bound, the
position of the amine group and the conformation of the solvating water molecules are in
striking agreement with those observed in the wt:amantadine case. M2WJ206 is
analogous to M2WJ180 when binding to wt, in that some of the water molecules
observed in the wt:amantadine complex are absent when M2WJ206 binds; however, in
the V27A:M2WJ206 complex, the entire water cluster is recovered. Furthermore, the
mobility of M2WJ206 in the V27A pore is significantly decreased from M2WJ180 in
the same conditions. Finally, the L26F:M2WJ206 closely resembles the wt:M2WJ206
structure.

7.4 Discussion
Despite extensive medicinal chemistry research efforts dedicated towards discovery of
influenza A virus M2 proton channel inhibitors, the druggability of A/M2 mutants has not
been demonstrated. As most of current circulating influenza A virus carry drug resistant
mutants and we can’t predict which mutation would be dominant in the next flu pandemic,
there is urgent need to develop novel antiflu drugs. Among variety of drug resistant
mutations, V27A is directly linked to drug selection pressure, thus poses a higher priority
to be targeted for drug discovery. Unlike the active sites of enzymes, the N-term side of
the pore of M2 does not feature any polar group, except for a ring of hydroxyls from the
Ser31 residues, constantly H-bonded to the backbone carbonyl oxygens of Val27.
Therefore the affinity of alkyl-amines for M2 results, at least in part, from finely-tuned
hydrophobic interactions between the side chains of the residues lining the channel pore
and the aliphatic scaffold of the drug molecule. Homology modeling suggests that
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mutation of valine residues into alanine at position 27 may increase the radius of the
channel pore at the N-terminal lumen site and create a shape mismatch between the
binding site and amantadine. A bulkier inhibitor is, thus, expected to show a higher
affinity. Guided by earlier ssNMR study of spiro-piperidine M2WJ10 binding to wt
A/M2 in DLPC bilayers, a series of spiran amines with expanded ring size and head
group were designed and found to inhibit V27A mutant with high potencies. Further
structure modification by integrating adamantane and spiro scaffold resulted in the most
of potent inhibitor M2WJ206 with IC50 of 0.3 µM. To further test our working
hypothesis we investigated the binding mode of these novel inhibitors by means of
computational molecular modeling techniques. The prominent role in determining the
affinity played by the relatively mobile pore waters, along with the intrinsic flexibility of
the target protein, poses serious computational challenges that cannot be addressed by the
commonly adopted semi-rigid docking approaches. Therefore we performed MD
simulations on theoretical structural models using the experimental structure of the
complex between wt-A/M2 and amantadine as initial configuration. By sampling the
equilibrium configurations of the wt:amantadine, wt:M2WJ180, wt:M2WJ260,
V27A:M2J180, V27A:M2WJ206, and L26F:M2WJ206 complexes, we were able to
single out similarities and differences in the average conformation and mobility of the
drug molecule and pore waters. Interestingly, the behavior of the bulky M2WJ180 and
M2WJ206 inhibitors in the pore of the mutated channels is similar to that of amantadine
in the binding site of wt-A/M2.

7.5 Methods
Inhibitor synthesis. All starting material chemicals were purchased from commercial
vendors and used without purification. Reactions were carried out using HPLC grade
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solvents under N2 atmosphere. Compounds were purified by silica gel flash column
chromatography and characterized by ESI-MS, 1H-NMR and 13C-NMR. Details about the
inhibitor synthesis procedure and characterization can be found in the supplement
information.
Peptide synthesis. A/M2(22-46)-V27A peptide with A27, V28 and G34 selectively 15N
and 13C labeled were manually synthesized using Fmoc chemistry at elevated temperature
(75˚C for both coupling and deprotection) in a semin-automated Quest synthesizer using
Rink Amide Chemmatrix resin (Matrix Innovation Inc, Canada). 5 eq amino acid, 5 eq
HCTU, 10 eq DIEA in NMP were used for 5 mins coupling. 5% piperazine and 0.1 M
HOBt in DMF were used as the deprotection solution in order to minimize aspartamide
formation. The peptide was cleaved from the resin using 95% TFA, 2.5% Tris, 2.5% H2O
and precipitated from ether after removal of TFA. Ether was decanted after centrifugation
and the peptide was washed with cold ether again. Final peptide was dissolved in 50% B’
(59.9% isopropanol, 30% acetonitrile, 10% H2O, and 0.1% TFA)/50% A (99.9% H2O,
0.1% TFA) and purified by preparative C4 reverse phase HPLC with a linear gradient of
70% B’ to 85% B’. The peptide was eluted at 78% B’. The purity and identify of the
peptide was confirmed by analytical HPLC and MALDI-MS. Calculated MS: 2782.38,
Observed MS: 2782.90.

Molecular Dynamics (MD) simulations
All simulations in this work were performed on the transmembrane region of the A/M2
bundle, spanning residues 25 to 46 and identified in the following as M2TM. The highresolution structure of M2TM from Acharya et al19 was used as initial configuration.
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M2TM was embedded in a hydrated membrane of Dimyristoylphosphatidylcholine
(DMPC) molecules, and periodic boundary conditions were applied with a 87 Å x 87 Å x
77 Å periodic box. The protein and the lipids were modeled using the CHARMM27 force
field29, and water molecules using the TIP3P force field30. The electrostatic potential was
solved by the particle mesh Ewald (PME) method31 with an accuracy threshold of 10-6, a
real space spherical cutoff of 12 Å, and a fast Fourier transform (FFT) grid spacing of 0.8
Å. Lennard-Jones interactions were cut off at 12 Å, with a switching function starting
from 10 Å. The equations of motion were solved with the velocity Verlet integrator
using a timestep of 1.5 fs. The lengths of all bonds involving hydrogen atoms were kept
constrained with the SHAKE method32. The system was run at 310 K and 1 atm using
Langevin temperature33 and Langevin piston pressure34,35, coupling schemes. Decay
times for the thermostat and barostat were chosen to be 1 ps and 0.1 ps, respectively. MD
simulations were performed with NAMD36.

Solid State NMR (ssNMR)
Membrane sample preparation
1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC, Avanti Polar Lipids) was used to
reconstitute A27, V28 and G34 labeled V27A-M2TM by a detergent dialysis protocol .
The dry lipid powder was suspended in 1 mL of pH 7.5 phosphate buffer (10 mM
NaH2PO4/Na2HPO4, 1 mM EDTA, and 0.01 mM NaN3), votexed, and free-thawed 8
times to create uniform lipid vesicles. The peptide powder was codissolved with ~20 mg
octyl-b-D-glucopyranoside (OG, Sigma-Aldrich) in 1 mL of the same buffer. The
peptide/OG solution was then mixed with 1 mL lipid vesicle solution, votexed for 2 hours
and dialyzed with a 3.5-kDa molecular weight cutoff against 1 L buffer at 4°C for 3 days.
The buffer was changed every 8-12 hours to remove the detergent. The protein-lipid
precipitate appeared after one day of dialysis. The proteoliposome solution was
centrifuged at 150,000g and 6 °C for 4 hours to yield a membrane pellet with ~40 wt%
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water. The final protein : lipid molar ratio was 1 : 8. The pellet was packed into 4 mm
MAS rotors for solid-state NMR experiments.

One apo sample and two drug-bound samples were prepared. For the drug-bound
samples, M2WJ180 was dissolved in 0.5 ml methanol/water (1 : 1) solution and directly
titrated into the rotor to achieve a drug : channel ratio of 1 : 1 and 4 : 1, respectively.

Solid-state NMR
Solid-state NMR experiments were carried out on a 400 MHz (9.4 Tesla) and a 600 MHz
(14.1 Tesla) Bruker AVANCE spectrometer using 4 mm MAS probes. Typical radiofrequency fields were 40-50 kHz for

13

C and

15

N and 60-70 kHz for 1H.

13

C and

15

N

chemical shifts were referenced to the a-Gly CO signal at 176.49 ppm on the TMS scale
and the

15

N signal of N-acetyl-valine at 122 ppm on the liquid ammonia scale,

respectively.

Two-dimensional

13

C-13C correlation spectra were measured using a 1H-driven

13

C spin

diffusion pulse sequence [Takegoshi, 2001 #2] with a 40 ms DARR mixing time. 2D
heteronuclear 15N-13C correlation spectra were measured using a REDOR sequence with
a 0.8 ms mixing time for

13

C-15N coherence transfer [Hong, 1998 #1]. All experiments

were performed at 273 K and under 7 kHz MAS.

Additional information Supporting information including inhibitors and peptide
synthesis, characterization, ssNMR sample preparation, electrophysiology and plaque
reduction assay experimental conditions are available on the web.
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7.7 Supporting information
Designing inhibitors targeting drug resistant Influenza A virus
M2 proton channel
Chemical Synthesis. All chemicals were purchased from commercial vendors and used
without further purification unless otherwise noted. 1H and 13C NMR spectra were
recorded on a DMX-360 NMR spectrometer. Chemical shifts are reported in parts per
million referenced with respect to residual solvent (CHCl3) 7.26 ppm and (DMSO-d6)
2.50 ppm or from internal standard tetramethylsilane (TMS) 0.00 ppm. The following
abbreviations were used in reporting spectra: s ) singlet, d ) doublet, t ) triplet, q ) quartet,
m ) multiplet, dd ) doublet of doublets. All reactions were carried out under a N2
atmosphere, unless otherwise stated. HPLC grade solvents were used for all the reactions.
Column chromatography was performed using silica gel (230-400 mesh). Low-resolution
mass spectra were obtained using an ESI technique on 3200 Q Trap LC/MS/MS system
(applied biosystem).
General procedure for acid catalyzed robinson annulation reaction:
The procedure is modified from original reference to get better yield.
O
CHO

O
cat. H 2SO4
+
Benzene

n
n= 0, 1, 2

n

Carbaldehyde (10mmol), but-3-en-2-one (10mmol) was refluxed in benzene (10ml) with
catalytic amount H2SO4 (0.05ml) in a round bottom flask equipped with Dean-Stark trap.
The mixture was first heated to 45oC for 1.5hrs, and then increased to reflux until no
more H2O condensed from the reaction mixture (1.5hr). Another equivalent of bu-3-2one (10mmol) was added and refluxed for an additional 1.5hrs. The mixture was cooled
down and 20ml of 1 M NaHCO3 was added and the organic phase was separated. The
aqueous phase was extracted with benzene, and the combined organic phase was washed
with brine and dried over MgSO4. The solid was filtered, and concentrated in vacuo to
give crude dark brown oil which was separated by flash column chromatography (Ethyl
acetate/Hexane =15% to 25%) to give spiro enone as yellow oil.
spiro[4.5]dec-6-en-8-one (65% Yield)
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O

1

H-NMR (360 MHz, CDCl3) δ 6.74 (d, J = 7.2 Hz, 2H), 5.84 (d, J = 7.2 Hz, 2H), 2.44 (t,
J = 7.2 Hz, 2H), 1.89 (t, J = 7.2 Hz, 2H), 1.76-1.67 (m, 8H); 13C-NMR (90 MHz, CDCl3)
δ 200.19, 159.78, 126.76, 44.32, 38.31, 35.59, 34.15, 24.73; ESI-MS: Calculated for
C10H14O (M + H)+ 151.2, Found: 151.3
The characterization of spiro[5.5]undec-1-en-3-one was reported before.
O

.
Spiro[5.6]dodec-1-en-3-one
O

1

H-NMR (360 MHz, CDCl3) δ 6.75 (d, J = 7.2 Hz, 2H), 5.79 (d, J = 7.2 Hz, 2H), 2.39 (t,
J = 7.2 Hz, 2H), 1.81 (t, J = 7.2 Hz, 2H), 1.62-1.49 (m, 12H); 13C-NMR (90 MHz,
CDCl3) δ 199.89, 159.40, 126.02, 38.26, 37.81, 34.18, 33.61, 30.65, 23.10; ESI-MS:
Calculated for C12H18O (M + H)+ 179.3, Found: 179.3
General procedure for reduction of spiro enone with PdCl2/Et3SiH
O

O
Et3SiH
PdCl2
n

n

To spiro enone (10mmol) in absolute EtOH was added PdCl2 (0.2g), Et3SiH (20mmol)
was added dropwise to the mixture with stirring. The mixture was refluxed for 4hrs and
PdCl2 was filtered, washed with EtOH. The filtrate was concentrated and purified by
flash column chromatography (Ethyl acetate/Hexane =15% to 25%) to give spiro ketone
as yellow oil.
Spiro[4.5]decan-8-one (85% Yield)
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O

1

H-NMR (360 MHz, CDCl3) δ 2.34 (t, J = 7.2 Hz, 2H), 1.76 (t, J = 7.2 Hz, 2H), 1.71-1.67
(m, 4H), 1.59-1.55 (m, 4H); 13C-NMR (90 MHz, CDCl3) δ 212.97, 42.15, 39.31, 37.95,
37.48, 24.73; ESI-MS: Calculated for C10H16O (M + H)+ 153.2, Found: 153.2
The characterizations of spiro[5.5]undecan-3-one were reported before.
O

Spiro[5.6]dodecan-3-one (88% Yield)
O

1

H-NMR (360 MHz, CDCl3) δ 2.31 (t, J = 7.2 Hz, 2H), 1.67 (t, J = 7.2 Hz, 2H), 1.57-1.50
(m, 12H); 13C-NMR (90 MHz, CDCl3) δ 213.32, 38.65, 37.81, 37.71, 35.25, 30.66,
23.17; ESI-MS: Calculated for C12H20O (M + H)+ 181.3, Found: 181.3.
General procedure for reductive amination of spiro ketone
NH3+Cl-

O
1. NH2OH*HCl
CH3COONa

n

2. LiAlH 4
3. HCl

n=0 M2WJ189
n=1 M2WJ34
n=2 M2WJ164
n

To a solution of spiro ketone (10mmol) in EtOH (50ml) was added HONH2*HCl
(30mmol) and NaOAc (40mmol). The mixture was heated to reflux for 2hrs. Solvent was
removed in vacuo and the residue was extracted with CH2Cl2 and H2O. The aqueous
layer was extracted with CH2Cl2 again. The combined CH2Cl2 was dried with MgSO4 and
concentrated in vacuo. The resulting oxime was dissolved in anhydrous THF and cooled
down to 0oC. LiAlH4 (0.80g, 20mmol) was added portionwise to the solution and the
mixture was heated to reflux overnight. After cooling down to 0 oC, the solution was
quenched with H2O (0.8 mL), 15% NaOH (0.8 mL), and H2O (2.4 mL) sequentially. The
resulting slurry was filtered. The filtrate was acidified with 4M HCl in 1,4-dioxane and
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concentrated in vacuo. The final product was purified by flash chromatography to give
spirane amine hydrochloride salt as yellow solid.
Spiro[4.5]decan-8-aminium chloride (M2WJ189) (Yield: 75%)
NH 3+Cl-

1

H-NMR (360 MHz, CDCl3) δ 3.12-3.08 (m, 1H), 1.67-1.45 (m, 16H); 13C-NMR (90
MHz, CDCl3) δ 52.53, 42.96, 37.54, 36.52, 29.96, 26.63; ESI-MS: Calculated for
C10H19N (M + H)+ 154.3, Found: 154.3.
The characterizations of spiro[5.5]undecan-3-aminium chloride (M2WJ34) were reported
before.
NH 3+Cl-

Spiro[5.6]dodecan-3-aminium chloride (M2WJ164) (Yield: 72%)
NH 3+Cl-

1

H-NMR (360 MHz, CDCl3) δ 3.12-3.08 (m, 1H), 1.67-1.45 (m, 16H); 13C-NMR (90
MHz, CDCl3) δ 52.70, 45.53, 37.93, 36.51, 36.24, 32.64, 32.32, 28.20, 24.74, 24.55; ESIMS: Calculated for C12H23N (M + H)+ 182.3, Found: 182.3.
3-azaspiro[6.6]tridecan-3-ium chloride (M2WJ196)
O

O
NH 2OSO 3H
HCOOH

-Cl+H

HN

2N

1. LiAlH 4
2. HCl

M2WJ196

To a solution of hydroxylamine-O-sulfonic acid (1.70g, 15mmol) and 95% formic acid
(9ml) under N2 protection was added dropwise spiro[5.6]dodecan-3-one (1.80g, 10mmol)
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in 3ml of 95% formic acid. The solution was heated under reflux for 5hrs and then cooled
to ambient temperature. The reaction mixture was diluted with H2O (15ml) and
neutralized to pH 7 with 6 N NaOH. The aqueous solution was extracted three times with
30ml CHCl3. The combined organic layer was dried with MgSO4 and used for the next
step reduction without purification. 3-azaspiro[6.6]tridecan-4-one was dissolved in
anhydrous THF and cooled down to 0oC. LiAlH4 (0.80g, 20mmol) was added portionwise
to the solution and the mixture was heated to reflux overnight. After cooling down to
0oC, the solution was quenched with H2O (0.8 mL), 15% NaOH (0.8 mL), and H2O (2.4
mL) sequentially. The resulting slurry was filtered. The filtrate was acidified with 4M
HCl in 1,4-dioxane and concentrated in vacuo. The final product was purified by flash
chromatography to give 3-azaspiro[6.6]tridecan-3-ium chloride (M2WJ196) as yellow
solid (1.35g, 62% Yield). 1H-NMR (360 MHz, CD3OD) δ 3.31-3.27 (m, 2H), 3.12-3.10
(m, 2H), 1.73-1.65 (m, 4H), 1.52-1.47 (m, 6H), 1.30-1.27 (m, 8H); 13C-NMR (90 MHz,
CD3OD) δ 43.42, 40.75, 39.52, 39.47, 37.51, 36.64, 32.18, 23.76, 21.73; ESI-MS:
Calculated for C12H23N (M + H)+ 182.3, Found: 182.5.
General procedure for ring expansion reaction
O

N2

O
N2

HO
O

O
O
O

O
cat Rh(OCOCH 3)2

AcOH, TsOH

2

ref lux

LDA
n

O

O

n

n

n

To a solution of spiro ketone (5mmol) and ethyl diazoacetate (1.15g, 10mmol) in
anhydrous THF (20ml) at -78oC was added LDA (5ml, 2M in hexane) dropwise under N2
atmosphere. The reaction was stirred at the same temperature for 2hrs and warmed to
ambient temperature. Aqueous NH4Cl (40ml, 30% w/w) was added and extracted with
diethyl ether. The combined organic layers were washed with water, brine, dried over
anhydrous MgSO4, filtered and concentrated in vacuo to give the diazo-hyroxyl ester
intermediate as brown oil. CH2Cl2 (30ml) was added and the flask was flushed with N2
atmosphere. Rodium(II) acetate dimer (8mg) was then added and the mixture was stirred
at ambient temperature for 1hr. The catalyst was filtered and the filtrate was concentrated
in vacuo to give the crude β-keto ester as yellow oil which was used for the next step
hydrolysis without further purification. To a solution of β-keto ester, acetic acid (10ml),
water (5ml) was added para-toluenesulfonic acid (1mmol, 0.19g). The solution was
heated to reflux for 24hrs. After cooling to ambient temperature, the reaction mixture was
diluted with water (20ml) and extracted with diethyl ether (30ml×3). The combined ether
was dried over anhydrous MgSO4 and purified by flash column chromatography (2030% Ethyl acetate/Hexane) to give spiran ketone as yellow oil.
spiro[5.6]dodecan-9-one (Yield: 72%)
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O

1

H-NMR (360 MHz, CDCl3) δ 2.47 (t, J = 7.2 Hz, 2H), 2.42 (t, J = 7.2 Hz, 2H), 1.67-1.62
(m, 4H), 1.52-1.30 (m, 12H); 13C-NMR (90 MHz, CDCl3) δ 211.23, 43.95, 41.72, 38.81,
36.69, 35.39, 33.04, 26.69, 21.82, 19.31; ESI-MS: Calculated for C12H20O (M + H)+
181.3, Found: 181.1.
spiro[6.6]tridecan-3-one (Yield: 75%)
O

1

H-NMR (360 MHz, CDCl3) δ 2.46 (t, J = 7.2 Hz, 2H), 2.40 (t, J = 7.2 Hz, 2H), 1.70-1.63
(m, 2H), 1.59-1.55 (m, 2H), 1.51-1.41 (m, 14H); 13C-NMR (90 MHz, CDCl3) δ 215.17,
43.96, 41.44, 39.08, 39.03, 38.76, 35.24, 31.11, 22.80, 19.54; ESI-MS: Calculated for
C13H22O (M + H)+ 195.3, Found: 195.4.
Spiro[5.6]dodecan-9-aminium chloride (M2WJ152) was synthesized according to the
general reductive amination procedure. (Yield: 70%)
-

Cl+H3 N

1

H-NMR (360 MHz, CD3OD) δ 3.18-3.13 (m, 1H), 1.78-1.61 (m, 6H), 1.47-1.37 (m,
10H), 1.36-1.29 (m, 4H); 13C-NMR (90 MHz, CD3OD) δ 83.25, 67.76, 67.56, 64.45,
64.25, 56.25, 55.71, 51.08, 51.06, 48.02; ESI-MS: Calculated for C12H23N (M + H)+
182.3, Found: 182.4.
spiro[6.6]tridecan-3-aminium chloride (M2WJ180) was synthesized according to the
general reductive amination procedure (Yield: 75%)
-Cl+H N
3
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1

H-NMR (360 MHz, CD3OD) δ 3.14-3.13 (m, 1H), 1.74-1.48 (m, 12H), 1.48-1.28 (m,
6H), 1.18-1.09 (m, 4H); 13C-NMR (90 MHz, CD3OD) δ 55.47, 41.03, 41.01, 40.40,
39.88, 36.65, 35.82, 32.51, 28.39, 23.91, 23.87, 20.08; ESI-MS: Calculated for C13H25N
(M + H)+ 196.3, Found: 196.3.
Spiro[5.5]undecane-3-carbonitrile
O

CN
TOSMIC
tBuOK

To a solution of spiro[5.5]undecan-3-one (1.66g, 10mmol) and tosylmethylisocyanide
(2.54g, 13mmol) in DME (50ml) and abs. EtOH (1ml) was added KOtBu (2.69g,
24mmol) portionwise during 0.5 hr at -10oC. After addition, the reaction mixture was
stirred at 0oC for 1hr then 2hr at ambient temperature. Solvent was removed in vacuo and
the resulting residue was extracted with diethyl ether (50ml × 3) and the combined
organic layer was washed with water (50ml×3). The organic layer was dried with
anhydrous MgSO4, concentrated under reduced pressure and purified by flash column
chromatography (50% - 100% CH2Cl2/Hexane) to give the nitrile as colorless solid
(1.28g, 72% Yield). 1H-NMR (360 MHz, CDCl3) δ 2.58-2.53 (m, 1H), 1.83-1.70 (m,
4H), 1.63-1.58 (m, 2H), 1.40-1.26 (m, 8H), 1.28-1.20 (m, 4H); 13C-NMR (90 MHz,
CDCl3) δ 122.79, 34.41, 31.88, 28.37, 26.88, 24.73, 21.64, 21.55; ESI-MS: Calculated for
C12H19N (M + H)+ 178.3, Found: 178.2.
spiro[5.5]undecan-3-ylmethanaminium chloride (M2WJ151)
NH 3 +Cl-

CN
1. LiAlH 4
2. HCl

M2WJ151

Spiro[5.5]undecane-3-carbonitrile (1.77g, 10mmol) in anhydrous THF was cooled down
to 0oC. LiAlH4 (0.80g, 20mmol) was added portionwise to the solution and the mixture
was heated to reflux overnight. After cooling down to 0oC, the solution was quenched
with H2O (0.8 mL), 15% NaOH (0.8 mL), and H2O (2.4 mL) sequentially. The resulting
slurry was filtered. The filtrate was acidified with 4M HCl in 1,4-dioxane and
concentrated in vacuo. The final product was purified by flash chromatography to give
spiro[5.5]undecan-3-ylmethanaminium chloride (M2WJ151) as yellow solid (1.70g, 78%
Yield). 1H-NMR (360 MHz, CD3OD) δ 2.90 (m, 2H), 1.84-1.81 (m, 2H), 1.72-1.62 (m,
3H), 1.54-1.50 (m, 8H), 1.36-1.32 (m, 4H), 1.20-1.16 (m, 2H); 13C-NMR (90 MHz,
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CD3OD) δ 46.62, 42.61, 37.89, 36.98, 33.28, 33.20, 20.08, 26.35, 22.83, 22.71; ESI-MS:
Calculated for C12H23N (M + H)+ 182.3, Found: 182.3 (Take it again)
.
spiro[5.5]undecane-3-carboxylic acid
CN

COOH
AcOH, H 2SO 4
ref lux

spiro[5.5]undecane-3-carbonitrile (1.77g, 10mmol) was dissolved in AcOH (20ml),
H2SO4 (5ml) and H2O (10ml) was added and the mixture was heated to reflux overnight.
The solution was cooled down to ambient temperature and diluted with H2O (100ml).
The aqueous layer was extracted with diethyl ether (100ml×3), the combined organic
layer was dried over MgSO4 and concentrated in vacuo. The product was purified by
flash column chromatography (10%-20% CH3OH/CH2Cl2) to give colorless solid (1.53g,
78% Yield). 1H-NMR (360 MHz, CDCl3) δ 2.32-2.25 (m, 1H), 1.78-1.58 (m, 6H), 1.521.35 (m, 8H), 1.24-1.21 (m, 2H), 1.12-1.04 (m, 2H); 13C-NMR (90 MHz, CDCl3) δ
183.13, 43.55, 40.96, 35.78, 32.75, 32.05, 27.10, 23.97, 21.86, 21.71; ESI-MS:
Calculated for C12H20O2 (M - H)+ 195.3, Found: 195.3
O

COOH
CH 3Li

Spiro[5.5]undecane-3-carboxylic acid (1.96g, 10mmol) in anhydrous diethyl ether (50ml)
was cooled down to 0oC, CH3Li (22mmol) was added dropwise in 30mins. The resulting
mixture was stirred at the same temperature for two more hours and warmed to ambient
temperature overnight. Saturated NH4Cl aqueous solution was added and was extracted
with diethyl ether (50ml × 3). The organic layers were combined and dried over
anhydrous MgSO4. The product was purified by flash column chromatography (20%30% Ethyl acetate/Hexane) as yellow oil (1.40g, 72% Yield) 1H-NMR (360 MHz,
CDCl3) δ 2.30-2.22 (m, 1H), 2.11 (s, 3H), 1.71-1.63 (m, 4H), 1.55-1.47 (m, 2H), 1.471.36 (m, 8H), 1.23-1.20 (m, 2H), 1.87-1.01 (m, 2H); 13C-NMR (90 MHz, CDCl3) δ
212.44, 52.07, 41.32, 36.05, 32.39, 32.15, 28.10, 27.07, 23.60, 21.84, 21.67; ESI-MS:
Calculated for C13H22O (M + H)+ 195.3, Found: 195.3
1-(spiro[5.5]undecan-3-yl)ethanaminium chloride (M2WJ198)
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O

-

Cl+H 3N

1. NH2OH*HCl
CH3COONa
2. LiAlH 4
3. HCl
M2WJ198

1-(spiro[5.5]undecan-3-yl)ethanaminium chloride (M2WJ198) was synthesized according
to the procedure described above for reductive amination. 1H-NMR (360 MHz, CDCl3) δ
3.14-3.07 (m, 1H), 1.70-1.64 (m, 3H), 1.59-1.56 (m, 1H), 1.37-1.35 (m, 12H), 1.31-1.19
(m, 4H), 1.08-1.01 (m, 2H); 13C-NMR (90 MHz, CDCl3) δ 53.10, 42.14, 41.71, 36.12,
36.09, 32.16, 32.03, 27.11, 24.39, 23.29, 21.93, 21.77, 16.39; ESI-MS: Calculated for
C13H25N (M + H)+ 196.3, Found: 196.3

Figure 1. Synthesis scheme of spiroadamantane M2WJ206
2-adamantanecarbaldehyde was synthesized from 2-adamantone in two steps according
to literature procedures. It was first converted to vinyl ether by witting reaction, and then
followed by acid hydrolysis. Due to the instability of the aldehyde, it was used
immediately for the next step robinsin annelation reaction. The following enone reduction
and amination steps were performed as described above.
(1r,3r,5r,7r)-spiro[adamantane-2,1'-cyclohex[2]en]-4'-one

1

H-NMR (360 MHz, CDCl3) δ 7.50 (d, J = 10.8 Hz, 2H), 5.92 (d, J = 10.8 Hz, 2H), 2.43
(t, J = 6.48 Hz, 2H), 2.14-2.09 (m, 6H). 1.97 (d, J = 2.52 Hz, 1H), 1.89 (d, J = 2.52 Hz,
1H), 1.75-1.62 (m, 8H); 13C-NMR (90 MHz, CDCl3) δ 199.92, 158.61, 127.89, 40.29,
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39.14, 35.30, 33.36, 33.26, 32.97, 31.79, 28.22, 27.31; ESI-MS: Calculated for C15H20O
(M + H)+ 217.3, Found: 217.4.
(1r,3r,5r,7r)-spiro[adamantane-2,1'-cyclohexan]-4'-one

1

H-NMR (360 MHz, CDCl3) δ 2.30 (t, J = 6.84 Hz, 4H), 2.09-2.05 (m, 4H), 1.95 (t, J =
6.84 Hz, 4H), 1.90 (br s, 2H), 1.72 (br s, 4H), 1.65-1.61 (m, 4H); 13C-NMR (90 MHz,
CDCl3) δ 213.04, 39.46, 36.95, 36.77, 34.36, 33.93, 33.03, 28.36; ESI-MS: Calculated for
C15H22O (M + H)+ 219.3, Found: 219.4.
(1r,3r,5r,7r)-spiro[adamantane-2,1'-cyclohexan]-4'-aminium chloride (M2WJ206)

1

H-NMR (360 MHz, CD3OD) δ 3.10-3.05 (m, 1H), 2.45-2.42 (m, 2H), 2.16-2.13 (m,
2H), 2.07-2.04 (m 2H), 1.97 (br s, 1H), 1.84-1.82 (m, 4H), 1.73 (br s, 2H), 1.61-1.49
(6H), 1.26 (br s, 1H), 1.08-1.02 (m, 2H); 13C-NMR (90 MHz, CD3OD) δ 52.04, 40.73,
40.32, 37.61, 33.97, 33.38, 30.67, 29.83, 26.54; ESI-MS: Calculated for C15H25N (M +
H)+ 220.4, Found: 220.7.

Two-Electrode Voltage-Clamp Analysis.
WT A/M2-pGEM3 cDNA and mutant DNA V27A were linearized using HindIII, and
corresponding mRNAs were generated by in vitro transcription reactions on the
linearized cDNA using a T7 mMESSAGE mMACHINE transcription kit (Ambion,
Austin, TX) and injected into oocytes as described previously (1, 2). Currents were
measured 48–72 h after injection of oocytes as described (1, 2). Currents were acquired
and analyzed using the pCLAMP 10.0 software package (Axon Instruments, Sunnyvale,
CA).
Plaque Assays.
Cells, Viruses, and Plasmids. 293-T and Madin–Darby canine kidney (MDCK) cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen Invitrogen,
Carlsbad, CA) supplemented with 10% FBS. Influenza A/Udorn/72 virus (WT) and
mutant viruse (V27A) were propagated in MDCK cells overlaid with serum-free DMEM
containing 2.0 g/ml N-acetyl trypsin (NAT; Sigma-Aldrich, St. Louis,MO) at 37°C. WT
and mutant viruses were generated by using reverse genetics from cDNAs essentially as
described previously (3). Val27Ala mutation into the M2 gene in pHH21 was
generated using Quick Change mutagenesis (Stratagene, La Jolla, CA). 293-T cells were
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transfected using TransIT-LT1 (Mirus, Madison, WI) according to the manufacturer
protocols. Virus stocks were propagated in MDCK cells, and the virus titers were
determined by plaque assay on MDCK cells. The viral M gene sequences were
determined as described previously (2).
In vivo plaque reduction assay was carried out similarly as described previously (2).
Briefly, MDCK cell monolayers were preincubated with DMEM supplemented with the
drug at various concentrations at 37 °C for 30 min, and virus samples were preincubated
with DMEM 1% BSA with the drug at the same concentration for MDCK cells at 4 °C
for 30 min before infection. Then DMEM medium were replaced with virus samples with
or without drugs and incubated at 37 °C for 1hr. The inoculums were removed, and the
cells were washed with phosphate buffered saline (PBS). The cells were then overlaid
with DMEM containing 1.2% Avicel microcrystalline cellulose (FMC BioPolymer,
Philadelphia, PA) (4) and NAT (1.0 g/ml). To examine the effect of the drugs on plaque
formation, at 2 days after infection, the monolayers were fixed and stained with
naphthalene black dye solution (0.1% naphthalene black, 6% glacial acetic acid, 1.36%
anhydrous sodium acetate).

(1) Pinto LH, Holsinger LJ, Lamb RA (1992) Influenza virus M2 protein has ion
channel activity. Cell 69:517–528.
(2) Jing X, et al. (2008) Functional studies indicate amantadine binds to the pore of
the influenza A virus M2 proton-selective ion channel. Proc Natl Acad Sci USA
105:10967–10972
(3) Takeda M, Pekosz A, Shuck K, Pinto LH, Lamb RA (2002) Influenza A virus M2
ion channel activity is essential for efficient replication in tissue culture. J Virol
6:1391–1399
(4) Matrosovich M, Matrosovich T, Garten W, Klenk HD (2006) New low-viscosity
overlay medium for viral plaque assays. Virol. J. 3.63, doi: 10.1186/1743–422X3–63.
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Chapter 8
Exploring Silaspiran Amines as Potent Inhibitors of Influenza A Virus
M2 Channel

8.1 Abstract
Substitution of carbon with its close analog silicon yields organosilanes, which are
intrinsically unnatural and has yet to be found toxic. This transition has been successful
in pesticide industry and recently been explored in many aspects of medicinal chemistry
research, including protease inhibitors,1-3 kinase inhibitors,4 cyclooxygenase-2 (COX-2)
inhibitors.5,

6

As carbon to silicon switch increases both the molecule’s size and

hydrophobicity scale, and therefore is well suited in designing influenza A virus M2
channel inhibitors because of the positive correlation between hydrophobicity and
antiviral potency from the previous structure-activity relationship studies.7, 8 Herein, we
report the design of organosilane inhibitors based on spiran amine scaffold, which
yielded a series of silaspiran amine inhibitors that are more potent than their carbon
analogs.

8.2 Introduction
Influenza A virus is a serious human health threat and there is an urgent and continuing
effort in developing small molecule antiviral agents.9 Drug resistance is the predominant

271

issue in anti-influenza inhibitor research due to the reassortment ability of infecting
influenza A viruses across different species such as human, swine and pig.10

A/M2 forms a homotetrameric proton selective channel in viral membrane and plays an
essential role in mediating viral uncoating11 and budding.12 Additionally, it also
equilibrates the pH across the Golgi apparatus to prevent the premature conformational
switch of hemagglutinin.13-15 A/M2 is a proven antiviral target in the treatment of
influenza A virus infection. A/M2 inhibitors like amantadine and rimantadine have been
used for decades, but their effectiveness have been diminished due to emerging drug
resistance and side effects, which prompted the Centers for Disease Control and
Prevention (CDC) to recommend the discontinued use of this class of drugs.
Nevertheless, A/M2 is more conserved than other drug targets of influenza A virus with
only three major mutations, S31N, V27A and L26F, which locate at the transmembrane
domain drug binding site.16,

17

The structures of A/M2 transmembrane domain were

solved both by solution NMR18,

19

and X-ray crystallography,20,

21

which make the

rational design of A/M2 inhibitor feasible.

Carbon to silicon switch is a widely explored strategy in developing and marketing
organosilane pesticides.22, 23 There is a growing interest in the pharmaceutical industry to
fine tune the pharmacological or pharmacokinetic properties of marketed drugs using the
same transition.24-27 Apart from the increased size and hydrophobicity scale of silicon
comparing to its carbon counterpart, organosilane can also be designed to mimic the
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unstable carbon intermediate or lead to novel scale scaffolds that are not accessible to
carbon analogs.28,

29

The most common switch from a carbon to silicon can be

categorized in two classes (Scheme 8.1 a and 8.1 b). In the first case, a quaternary carbon
is replaced with a silicon4 (Scheme 8.1 a). In the second case, a carbonyl is replaced with
a sterically hindered silanediol to mimic the transition state of an amide bond hydrolysis
by protease3 (Scheme 8.1 b).

Scheme 8.1 | Common strategies of carbon to silicon switch in drug design

In designing A/M2 inhibitors as anti-influenza virus drugs, hydrophobicity plays a critical
role in improving potency. The pore facing residues of A/M2 channel are V27, A30, S31
and G34,20, 21 which form a hydrophobic binding pocket that favors binding of a cage
shape molecule like adamantane or spiran amines. The carbon to silicon switch is well
suited in this case because replacing the spiro carbon quaternary center by silicon
increases both the hydrophobicity and the size of the spiran amine (Scheme 8.2). This
strategy is more advantageous than introducing extra hydrophobic substitutions, as it
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might cause a shape mismatch between the inhibitor and the pore binding site,
consequently leading to a decreased potency.

Scheme 8. 2 | Design principle of A/M2 inhibitors

8.3 Results and Discussion
Silaspiran amines are more potent than their carbon analogs
To test the effectiveness of a carbon to silicon switch in A/M2 inhibitor design, we first
examined one of the commercially available silicon containing amine-3-aminopropyl
trimethylsilane hydrochloride M2WJ212 (Gelest, Cat # SIA0612.0, Figure 8.1).
Encouragingly, it showed 75.5 ± 0.5% inhibition against wt A/M2 at 100 µM
concentration in two electrode voltage clamp (TEVC) assay with full length Udorn AM2
protein in the Xenopus oocytes membrane30. In comparison, amantadine showed 86.5%
inhibition at the same concentration. This is by far the smallest molecule (less than 8
carbons) that is active against A/M2 at this level.

Figure 8. 1 | The smallest influenza A virus M2 inhibitor
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Next, two silicon containing spiran amines (M2WJ224 and M2WJ210) were designed
and synthesized based on the previously identified spiran amines. The synthesis started
from dichlorosilane, double substitution of the chlorides with vinyl magnesium bromide
yielded the divinyl cyclosilane.31,

32

Without purification,

it underwent an initial

hydroboration with 9-borabicyclo[3.3.1]nonane (9-BBN), followed by an exchange
reaction with borane-methyl sulfide complex (BMS) and methanolysis to give the
silaborinane intermediate.33 Next following Brown’s dichloromethyl methyl ether
(DCME) process and oxidation with 30% H2O2 furnished the spirosilicon ketone
intermediate in a one pot process with 40~50% overall yield.31, 32 Finally, the ketone was
converted to amine using the two step hydroxylamine condensation/reduction followed
by the previous published procedure with ~75% yield.8

Scheme 8.3 | Synthesis scheme of silaspiran amines

Our previous structure-activity relationship study of BL-1743 revealed a series of spiran
amines that are not only active against wt A/M2, but also V27A mutant.7, 8 A positive
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correlation of hydrophobicity and potency was seen for spiran amines. As expected, both
the silaspiran amines were equally potent as their carbon counterparts against wt A/M2
(Table 8.1). More interestingly; there is a dramatic increase in potency of silaspiran
amine inhibitors for V27A inhibition. This enhanced activity might correlate with 20%
longer bond length of Si-C (1.87Å) compared to the C-C (1.54Å) bond, and the increased
volume of the inhibitor can fill in the extra space created by the bulkier Val to smaller
Ala mutation.

Table 8. 1 | Comparison of influenza A virus M2 inhibition between silaspiran amines
and its carbon analogs

Additionally, two 4,4-disubstituted silacyclohexane amine derivatives (M2WJ225 and
M2WJ226) were designed and synthesized (Scheme 8.4). The synthesis of M2WJ225
was accomplished using the procedures described above. For the synthesis of M2WJ226,
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the intermediate ketone, 1,1-dimethylsilinan-4-one, was converted to nitrile using
TOSMIC, which was subsequently reduced by LiAlH4.

Scheme 8. 4 | Synthesis scheme of 4,4-dimthyl silacyclohexane amines
Both inhibitors showed high potency against wt A/M2 and only minimal inhibition
against V27A mutant (Table 8.2), which is consistent with our previous structure-activity
relationship studies results that V27A mutation expands the drug binding site, thus
requires bulkier molecules to fill in the extra space.

Table 8. 2 | Influenza A virus M2 channel inhibition by 4,4-dimethyl silacyclohexane
amines
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8.4 Conclusion
Biologically active organosilanes, which are discovered through either rational design or
high throughput screening, are attractive analogs of their carbon counterparts due to their
unique properties. A carbon to silicon switch retains the overall 3-D conformation of the
inhibitor, thus providing a minimal perturbation of the binding between the ligand and the
receptors. Nevertheless, the larger covalent radius of silicon (1.17Å) compare to carbon
(0.77Å), and the higher hydrophobicity renders the organosilane based inhibitors with
improved bioavailability. Organosilanes are also in general easier to synthesize than their
carbon analogs. In certain cases allow access to novel scaffolds that are not accessible by
the standard carbon chemistry.28 In this report, we explored the carbon to silicon switch
in designing A/M2 inhibitors against influenza virus infection. The silaspiran amines are
found to be equally potent as the their carbon counterparts against wt A/M2, and are more
potent in targeting drug resistant A/M2-V27A mutant, which highlight their promise for
further optimization.

8.5 Experimental details
Two electrode voltage (TEV) clamp assay
Details about the experimental set up can be found in previous reports.8

Chemical synthesis
All chemicals were purchased from commercial vendors and used without further
purification. Cyclotrimethylenedimethylsilane and Cyclotetramethelenedimethylsilane
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were

purchased

from

Gelest

(PA,

USA)

and

used

without

Dimethyldivinylsilane was purchased from Sigma-Aldirch. 1H and

13

purification.

C NMR spectra

were recorded on either DMX-360 or DRX-500 NMR spectrometer. Chemical shifts are
reported in parts per million referenced with respect to residual solvent (CDCl3 = 7.27
ppm and DMSO-d6 = 2.50 ppm) or from internal standard tetramethylsilane (TMS = 0.00
ppm). The following abbreviations were used in reporting spectra: s = singlet, d =
doublet, t = triplet, q = quartet, m = multiplet. All reactions were carried out under a N2
atmosphere, unless otherwise stated. HPLC grade solvents were used for all the reactions.
Column chromatography was performed using silica gel (230-400 mesh). Low-resolution
mass spectra were obtained on an LC platform from Micromass using an ESI technique.
General procedure of dichloro substitution with divinyl magnisum bromide
Dichlorosilane (10 mmol) in ether (20 ml) was cooled down to 0oC using ice-water bath.
Vinyl magnesium bromide (22 ml, 1M in THF, 22 mmol) was added dropwise via
syringe over 30 mins. The resulting solution was slowly warm to room temperature and
continued stirring for 3h. The reaction was quenched with water (5 ml), and extracted
with saturated NH4Cl and ether. The aqueous phase was extracted two times with ether.
The ether layers were combined and washed with brine, dried with MgSO4, filtered, and
the solvent was removed under reduced pressure with cool water bath (~10oC in order to
prevent the evaporation of the product due to low boiling point). The final product
appeared as a yellow oil.

General procedure of converting divinylsilane to 1-silacyclohexan-4-one
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Hydroboration and methanolysis reaction
To a divinylsilane (10 mmol) in n-hexane (20 ml) was added 9-borabicyclo[3.3.1]nonane
(9-BBN) dimer (10 mmol), the mixture was heated to reflux for 2hrs. After cooling the
reaction mixture to room temperature, BH3•SMe2 (10 mmol) was added dropwise with
caution and the mixture was refluxed for 1h. The borane mixture was cooled to room
temperature, methanol (3.5 ml) was added dropwise, which resulted in vigorous hydrogen
gas formation. The mixture was stirred overnight and concentrated in vacuo.

Brown’s DCME process and oxidation reaction
The above borinane was dissolved in THF (30 ml) and cooled down to 0oC with icewater bath. Dichloromethyl methyl ether (10 mml) was added, followed by lithium tbutoxide (50 ml, 1M in THF, 50 mmol). The temperature was raise to rt and stirred for
30mins. Ethanol (12 ml) and NaOH (1.2 g, 30 mmol) dissolved in H2O (3.5 ml) were
added sequentially, followed by dropwise addition of 30% H2O2 (3.3 ml). The solution
was heated to reflux for 3 hrs and hydrolyzed with water (100 ml). The product was
extracted with ethyl acetate (3 × 100ml), the combined organic layers were dried over
MgSO4, filtered and concentrated in vacuo. The residue was purified by flash column
chromatography (10-20% Ethyl acetate/hexane) to give the silaspiro ketone as yellow oil.

6-silaspiro[5.5]undecan-3-one
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1

H NMR (360 MHz, CDCl3) δ 2.50 (t, J = 5.4 Hz, 4H), 1.71-1.66 (m, 4H), 1.44-1.42 (m,

2H), 0.95 (t, J = 5.4 Hz, 4H), 0.716 (t, J = 4.68 Hz, 4H);

13

C NMR (90 MHz, CDCl3) δ

215.27, 37.84, 30.07, 24.67, 11.60, 8.02.

5-silaspiro[4.5]decan-8-one
1

H NMR (360 MHz, CDCl3) δ 2.545 (t, J = 7.2 Hz, 4H), 1.64-1.60 (m, 4H), 1.03 (t, J =

7.2 Hz, 4H), 0.69-0.65 (m, 4H);

13

C NMR (90 MHz, CDCl3) δ 214.72, 68.13, 25.79,

10.98, 9.73.

1,1-dimethylsilinan-4-one
1

H NMR (360 MHz, CDCl3) δ 2.48 (t, J = 5.4 Hz, 4H), 0.92 (t, J = 5.4 Hz, 4H), 0.14 (s,

6H); 13C NMR (90 MHz, CDCl3) δ 215.20, 37.96, 10.84, -2.92.

5-silaspiro[4.5]decan-8-aminium chloride
1

H NMR (360 MHz, DMSO) δ 8.07 (brs, 3H), 2.92-2.90 (m, 1H), 2.15-2.13 (m, 2H),

1.54-1.52 (m, 6H), 0.79-0.66 (m, 4H), 0.56-0.51 (m, 4H); 13C NMR (90 MHz, DMSO) δ
51.28, 28.90, 26.35, 26.31, 9.74, 9.68, 8.85; The calculated mass for C9H19NSi (M + H)+
is 170.3, Found 170.3.

6-silaspiro[5.5]undecan-3-aminium chloride
1

H NMR (360 MHz, CD3OD) δ 3.03-2.99 (m, 1H), 2.19-2.17 (m, 2H), 1.73-1.62 (m, 6H),

1.46-142 9m, 2H), 1.00-0.97 (m, 2H), 0.78-0.75(m, 2H), 0.70-0.61 (m, 4H);

13

C NMR
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(90 MHz, CD3OD) δ 54.28, 31.29, 29.83, 25.63, 25.51, 12.83, 10.88, 9.44; The calculated
mass for C10H21NSi (M + H)+ is 184.4, Found 184.3.

1,1-dimethylsilinan-4-aminium chloride
1

H NMR (360 MHz, DMSO) δ 2.89-2.84 (m, 2H), 2.08-2.06 (m, 2H), 1.59-10.56 (m,

2H), 0.76-0.73 (m, 2H), 0.57-0.51 (m, 2H), 0.04 (s, 3H), 0.01 (s, 3H);

13

C NMR (90

MHz, DMSO) δ 51.62, 27.84, 10.34, -2.71, -4.55; The calculated mass for C7H17NSi (M
+ H)+ is 144.4, Found 144.3.

1,1-dimethylsilinane-4-carbonitrile
1

H NMR (360 MHz, CDCl3) δ 2.66-2.62 (m, 1H), 1.98-1.95 (m, 4H), 0.90-0.84 (m, 2H),

0.67-0.61 (m, 2H), 0.08 (s, 3H), 0.04 (s, 3H);

13

C NMR (90 MHz, CDCl3) δ 122.39,

30.91, 27.51, 11.50, -3.15, -3.41.

(1,1-dimethylsilinan-4-yl)methanaminium chloride
1

H NMR (360 MHz, DMSO) δ 8.02 (brs, 3H), 2.61-2.60 (m, 2H), 1.90-1.88 (m, 2H),

1.48-1.46 (m, 2H), 1.25-1.18 (m, 2H), 0.71-0.68 (m, 2H), 0.48-0.43 (m, 2H), 0.03 (s,
3H), 0.00 (s, 3H); 13C NMR (90 MHz, DMSO) δ 44.05, 37.97, 27.19, 11.93, -2.23, -4.33;
The calculated mass for C8H19NSi (M + H)+ is 158.3, Found 158.4.
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9.1 ABSTRACT Inhibitors targeting the influenza A virus M2 (A/M2) proton channel,
have lost their effectiveness due to widespread resistance.

As a first step in the

development of new inhibitors that address this problem, we have screened several
focused collections of small molecules using two electrode voltage patch clamp assay
(TEV) on Oocyte. M2 inhibitors generally contain a polar amine group and an apolar
hydrophobic scaffold. In this study, diverse head group and scaffolds have been explored.
It has been found that not only amine, but also hydroxyl, aminooxyl, guanidine, amidine
compounds are active against A/M2 proton channel. Moreover, A/M2 proton channel is
able to accommodate a wide range of structural variation in the apolar scaffold. This
study offers information to guide the next generation of A/M2 proton channel inhibitor
design.

9.2 INTRODUCTION
Influenza A viruses present a severe human health threat due to the ease of transmission
via the upper respiratory system.

Influenza A virus constantly undergoes antigenic drift
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and antigenic shift, which allow them to escape from immunization.1 Although
vaccination is the first line defense against influenza A virus infection, its effecitiveness is
diminished by the continuing development of novel strains that escape neutralization, as
well as the delay between the observation of the predominant seasonal strains and the
development and dissemination of an effective vaccine. Currently there are two classes of
small molecule anti-influenza virus drugs:2 one class is zanamivir and oseltamivir that
targets neuraminidase; another class is A/M2 channel inhibitors including amantadine and
rimantadine. Widespread resistance to both oseltamivir (the only orally bioavailable
neuraminidase inhibitor) as well as A/M2 inhibitors presents a major health risk.

The A/M2 protein forms a homotetrameric proton selective channel

3, 4

that is essential

for viral replication.5, 6 Once influenza virus enters cell by endocytosis, A/M2 channel is
activated by the low pH of the endosome and facilitates acidification of the viral interior,
which results in the dissociation of ribonucleoprotein from matrix protein M1 required
for virus infection.5 Amantadine targets A/M2 channel by blocking its pore.

7, 8

The

number of drug-resistant variants of A/M2 is limited by the very conserved nature of the
binding site within the channel. V27A, L26F and S31N are the only widely occurring
drug-resistant variants seen in transmissible strains of the virus.9-11

Other mutations are

observed in vitro or in patients undergoing treatment with amantadine or rimantadine,
13

12,

but the channel of these variants tend to have altered properties that appear to decrease

their fitness for transmission in viruses that infect humans, swines, or birds. 14-16

Extensive medicinal chemistry efforts have been devoted to identify A/M2 channel
inhibitor with higher potency and reduced side effects.2

However, very few chemotypes

other than the adamantane scaffold have been studied for A/M2 channel inhibition.2, 17
One exception is a spiro-piperidine (Figure 1), which emerged from our previous
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structure-activity relationship (SAR) study of 2-[3-azaspiro(5,5)undecanol]-2-imidazoline
(BL-1743).18

Further structure modification yielded another class of spiran amines

(Figure 1) that are not only active against wide type (WT) A/M2 but also A/M2-V27A
mutant channel.19 Encouraged by these initial results, we decided to explore both head
group and scaffold diversity to develop new generations of A/M2 inhibitors, which might
similarly be modified to improve potency towards drug-resistant mutants in subsequent
studies. Inhibitors tested in this study were either synthesized or purchased through
commercial vendors.

NH 3+Cl-

Amantadine

H2 +ClN

Spiro-piperidine

NH 3+Cl-

Spiran amine

Figure 1. Chemical structures of known A/M2 inhibitors.
Herein we described our rationale for compound selection, assay results and
structure-activity relationships (SAR) of these A/M2 channel inhibitors.
9.3 RESULTS AND DISCUSSION
The inhibitors were tested in two electrode patch clamp assay (TEVC) using Xenopus
laevis frog oocytes microinjectected with RNA expressing the A/M2 protein as in a
previous report.20 Oocytes expressing A/M2 channel were initially clamped at -20 mV in
pH 8.5 buffer, in which the A/M2 channel is inactive; then the A/M2 channel was
activated by lowering the buffer solution to pH 5.5. When the inward A/M2 current
reached a maximum, 100 µM inhibitor was applied for 2 min at pH 5.5 buffer solution.
The remaining current after 2 min application was compared to the maximal current
before the application of the inhibitor. The potency of the inhibitors was expressed as the
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percentage inhibition of A/M2 current observed after 2 min incubation with 100 µM
compounds, and IC50’s were collected for selected potent compounds. We note that,
because small molecule inhibitors bind relatively slowly to A/M2, the inhibition does not
reach equilibrium during the two-minute incubation period. Thus, the IC50 values
reported here are greater (lower apparent potency) than the true dissociation constants. 19,
21

9.3.1 SAR of the polar headgroup
A common feature of all known M2 channel inhibitors is the presence of a polar head
group, generally a primary or secondary amine, connected to a hydrophobic scaffold.
Interestingly, the crystal structure and SSNMR structure of amantadine complexed A/M2
did not identify any specific interactions with the amino group and protein;22, 23 instead,
our most recent high resolution X-ray structure showed a cluster of well organized water
molecules that might mediate a hydrogen bond with His37.24

The water cluster is

highly polarized to stabilize an incoming hydronium ion, which might be mimicked by
the ammonium group.

This observation led us to ask whether the primary ammine

might be substituted by other polar groups without significantly affecting the activity.

Inhibitors bearing one polar head group
To explore whether the amine can be substituted by any other polar head groups, we
examined the following panel of compounds based on adamantane scaffold (Table 1).
Table 1. Activities of Adamantane analogs with diverse polar head groups on WT A/M2
inhibition in two electrode voltage clamp assay (TEV).
Compound

Amantadine

M2WJ116

M2WJ99

M2WJ140

M2WJ75

M2WJ161

ID
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SO3 H

NH 3+Cl-

O

NH 3+Cl-

-Cl+H N
2

OH

NH2

-

Cl+H 2N

NH 2

NH

Structure

% inhibition

90.8 ± 2.5%

3.4 ± 2.9%

87.0 ± 4.1%

85.4 ± 1.1%

97.0 ± 0.8%

95.2 ± 0.8%

IC50 (µM)

16.0

N.A

N.A

20.6

14.6

4.4

M2WJ77

M2WJ112

M2WJ117

M2WJ119

M2WJ127

M2WJ120

O

OH

Compound
ID

-Cl+H

Structure

NH 2+Cl-

2N

NH

N
H

-

Cl+H 2N

NH2

H
N

O

NH 2

OH

NH3+Cl-

% inhibition

70.0 ± 3.5%

72.3 ± 2.6%

74.9 ± 0.7%

68.8 ± 4.0%

85.8 ± 2.0%

92.3 ± 1.7%

IC50 (µM)

N.A

N.A

N.A

28.8

13.5

14.3

Amantadine showed 90.8 ± 2.5 % inhibition (IC50 = 16.0 µM) against WT A/M2 channel
and was used as benchmark for comparison. The negatively charged 1-adamantyl
sulfonic acid M2WJ116 was inactive, consistent with M2’s function of stabilizing a
positively charged permeant ion. Amino-oxyl M2WJ99 and 1-adamantol M2WJ140 were
nearly as active as the corresponding amine, giving a similar degree of inhibition at 100
µM. When the amine was substituted by guanidine M2WJ75 (IC50 = 14.6 µM), the
activity was retained at the same level. In contrast, the 1-adamantyl biguanidine M2WJ77
was much less active than 1-adamantyl guanidine M2WJ75, possibly due to the decrease
of hydrophobicity or the increase bulk of the polar group. Interestingly, when the amine
was substituted by amidine M2WJ161, the potency increased nearly four-fold with an
IC50 of 4.4 µM.

N'-hydroxyadamantane-1-carboximidamide M2WJ112 was also less
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active than amantadine when comparing percentage inhibition at 100 µM. Neutral
compounds such as amide M2WJ117 and 2-adamantanone M2WJ119 both showed
decreased activities relative to the corresponding amine. 2-methyl -2-adamantanol
M2WJ127 (IC50 = 13.5 µM) had activity similar to the 1-adamantol M2WJ140 (IC50 =
20.6 µM), being slightly more active than amantadine (IC50 = 16.0 µM). This finding was
consistent with earlier in vitro activity of 2-methyl-2-adamantol in influenza virus
induced cytopathic effect (CPE) assay, despite it didn’t show any binding in the Trp-41
fluorescence assay.25 2-aminoadamantane was shown to have similar activity as
amantadine. In fact, a series of 2-substitited adamantane molecules are highly active
against influenza A virus in in vitro viral CPE assay.26

Additionally, for the spiran class of inhibitors, converting either the primary amine of
M2WJ34 or the secondary amine of M2WJ10 to the corresponding hydrazine in
M2WJ124 and M2WJ98, respectively, decreased potency. This is possibly due to a
decrease in the basicity of the terminal amine (Table 2).

In comparison, both the

glutarimide M2WJ51 and aminoglurarimide M2WJ85 were only weakly active against
A/M2, probably due to the introduction of hydrogen bond acceptors and the strong
decrease in basicity.
Table 2. Activities of spiran amines/hydrazines on WT A/M2 inhibition in two electrode
voltage clamp assay (TEV).
Compound

M2WJ34

M2WJ124

M2WJ10

M2WJ98

M2WJ51

M2WJ85

ID

NH 3+Cl-

NH

NH3+Cl-

H2 +ClN

NH 3+ClN

O

H
N

O

O

NH 2
N
O

Structure
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%
inhibition

89.0 ± 1.3%

78.8 ± 1.5%

95.0 ± 0.9%

95.8 ± 0.3%

35.0 ± 2.9%

29.0 ± 3.7%

IC50

12.6

30.6

0.9

7.1

N. A

N. A

(µM)

In conclusion, these results are consistent with previous studies showing that alcohols can
substitute for amines in M2 inhibitors25 and expand the range of groups that can be
considered for design. Inhibitors with negatively charged compounds are strongly
disfavored.

Inhibitors bearing more than one polar head groups
Pentacyclo[5.4.0.02,6.03,10.05,9]undecane is a particularly good synthetic precursor for
multi-functional inhibiors, as the diketone can be easily converted to a diol, hydroxyl
amine, or hydroxyl ketone.27 Our recent high resolution X-ray crystal structure of A/M2
revealed two layers of well organized water molecule positioned above the
proton-accepting H37 residues.24 We rationalized that an additional polar head group
might potentially hydrogen bonds to or displace these water molecules.

The desired compounds were synthesized by standard procedures from the starting
diketone (Scheme 1).

In this series, the mono-amine M2WJ199 showed the most potent

inhibition against A/M2 channel (IC50 = 7.8 µM), followed by amino alcohol M2WJ208
(IC50 = 24.3 µM). Diol M2WJ136 was also active, but to a less extent than the amino
alcohol at 100 µM percentage inhibition.

Mono-alcohol M2WJ194 showed only

moderate inhibition against A/M2 channel. The lower activities of compounds with an
additional polar head group might be due to the increased polarity leading to a greater
dehydration penalty upon entering the A/M2 channel pore.
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Scheme 1. Synthesis scheme of A/M2 inhibitors with more than one polar head groups

NH 3+ClOH
M2WJ208
1. NH2 OH*HCl
CH 3COONa
2. LiAlH 4
3. HCl
1. HO(CH 2) 2OH, TsOH (cat)
benzene, reflux
O
O

2. NaBH 4, EtOH
3. HCl, CH3 OH

1. H 2NNH2 , diglycol, 120oC
O
OH

2. KOH, 190 oC

Intermediate I

OH
M2WJ194
CrO3 , AcOH
H 2O, 90 oC

1. NH2 OH*HCl
CH 3COONa
NH 3 +ClM2WJ199

2. LiAlH 4
3. HCl

O
Intermediate II

Table 3. Activities of A/M2 inhibitor with more than one polar head groups on A/M2
inhibition in two electrode voltage clamp assay (TEV).
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Compound ID

M2WJ136

M2WJ194

M2WJ199

M2WJ208

M2WJ59
OH
OH

Structure
OH
OH

NH 3+Cl-

OH

NH 3+ClOH

% inhibition

76.2 ± 0.7%

56.7 ± 2.1%

95.5 ± 0.6%

86.0 ± 0.5%

80.0 ± 2.2%

IC50 (µM)

N.A

N.A

7.8

24.3

N.A

M2WJ63

M2WJ61

M2WJ56

M2WJ209

M2WJ218*

Compound
ID

OHOH

OH

OH

-

Cl+H3N

OH

OH

Structure

OH

NH 3+Cl-

O
NH 3+Cl-

% inhibition

50.0 ± 3.0%

5.0 ± 2.8%

13.0 ± 1.5%

40.2 ± 0.8%

90.3 ± 1.3%

IC50 (µM)

N.A

N.A

N.A

N.A

16.0

*The percentage inhibition of M2WJ218 against V27A and S31N mutant of A/M2 was
3.9 ± 1.1 µM and 15.3 ± 1.7 µM respectively.
Encouraged by the result that diol compounds showed good activity against A/M2, we
next

examined

two

commercially

available

diols

(M2WJ59

and

M2WJ63,

stereochemistry is not defined by the vendor). Both were found be less active than
amantadine at 100 µM percentage inhibition. An additional hydroxyl group at the 3
position of amantadine caused a dramatic decrease on A/M2 inhibition (M2WJ61).
Another disubstituted oxyadamantane analog M2WJ56 was also not active. Taking
together, this might due to either steric mismatch or decreased hydrophobicity. The ring
contracted bisnoradamantane diol M2WJ209 was only moderately active, highlighting
hydrophobic contact is important for tight binding.

Earlier work by Clercq et al examined additional 2-amino substitution on the potency of
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rimantadine against influenza A virus, two compounds with 1,2-diaminoethyl groups
were just equally potent to rimantadine.26, 28 Taken together with our data, we conclude
that additional polar groups have so far been tolerated, but do not enhance the potency.

M2WJ218 was designed by Chou et al29 to potentially targeting drug resistant A/M2
mutants based on the solution NMR structure of WT A/M2.30 The design principle was
based on introducing additional hydroxyl group at the 2 position of rimantadine to tie the
two adjacent helices together; this inhibitor was equally potent as amantadine (IC50 =
16.0 µM) and had no inhibitory effect on either S31N or V27A mutants (Table 3). These
results agreed with our crystal structure of A/M2, which showed inhibitor bind inside the
channel with no specific interaction between inhibitor and protein.

9.3.2 Diverse hydrophobic scaffolds
Chen et al reported their screening of 70 primary amines including linear, aromatic,
monocyclic, bicyclic and tricyclic compounds as inhibitors of A/M2.31 Five compounds
were found to have potency against A/M2 comparable to amantadine. We have
examined >30 amines with various sized apolar groups, focusing primarily on
compounds with sizes and shapes roughly conforming the steric requirements of the
binding site. Some of the structures are shown in Table 4. Consistent with previous
findings; amines with aromatic substitutions (M2WJ176 and M2WJ177) are significantly
less active than the corresponding hydrocarbons. This inactivity might reflect decreased
hydrophobicity, increased planarity, and a less optimal fit to the binding site.

Table 4. Activities of A/M2 inhibitor with diverse scaffolds on A/M2 inhibition in two
electrode voltage clamp assay (TEV).
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Compound ID

M2WJ176

M2WJ177

M2WJ179

M2WJ187

M2WJ36

M2WJ139

NH 3+Cl-

Cl+H 3N

Structure

NH 3+Cl-

NH3

NH3+Cl-

NH 2+Cl-

+Cl-

% inhibition

39.7 ± 0.5%

5.8 ± 2.8%

86.6 ± 1.1%

27.9 ± 0.8%

94.1 ± 0.5%

74.8 ± .02%

IC50 (µM)

N.A

N.A

20.7

N.A

9.2

N.A

M2WJ186

M2WJ105

M2WJ55

M2WJ113

M2WJ200

M2WJ201

NH3 +Cl-

NH3+Cl-

Compound
ID

NH 2+Cl+

NH2 Cl

Structure

-

NH 2+Cl-

HN

NH 2+Cl-

NH2

% inhibition

45.3 ± 0.4%

74.0 ± 3.4%

90.2 ± 2.5%

83.8 ± 0.6%

92.0 ± 0.5%

81.3 ± 2.2%

IC50 (µM)

N.A

N.A

N.A

N.A

29.1

23.5

All linear alkyl amines tested (up to 8 carbon atoms) in a previous report were found to
be inactive, and to the best of our knowledge, active acyclic compounds have yet to be
characterized.

Surprisingly, the branched alkyl amine M2WJ179 was nearly as active as

amantadine (IC50 = 20.7 µM), suggesting A/M2 channel can accommodate a wide range
of structural diversity.

The pore-lining residues that contact the apolar region of amantadine include V27, A30
and G34, which create a hydrophobic drug binding pocket that shows a preference for
inhibitors with clogP > 1.5.22 The results presented here, together with previous studies
by Chen et al31 show that a minimum of eight aliphatic carbons are required for potent
inhibition. Tetramethyl cyclopropane amine M2WJ187, which has 7 aliphatic carbons,
showed weak inhibition (27.9% inhibition), which is the maximum we have observed for
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a compound of this molecular weight. M2WJ36 showed higher activity than amantadine
and has the same number of carbon as amantadine (IC50 = 9.2 µM). Three bicyclic
inhibitors (M2WJ139, M2WJ186 and M2WJ105) were also tested and found to be less
active than amantadine at 100 µM percentage inhibition. Four ring expanded adamantane
inhibitors (M2WJ55, M2WJ113, M2WJ200 and M2WJ201) showed similar activity as
amantadine, this result suggests A/M2 is insensitive to slightly scaffold modification.

9.4 CONCLUSION
As an initial step towards the design of inhibitors of drug-resistant inhibitors of M2, it is
important to first understand the mechanism by which the WT protein binds inhibitors.
X-ray crystal structures22, 24 and SSNMR structures23 of the channel have indicated that
amantadine binds with its aliphatic region projecting towards an apolar pocket (Figure 2).
These structures indicate that there is sufficient space in the pocket accommodate larger
hydrophobic groups, by displacing the polar group downward towards His37, with
concomitant rearrangement or displacement of the water seen in the unliganded structure.
The SAR shown in this paper for both the polar head group and apolar scaffold is
consistent with this mode of binding. In the previous literature, almost all potent A/M2
channel inhibitors are cyclic compounds with an amine head group.2 In this study we
found that 1) amine is not essential for the activity and can be substituted by hydroxyl,
guanidine, amidine, aminooxyl groups; 2) potent inhibition does not require a cyclic
scaffold, so long as the shape of the molecule conforms to the cavity, such as the linear
branched amine (M2WJ179); 3) compound hydrophobicity is very important for the
potency of the inhibitor, the effective A/M2 inhibitor should be with clogP >1.5 or the
number of aliphatic carbon equal to or more than 8. While these compounds are active
against the WT protein, they were found to be less potent or inactive against V27A and/or
S31N. This is understandable, because both mutations would increase the polarity of
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the pore.
Fig. 2. Structure of amantadine (purple
carbon atoms) in complex with the
transmembrane domain of M2, as
determined by solid-state NMR23
(PDB: 2KQT) , with the water structure
seen
in
the
high-resolution
crystallographic
structure
(PDB:
3LBW) superimposed. Six water
molecules from 3LBW, shown as red
spheres lie above the four His37 and
Trp41 residues shown near the bottom
of the structure (sidechains shown in
stick). The apolar region of the drug
projects into the cavity formed by
Val27, Ser31, and Ala30 (near the
upper portion of the structure), while
the
ammonium
group
projects
downwards towards the water cluster.
One helix has been removed for clarity.
A second mode of binding suggested by Chou and coworkers involves a more peripheral
site on the surface of the protein.30 Chou et al proposed that, if this mode of binding were
correct, compound M2WJ218 should be a potent inhibitor of both WT protein as well as
S31N, given that the peripheral binding sites were on the surface of the protein.29

On

the other hand, the prediction of the pore-binding model was that this compound should
bind only to the WT protein. We therefore have tested this compound, and found it to be a
good inhibitor of WT. However, it did not show significant inhibition of the mutants.
Thus, these results are fully consistent with the pore-binding site being the
pharmacologically relevant site of inhibitor binding, and do not support the peripheral
mode of binding.

In summary, these results are fully consistent with the expectation that

drugs bind within the pore, and focus future work on this location for the design of future
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inhibitors.

SUPPORTING INFORMATION AVAILABLE Experimental procedures for the
synthesis and characterization of A/M2 inhibitors (1H, 13C and ESI-MS). This material is
available free of charge via the Internet at http://pubs.acs.org
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9.6 Supporting Information
Exploring head groups and scaffold diversities of
Influenza A virus M2 channel inhibitors
Jun Wang, # Chunlong Ma, § Victoria Balannik, § Lawrence H. Pinto, § Robert A. Lamb, ¶,
&

and William F. DeGrado #,+,*

Chemical Synthesis. All chemicals were purchased from commercial vendors and used
without further purification unless otherwise noted. 1H and 13C NMR spectra were
recorded on a DMX-360 NMR spectrometer. Chemical shifts are reported in parts per
million referenced with respect to residual solvent (CHCl3) 7.26 ppm (CH3OH) 3.31 ppm
and (DMSO-d6) 2.50 ppm or from internal standard tetramethylsilane (TMS) 0.00 ppm.
The following abbreviations were used in reporting spectra: s ) singlet, d ) doublet, t )
triplet, q ) quartet, m ) multiplet, dd ) doublet of doublets. All reactions were carried out
under a N2 atmosphere, unless otherwise stated. HPLC grade solvents were used for all
the reactions. Column chromatography was performed using silica gel (230-400 mesh).
Low-resolution mass spectra were obtained using an ESI technique on 3200 Q Trap
LC/MS/MS system (applied biosystem).

M2WJ116 was ordered from ChemBridge Cooperation, Cat #: 5163148
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M2WJ99 was synthesized according to the literature reported procedure.1 (Yield: 72%
over two steps). 1H NMR (360 MHz, DMSO) δ 5.24 (m, 2H), 2.07 (br s, 3H), 1.65 (br s,
6H), 1.60-1.52 (m, 6H); 13C NMR (90 MHz, DMSO) δ 74.13, 40.31, 36.15, 29.77; The
calculated mass for C10H17NO (M + H)+ is 168.1, Found 168.2.

M2WJ116 was purchased from Sigma-Aldrich, Cat #: 130346

M2WJ75 was synthesized according to the previous published procedure. 2 1H NMR (360
MHz, CD3OD) δ 2.14-2.12 (m, 3H), 1.99-1.96 (m, 6H), 1.77-1.74 (m, 6H); 13C NMR (90
MHz, CD3OD) δ 154.26, 53.83, 42.51, 36.86, 31.03; The calculated mass for C11H19N3
(M + H)+ is 194.2, Found 194.7.
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M2WJ161 was purchased from Matrix Scientific, Cat #: 007343

M2WJ77 was purchased from Sigma-Aldrich, Cat #: L254843

A suspension of 1-adamantyl carbonitrile (1.61g, 10mmol), hydroxylamine hydrochloride
(1.04g, 15mmol) and NaHCO3 (1.25g, 15mmol) in CH3OH (25ml) was heated to reflux
for 4hrs. After cooling down to rt, solvent was removed under reduced pressure and the
crude product was extracted with ethyl acetate and H2O. The organic layer was dried over
MgSO4 and filtered, 4M HCl in dioxane (3ml) was added to the filtrate and it was
concentrated. The product was purified by flash column chromatography (5-15%
CH3OH/CH2Cl2) to give M2WJ112 as white solid (Yield 75%). 1H NMR (360 MHz,
CD3OD) δ 2.06-2.04 (m, 4H), 2.02-2.00 (m, 3H), 1.86-1.84 (m, 2H), 1.80-1.72 (m, 6H);
13
C NMR (90 MHz, CD3OD) δ 126.30, 41.09, 40.87, 37.92, 36.88, 29.88, 28.78; The
calculated mass for C11H18N2O (M + H)+ is 195.1, Found 195.0.

M2WJ117 was purchased from Sigma-Aldrich, Cat #: 390607.
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M2WJ119 was purchased from Sigma-Aldrich, Cat #: 146048.

M2WJ127 was purchased from Fisher Scientific, Cat #:33927.

M2WJ120 was purchased from Sigma-Aldrich, Cat #: 153818.

The synthesis of spiran hydrazine M2WJ124 started from spiro[5.5]undecan-3-one,
which
was
prepared
according
to
previous
published
procedure.3
Spiro[5.5]undecan-3-one (1.66g, 10mmol) and hydrazine hydrate (0.50g, 10mmol) was
refluxed in CH3OH (20ml) for 3hrs.4 The reaction mixture was cooled down to rt and
concentrated in vacuo. The amino imine intermediate was used for the next step without
purification. To a solution of the crude amino imine in THF (10ml) was added a solution
of borane-THF (1M, 30ml, 30mmool) at room temperature. The reaction was stirred at
room temperature for 15hrs and concentrated in vacuo. The residue was dissolved in 6M
HCl (20ml) and heated to 100oC refluxing for 2hrs. After cooling to room temperature,
the solution was basified to pH 12 with 6M NaOH and extracted with CHCl3 three times.
The combined organic layer was dried over MgSO4 and filtered. 4M HCl in dioxane
(4ml) was added and the filtrate was concentrated under reduced pressure. The final
product was purified by flash column chromatography (10-20% CH3OH/CH2Cl2) to give
M2WJ124 as white solid. (Yield: 68% over two steps). 1H NMR (360 MHz, CDCl3) δ
8.49 (br s, 4H), 3.44-3.37 (m, 1H), 2.02-2.01 (m, 2H), 1.81-1.73 (m, 4H), 1.39-1.36 (m,
8H), 1.19-1.11 (m, 2H), 1.10-1.04 (m, 2H); 13C NMR (90 MHz, CDCl3) δ 61.21, 40.68,
34.37, 32.26, 32.04, 26.98, 23.12, 21.99, 21.84; The calculated mass for C11H22N2 (M +
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H)+ is 183.2, Found 183.7.

Hydrazine hydrate (0.5g, 10mmol) was added dropwise to a refluxing solution of
3-Oxaspiro[5,5]undecane-2,4-dione in DMF (20ml). After addition, the solution was
slowly cooled down to room temperature. Solvent was removed under reduced pressure
and the crude product was purified by flash column chromatography (2-5%
CH3OH/CH2Cl2) to give M2WJ85 as white solid. (Yield: 72%). 1H NMR (360 MHz,
CD3OD) δ 2.52 (s, 2H), 2.46 (s, 2H), 1.53-1.46 (m, 10H); 13C NMR (90 MHz, CDCl3) δ
176.14, 42.38, 37.12, 36.89, 27.05, 22.71; The calculated mass for C10H16N2O2 (M + H)+
is 197.1, Found 197.2.
M2WJ98 was synthesized by LiAlH4 reduction of M2WJ85. To M2WJ85 (1.96g,
10mmol) in anhydrous THF was added LiAlH4 (0.76g, 20mmol) at 0oC, the resulting
slurry was heated to reflux for 4 hrs. The solution was cooled to 0oC and quenched with
H2O (0.75 mL), 15% NaOH (0.75 mL), and H2O (2.25 mL) sequentially. The resulting
slurry was filtered. The filtrate was dried over MgSO4, filtered, concentrated in vacuo.
Hydrochloride salt was made by adding 4M HCl in 1,4-dioxane to the ether solution of
the above amine at 0oC, followed by centrifuge and decant the ether supernatant. The
final product was purified by flash chromatography to give the hydrazine M2WJ98 as
white solid. (Yield: 65%). 1H NMR (360 MHz, CDCl3) δ 2.60 (t, J = 5.52 Hz, 4H), 1.52
(t, J = 5.52 Hz, 4H), 142-1.40 (m, 6H), 1.33-1.26 (m, 4H); 13C NMR (90 MHz, CDCl3) δ
56.05, 36.87, 36.44, 30.14, 26.99, 21.82; The calculated mass for C10H20N2 (M + H)+ is
169.2, Found 169.2.

M2WJ51 was purchased from Bosche Scientific, Cat #:P3149
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Pentacyclo[5.4.0.02,6.03,10.05,9]undecane-8,11-dione was purchased from Sigma-Aldrich,
Cat #309575, 98%
General procedure of converting ketone to amine
A solution of ketone (1mmol), NH2OH*HCl (208.5mg, 3mmol) and CH3COONa
(328.1mg, 4mmol) in EtOH (10ml) and H2O (1ml) was heated to reflux for 2hrs. Solvent
was removed in vacuo and the residue was dissolved in CH2Cl2 and extracted with H2O
twice. The organic layer was dried with MgSO4 and the solvent was removed in vacuo to
give the oxime intermediate. Without further purification, the oxime was dissolved in
anhydrous THF (10ml) and cooled to 0oC on an ice-water bath. LiAlH4 (0.4g, 10.5mmol)
was added portion-wise to the stirring mixture. The solution was warmed up to ambient
temperature and heated at reflux for 4hrs. The reaction was quenched by sequentially
addition of 0.4 ml H2O, 0.4 ml 15% NaOH solution and 1.2 ml H2O. The resulting slurry
was filtered and the solvent was removed in vacuo. 4M HCl in 1,4-dioxane (1ml) was
added to the oily residue and the solvent was removed again in vacuo to give white solid
crude product which was subsequently purified by silica gel flash column
chromatography to yield the final amino hydrochloride salt.
The ketone alcohol intermediate I was synthesized according to the literature procedure
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without modification.5 It was converted to the amino alcohol M2WJ208 according to the
above general procedure of converting ketone to amine. (Yield: 75%). 1H NMR (360
MHz, DMSO) δ 8.55 (br s, 3H), 7.09 (br s, 1H), 3.76-3.75 (m, 1H), 2.94-2.93 (m, 1H),
2.72-2.712 (m, 1H), 2.62-2.61 (m, 1H), 2.55-2.54 (m, 1H), 2.35-2.34 (m, 1H), 2.27-2.22
(m, 2H), 1.59 (d, J = 7.56 Hz, 1H), 1.59-1.45 (m, 2H), 1.00 (d, J = 7.56 Hz, 1H); 13C
NMR (90 MHz, DMSO) δ 69.41, 49.07, 44.23, 44.20, 42.82, 42.42, 42.25, 37.30, 35.43,
33.52, 20.31; The calculated mass for C11H15NO (M + H)+ is 177.2, Found 177.2.
M2WJ194 was synthesized from reduction of intermediate I according to the published
procedure. 5 (Yield: 80%). 1H NMR (360 MHz, CDCl3) δ 3.95-3.93 (m, 1H), 2.79-2.70
(m, 1H), 2.69-2.50 (m, 2H), 2.48-2.35 (m, 2H), 2.32-2.15 (m, 4H), 1.72-1.69 (m, 1H),
1.50 (br s, 1H), 1.19-1.12 (m, 1H), 1.11-1.06 (m, 1H). 13C NMR (90 MHz, CDCl3) δ
74.60, 47.25, 45.98, 43.34, 42.25, 42.23, 40.14, 39.07, 36.16, 35.36, 29.02; The
calculated mass for C11H14O (M + H)+ is 163.1, Found 162.8.
M2WJ199 was synthesized from the ketone intermediate II according to the above
general procedure of converting ketone to amine. (Yield: 78%). 1H NMR (360 MHz,
CDCl3) δ 8.23 (br s ,3H), 3.26-3.24 (m, 1H), 2.92-2.89(m, 2H), 2.68-2.58 (m, 4H),
2.32-2.30(m, 2H), 1.89-1.74 (m, 2H), 1.30-1.21 (m, 2H). 13C NMR (90 MHz, CDCl3) δ
51.69, 47.14, 44.83, 43.69, 42.07, 41.26, 40.57, 37.15, 35.37, 34.48, 29.58; The
calculated mass for C11H15N (M + H)+ is 162.2, Found 162.1.

M2WJ66 was purchased from Enamine, Cat #:T0500-7514

M2WJ59 was purchased from Cambridge Corporation, Cat # 5190950
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M2WJ63 was purchased from Sigma-Aldrich, Cat # S434051

M2WJ61 was purchased from ChemBridge cooperation, Cat #:4003530

M2WJ56 was purchased from Aurora Fine Chemicals, Cat #: K00.039.656

M2WJ209 was synthesized according to the literature reported procedure using SmI2
reduction. 6 (Yield: 32%). 1H NMR (360 MHz, CDCl3+CD3OD) δ 1.70 (d, J = 4.68 Hz,
4H), 1.54 (d, J = 4.68 Hz, 4H), 1.04 (s, 6H). 13C NMR (90 MHz, CDCl3+CD3OD) δ
78.92, 56.92, 41.85, 16.37; The calculated mass for C10H16O2 (M + H)+ is 169.1, Found
169.4.
General procedure of LiAlH4 mediated reduction
In anhydrous THF was added LiAlH4 (X g) at 0oC, the resulting slurry was heated to
reflux for 4 hrs. The solution was cooled to 0oC and quenched with H2O (X mL), 15%
NaOH (X mL), and H2O (3X mL) sequentially. The resulting slurry was filtered. The
filtrate was dried over MgSO4, filtered, concentrated in vacuo. Hydrochloride salt was
made by adding 4M HCl in 1,4-dioxane to the ether solution of the above amine at 0oC,
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followed by decanting the ether supernatant. The final product was purified by flash
chromatography to give the ammonium hydrochloride.

M2WJ218 was synthesized according to the above general procedure of LiAlH4 mediated
reduction. The starting material 1-Adamantyl(amino)acetic acid was purchased from
Matrix Scientific, Cat #: 027469. (Yield: 82%). 1H NMR (360 MHz, CD3OD) δ 3.88 (dd,
J = 11.52 Hz, 3.6 Hz, 1H), 3.62-3.57 (m, 1H), 2.78 (dd, J = 9.18 Hz, 3.6 Hz, 1H), 2.03
(br s, 3H), 1.81-1.74 (m, 6H), 1.68-1.66 (m, 6H). 13C NMR (90 MHz, CD3OD) δ 64.01,
59.27, 39.47, 37.75, 35.16, 29.65; The calculated mass for C12H21NO (M + H)+ is 196.2,
Found 196.2.

M2WJ176 4-tert-butylbenzylamine was purchased from Sigma-Aldrich. Cat #631280
97%

M2WJ177 2-aminoindan was purchased from Sigma-Aldrich. Cat # 479128. 97%

M2WJ179 tert-Octylamine was purchased from Sigma-Aldrich, Cat #: O6000 95%
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Diphenylphosphorylazide (DPPA) (1.29 ml, 6 mmol) and triethylamine (0.84ml, 6mmol)
were added to a solution of 2,2,3,3-Tetramethylcyclopropanecarboxylic acid (0.71 g, 5
mmol) in 10 ml toluene at ambient temperature. The reaction was heated to reflux for 3
hours. The mixture was concentrated in vacuo. An additional 10 ml CH2Cl2 and 10 ml
H2O were added to the reaction mixture, the organic layer was separated and washed
sequentially with H2O, saturated NaHCO3 and brine and dried over MgSO4. Solvent was
removed by rotary evaporation and 50ml of 6 N HCl was added. The solution was stirred
at ambient temperature for 3 hours. NaOH solution was added until pH 10, the resulting
solution was extracted by CH2Cl2 (30ml) for 3 times. 4M HCl in dioxane (3 ml) was
added to the combined CH2Cl2 layers and the mixture was dried over MgSO4. Further
flash column chromatography purification gave 2,2,3,3-tetramethylcyclopropanaminium
chloride as a white power (0.83g, Yield: 82%). 1H NMR (360 MHz, CD3OD) δ 3.35 (s,
1H), 1.16 (s, 12H); 13C NMR (90 MHz, CD3OD) δ 43.02, 23.24, 22.19; The calculated
mass for C7H15N (M + H)+ is 114.1, Found 114.2

M2WJ36 was synthesized according to the above general procedure of converting ketone
to amine. (Yield: 78.2%) 1H-NMR (360 MHz, CD3OD) δ 3.49-3.44 (m, 1H), 2.25-2.24
(m, 1H), 2.11-2.05 (m, 3H), 2.00-1.93 (m, 3H), 1.72-1.70 (m, 1H), 1.60-1.57 (m, 1H),
1.29-1.20 (m, 2H), 1.04-0.93 (m, 3H); 13C-NMR (90 MHz, CD3OD) δ 50.98, 43.69,
40.69, 38.66, 33.95, 32.07, 31.71, 31.50, 26.36; The calculated mass for C10H17N (M +
H)+ is 152.1, Found 152.5.
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3-Azabicyclo[3.2.2]nonane 99% was purchased from ChemService Inc. Cat # 2040

4-Oxo-3-aza-tricyclo[4.2.1.0(2.5)]nonane was purchased from Fisher Scientific Cat
#26810. It was reduced to M2WJ186 with LiAlH4 according to the general procedure of
LiAlH4 reduction described above. (Yield: 80%). 1H NMR (360 MHz, CD3OD) δ
4.40-4.36 (m, 1H), 4.19-4.17 (m, 1H), 3.85-3.82 (m, 1H), 2.78-2.10 (m, 4H), 1.70-1.64
(m, 3H), 1.19-1.16 (m, 2H); 13C NMR (90 MHz, CD3OD) δ 65.80, 48.26, 38.96, 36.97,
36.93, 30.49, 25.25, 22.63; The calculated mass for C8H13N (M + H)+ is 124.1, Found
124.2

Bicyclo[2.2.1]heptane-2,3-dicarboxylic Acid was purchased from TCI America, Cat
#N0753. The diacid (1.84g, 10mmol) and urea (2.40g, 40mmol) was heated to 180oC
under N2 atmosphere for 3hrs. When it was cooled down to room temperature, anhydrous
THF was added, and the solution was cooled to 0oC with ice bath. LiAlH4 (3.04g,
80mmol) was added portionwise to the solution, and heated to reflux for 4hrs. The
solution was cooled down to 0oC with ice bath, 3ml of H2O, 3ml 15% NaOH and 9ml of
H2O was sequentially added. The resulting slurry was filtered. 5ml of 4M HCl in
1,4-dioxane was added and the solvent was removed under reduced pressure. The crude
product was purified by flash column chromatography (10% CH3OH/CH2Cl2) to give
M2WJ105 as white solid (1.24g, Yield: 72.0%). 1H NMR (360 MHz, CDCl3) δ 3.32-3.30
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(m, 2H), 3.26-3.21 (m, 2H), 2.93-2.90 (m, 2H), 2.36-2.34 (m, 2H), 1.78-1.74 (m, 1H),
1.68-1.65 (m, 1H), 1.58-1.51 (m, 4H); 13C NMR (90 MHz, CDCl3) δ 47.11, 45.78, 44.34,
41.30, 23.23; The calculated mass for C9H15N (M + H)+ is 138.1, Found 138.2.

M2WJ55 was purchased from Chembridge Corporation. Cat # 5875453.

4-Azatricyclo[4.3.1.13,8]undecan-5-one was purchased from Sigma-Aldrich. Cat
#403164. 98%. It was reduced to M2WJ113 according to the above general procedure of
LiAlH4 mediated reduction. (Yield: 82%). 1H-NMR (360 MHz, CD3OD) δ 2.80-2.77 (m,
3H), 1.84-1.82 (m, 1H), 1.61-1.52 (m, 6H), 1.36-1.31 (m, 2H), 1.17-1.36 (m, 4H);
13
C-NMR (90 MHz, CD3OD) δ 53.72, 52.61, 37.17, 34.98, 34.87, 32.09, 27.27; ESI-MS:
Calculated for C10H17N (M + H)+ 152.2, Found: 152.3

M2WJ200 was purchased from Matrix Scientific, Cat #:038588
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M2WJ201 was synthesized according to literature reported procedure using curtius
rearrangement reaction.7, 8 The starting material was purchased from Matrix Scientific,
Cat #: 037551 (Yield: 76%). 1H-NMR (360 MHz, CD3OD) δ 2.28-2.24 (m, 2H),
1.96-1.91 (m, 4H), 1.89-1.82 (m, 4H), 1.76-1.72 (m, 4H), 1.55-1.52 (m, 2H); 13C-NMR
(90 MHz, CD3OD) δ 53.91, 43.16, 42.46, 40.72, 38.90, 37.36, 35.87, 33.76, 32.54, 30.98,
28.38; ESI-MS: Calculated for C11H19N (M + H)+ 166.2, Found: 166.3
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